戸井 雅和

最終更新日時: 2019/06/20 16:11:26

印刷する

氏名(漢字/フリガナ/アルファベット表記)
戸井 雅和/トイ マサカズ/Toi, Masakazu
所属部署・職名(部局/所属/講座等/職名)
医学研究科/医学専攻外科学講座乳腺外科学/教授
学部兼担
部局 所属 講座等 職名
医学部
連絡先住所
種別 住所(日本語) 住所(英語)
職場 京都市左京区聖護院川原町54 54 Shogoin-Kawara-cho, Sakyo, Kyoto, Japan
連絡先電話番号
種別 番号
職場 81-75-751-3660
取得学位
学位名(日本語) 学位名(英語) 大学(日本語) 大学(英語) 取得区分
医学博士 広島大学
プロフィール
(日本語)
乳癌に関する診療、研究、教育を行っている。 腫瘍血管新生の研究を行っている。
(英語)
Involved in oncology clinic, oncology research and clinical education. Special field: breast cancer
使用言語
言語名(japanese) 言語名(english) コード
English
researchmap URL
https://researchmap.jp/read0143558
研究テーマ
(日本語)
乳癌診療の最適化、血管新生、乳癌の新規診断法、新規癌治療法の開発、意思決定過程の数理モデル化、乳癌予防
論文
著者 著者(日本語) 著者(英語) タイトル タイトル(日本語) タイトル(英語) 書誌情報等 書誌情報等(日本語) 書誌情報等(英語) 出版年月 査読の有無 記述言語 掲載種別 公開
Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Breast Cancer (Tokyo, Japan) Breast Cancer (Tokyo, Japan) Breast Cancer (Tokyo, Japan) 2019/06 公開
Takada M, Toi M Takada M, Toi M Takada M, Toi M Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. International Journal of Clinical Oncology, 24, 6, 608-613 International Journal of Clinical Oncology, 24, 6, 608-613 International Journal of Clinical Oncology, 24, 6, 608-613 2019/06 公開
Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC cancer, 19, 1, 517 BMC cancer, 19, 1, 517 BMC cancer, 19, 1, 517 2019/05 公開
Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, Toi M Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, Toi M Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, Toi M Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. Journal of Global Oncology, 5, 1-19 Journal of Global Oncology, 5, 1-19 Journal of Global Oncology, 5, 1-19 2019/05 公開
Sakaguchi R, Kataoka M, Kanao S, Miyake KK, Nakamoto Y, Sugie T, Toi M, Mikami Y, Togashi K Sakaguchi R, Kataoka M, Kanao S, Miyake KK, Nakamoto Y, Sugie T, Toi M, Mikami Y, Togashi K Sakaguchi R, Kataoka M, Kanao S, Miyake KK, Nakamoto Y, Sugie T, Toi M, Mikami Y, Togashi K Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer. Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer. Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer. Annals of Nuclear Medicine Annals of Nuclear Medicine Annals of Nuclear Medicine 2019/05 公開
Poudel S, Hirano S, Kurashima Y, Stefanidis D, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hashimoto D, Hida K, Izaki T, Iwase H, Kawamoto S, Otomo Y, Nagai E, Saito M, Takami H, Takeda Y, Toi M, Yamaue H, Yoshida M, Yoshida S, Kodera Y Poudel S, Hirano S, Kurashima Y, Stefanidis D, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hashimoto D, Hida K, Izaki T, Iwase H, Kawamoto S, Otomo Y, Nagai E, Saito M, Takami H, Takeda Y, Toi M, Yamaue H, Yoshida M, Yoshida S, Kodera Y Poudel S, Hirano S, Kurashima Y, Stefanidis D, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hashimoto D, Hida K, Izaki T, Iwase H, Kawamoto S, Otomo Y, Nagai E, Saito M, Takami H, Takeda Y, Toi M, Yamaue H, Yoshida M, Yoshida S, Kodera Y A snapshot of surgical resident training in Japan: results of a national-level needs assessment survey. A snapshot of surgical resident training in Japan: results of a national-level needs assessment survey. A snapshot of surgical resident training in Japan: results of a national-level needs assessment survey. Surgery Today Surgery Today Surgery Today 2019/05 公開
Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC Insights Into Breast Cancer in the East vs the West: A Review. Insights Into Breast Cancer in the East vs the West: A Review. Insights Into Breast Cancer in the East vs the West: A Review. JAMA oncology JAMA oncology JAMA oncology 2019/05 公開
Benson JR, Jatoi I, Toi M Benson JR, Jatoi I, Toi M Benson JR, Jatoi I, Toi M Surgical management of multiple ipsilateral breast cancers. Surgical management of multiple ipsilateral breast cancers. Surgical management of multiple ipsilateral breast cancers. Future oncology (London, England), 15, 11, 1185-1191 Future oncology (London, England), 15, 11, 1185-1191 Future oncology (London, England), 15, 11, 1185-1191 2019/04 公開
Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. ESMO open, 4, 1, e000476 ESMO open, 4, 1, e000476 ESMO open, 4, 1, e000476 2019 公開
Kiso M, Tanaka S, Saji S, Toi M, Sato F. Kiso M, Tanaka S, Saji S, Toi M, Sato F. Kiso M, Tanaka S, Saji S, Toi M, Sato F. Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. Int J Cancer, 1;143, 11, 2905-2918 Int J Cancer, 1;143, 11, 2905-2918 Int J Cancer, 1;143, 11, 2905-2918 2018/12 公開
Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M. Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M. Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M. Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. Breast Cancer Res Treat, 172, 3, 611-618 Breast Cancer Res Treat, 172, 3, 611-618 Breast Cancer Res Treat, 172, 3, 611-618 2018/12 公開
Sagawa H, Kataoka M, Kanao S, Onishi N, Nickel MD, Toi M, Togashi K. Sagawa H, Kataoka M, Kanao S, Onishi N, Nickel MD, Toi M, Togashi K. Sagawa H, Kataoka M, Kanao S, Onishi N, Nickel MD, Toi M, Togashi K. Impact of the Number of Iterations in Compressed Sensing Reconstruction on Ultrafast Dynamic Contrast-enhanced Breast MR Imaging. Impact of the Number of Iterations in Compressed Sensing Reconstruction on Ultrafast Dynamic Contrast-enhanced Breast MR Imaging. Impact of the Number of Iterations in Compressed Sensing Reconstruction on Ultrafast Dynamic Contrast-enhanced Breast MR Imaging. Magn Reson Med Sci, 9, doi: 10.2463/mrms.mp.2018-0015 Magn Reson Med Sci, 9, doi: 10.2463/mrms.mp.2018-0015 Magn Reson Med Sci, 9, doi: 10.2463/mrms.mp.2018-0015 2018/11 公開
Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. Breast Cancer Res Treat, 171, 3, 675-683 Breast Cancer Res Treat, 171, 3, 675-683 Breast Cancer Res Treat, 171, 3, 675-683 2018/10 公開
Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, Nussenzweig A, Takeda S. Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, Nussenzweig A, Takeda S. Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, Nussenzweig A, Takeda S. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proc Natl Acad Sci U S A, 6;115, 45, E10642-E10651 Proc Natl Acad Sci U S A, 6;115, 45, E10642-E10651 Proc Natl Acad Sci U S A, 6;115, 45, E10642-E10651 2018/10 公開
Saito S, Bise R, Yoshikawa A, Sekiguchi H, Tsuge I, Toi M. Saito S, Bise R, Yoshikawa A, Sekiguchi H, Tsuge I, Toi M. Saito S, Bise R, Yoshikawa A, Sekiguchi H, Tsuge I, Toi M. Digital artery deformation on movement of the proximal interphalangeal joint Digital artery deformation on movement of the proximal interphalangeal joint Digital artery deformation on movement of the proximal interphalangeal joint J Hand Surg Eur, 18:1753193418807833, doi: 10.1177/1753193418807833. J Hand Surg Eur, 18:1753193418807833, doi: 10.1177/1753193418807833. J Hand Surg Eur, 18:1753193418807833, doi: 10.1177/1753193418807833. 2018/10 公開
Suzuki E, Sugimoto M, Kawaguchi K, Pu F, Uozumi R, Yamaguchi A, Nishie M, Tsuda M, Kotake T, Morita S, Toi M. Suzuki E, Sugimoto M, Kawaguchi K, Pu F, Uozumi R, Yamaguchi A, Nishie M, Tsuda M, Kotake T, Morita S, Toi M. Suzuki E, Sugimoto M, Kawaguchi K, Pu F, Uozumi R, Yamaguchi A, Nishie M, Tsuda M, Kotake T, Morita S, Toi M. Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. Breast Cancer, 13, doi: 10.1007/s12282-018-0920-2 Breast Cancer, 13, doi: 10.1007/s12282-018-0920-2 Breast Cancer, 13, doi: 10.1007/s12282-018-0920-2 2018/10 公開
Matsumoto Y, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Nagae KI, Kobayashi S, Tsuge I, Saito S, Takada M, Ishida Y, Kataoka M, Sakurai T, Yagi T, Kabashima K, Suzuki S, Togashi K, Shiina T, Toi M. Matsumoto Y, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Nagae KI, Kobayashi S, Tsuge I, Saito S, Takada M, Ishida Y, Kataoka M, Sakurai T, Yagi T, Kabashima K, Suzuki S, Togashi K, Shiina T, Toi M. Matsumoto Y, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Nagae KI, Kobayashi S, Tsuge I, Saito S, Takada M, Ishida Y, Kataoka M, Sakurai T, Yagi T, Kabashima K, Suzuki S, Togashi K, Shiina T, Toi M. Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging. Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging. Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging. Sci Rep, 8;8, 1, 14930-doi: 10.1038/s41598-018-33255- Sci Rep, 8;8, 1, 14930-doi: 10.1038/s41598-018-33255- Sci Rep, 8;8, 1, 14930-doi: 10.1038/s41598-018-33255- 2018/10 公開
Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S. Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S. Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS s A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS s A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS s Jpn J Clin Oncol, 1;48, 9, 855-859 Jpn J Clin Oncol, 1;48, 9, 855-859 Jpn J Clin Oncol, 1;48, 9, 855-859 2018/09 公開
Fukui Y, Kawashima M, Kawaguchi K, Takeuchi M, Hirata M, Kataoka TR, Sakurai T, Kataoka M, Kanao S, Nakamoto Y, Hirata K, Yoshimura M, Yoshikawa K, Ishiguro H, Toi M Fukui Y, Kawashima M, Kawaguchi K, Takeuchi M, Hirata M, Kataoka TR, Sakurai T, Kataoka M, Kanao S, Nakamoto Y, Hirata K, Yoshimura M, Yoshikawa K, Ishiguro H, Toi M Fukui Y, Kawashima M, Kawaguchi K, Takeuchi M, Hirata M, Kataoka TR, Sakurai T, Kataoka M, Kanao S, Nakamoto Y, Hirata K, Yoshimura M, Yoshikawa K, Ishiguro H, Toi M Granulocyte-colony-stimulating factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 and vascular endothelial growth factor levels. Granulocyte-colony-stimulating factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 and vascular endothelial growth factor levels. Granulocyte-colony-stimulating factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 and vascular endothelial growth factor levels. International cancer conference journal, 7, 3, 107-113 International cancer conference journal, 7, 3, 107-113 International cancer conference journal, 7, 3, 107-113 2018/07 公開
Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M. Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M. Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M. Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study Breast Cancer, 5;12, :1178223418786243. Breast Cancer, 5;12, :1178223418786243. Breast Cancer, 5;12, :1178223418786243. 2018/07 公開
Yamaga I, Kawaguchi-Sakita N, Asao Y, Matsumoto Y, Yoshikawa A, Fukui T, Takada M, Kataoka M, Kawashima M, Fakhrejahani E, Kanao S, Nakayama Y, Tokiwa M, Torii M, Yagi T, Sakurai T, Haga H, Togashi K, Shiina T, Toi M. Yamaga I, Kawaguchi-Sakita N, Asao Y, Matsumoto Y, Yoshikawa A, Fukui T, Takada M, Kataoka M, Kawashima M, Fakhrejahani E, Kanao S, Nakayama Y, Tokiwa M, Torii M, Yagi T, Sakurai T, Haga H, Togashi K, Shiina T, Toi M. Yamaga I, Kawaguchi-Sakita N, Asao Y, Matsumoto Y, Yoshikawa A, Fukui T, Takada M, Kataoka M, Kawashima M, Fakhrejahani E, Kanao S, Nakayama Y, Tokiwa M, Torii M, Yagi T, Sakurai T, Haga H, Togashi K, Shiina T, Toi M. Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer. Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer. Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer. Photoacoustics, 20;11, 6-13 Photoacoustics, 20;11, 6-13 Photoacoustics, 20;11, 6-13 2018/06 公開
Mackenzie LJ, Carey ML, Suzuki E, Sanson-Fisher RW, Asada H, Ogura M, D'Este C, Yoshimura M, Toi M. Mackenzie LJ, Carey ML, Suzuki E, Sanson-Fisher RW, Asada H, Ogura M, D'Este C, Yoshimura M, Toi M. Mackenzie LJ, Carey ML, Suzuki E, Sanson-Fisher RW, Asada H, Ogura M, D'Este C, Yoshimura M, Toi M. Agreement between patients' and radiation oncologists' cancer diagnosis and prognosis perceptions: A cross sectional study in Japan. Agreement between patients' and radiation oncologists' cancer diagnosis and prognosis perceptions: A cross sectional study in Japan. Agreement between patients' and radiation oncologists' cancer diagnosis and prognosis perceptions: A cross sectional study in Japan. PLoS One, 8;13, 6, :e0198437. doi: 10.1371/journa PLoS One, 8;13, 6, :e0198437. doi: 10.1371/journa PLoS One, 8;13, 6, :e0198437. doi: 10.1371/journa 2018/06 公開
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Cancer Med, 14, 1002/cam4.1600. [Epub ahead of Cancer Med, 14, 1002/cam4.1600. [Epub ahead of Cancer Med, 14, 1002/cam4.1600. [Epub ahead of 2018/06 公開
Takada M, Takeuchi M, Suzuki E, Sato F, Matsumoto Y, Torii M, Kawaguchi-Sakita N, Nishino H, Seo S, Hatano E, Toi M. Takada M, Takeuchi M, Suzuki E, Sato F, Matsumoto Y, Torii M, Kawaguchi-Sakita N, Nishino H, Seo S, Hatano E, Toi M. Takada M, Takeuchi M, Suzuki E, Sato F, Matsumoto Y, Torii M, Kawaguchi-Sakita N, Nishino H, Seo S, Hatano E, Toi M. Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence. Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence. Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence. Breast Cancer, 9, doi: 10.1007/s12282-018-0868-2 Breast Cancer, 9, doi: 10.1007/s12282-018-0868-2 Breast Cancer, 9, doi: 10.1007/s12282-018-0868-2 2018/05 公開
Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S, Morita S, Toi M. Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S, Morita S, Toi M. Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S, Morita S, Toi M. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. Cancer Med, 7, . doi: 10.1002/cam4.1516. [Epu Cancer Med, 7, . doi: 10.1002/cam4.1516. [Epu Cancer Med, 7, . doi: 10.1002/cam4.1516. [Epu 2018/05 公開
Shiina T, Toi M, Yagi T. Shiina T, Toi M, Yagi T. Shiina T, Toi M, Yagi T. Development and clinical translation of photoacoustic mammography. Development and clinical translation of photoacoustic mammography. Development and clinical translation of photoacoustic mammography. Biomed Eng Lett., 7;8, 2, 157-165 Biomed Eng Lett., 7;8, 2, 157-165 Biomed Eng Lett., 7;8, 2, 157-165 2018/05 公開
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 . Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 . Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 . De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol, 3, doi: 10.1093/annonc/mdx806. [E Ann Oncol, 3, doi: 10.1093/annonc/mdx806. [E Ann Oncol, 3, doi: 10.1093/annonc/mdx806. [E 2018/05 公開
Tsuge I, Saito S, Sekiguchi H, Yoshikawa A, Matsumoto Y, Toi M, Suzuki S. Tsuge I, Saito S, Sekiguchi H, Yoshikawa A, Matsumoto Y, Toi M, Suzuki S. Tsuge I, Saito S, Sekiguchi H, Yoshikawa A, Matsumoto Y, Toi M, Suzuki S. Photoacoustic Tomography Shows the Branching Pattern of Anterolateral Thigh Perforators In Vivo. Photoacoustic Tomography Shows the Branching Pattern of Anterolateral Thigh Perforators In Vivo. Photoacoustic Tomography Shows the Branching Pattern of Anterolateral Thigh Perforators In Vivo. Plast Reconstr Surg, 141, 5, 1288-1292 Plast Reconstr Surg, 141, 5, 1288-1292 Plast Reconstr Surg, 141, 5, 1288-1292 2018/05 公開
Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, Kawakami K. Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, Kawakami K. Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, Kawakami K. Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. Jpn J Clin Oncol, 1;48, 5, 410-416 Jpn J Clin Oncol, 1;48, 5, 410-416 Jpn J Clin Oncol, 1;48, 5, 410-416 2018/05 公開
Kotake T, Toi M. Kotake T, Toi M. Kotake T, Toi M. Abemaciclib for the treatment of breast cancer. Abemaciclib for the treatment of breast cancer. Abemaciclib for the treatment of breast cancer. Expert Opin Pharmacother., 19, 5, 517-524 Expert Opin Pharmacother., 19, 5, 517-524 Expert Opin Pharmacother., 19, 5, 517-524 2018/04 公開
Itou J, Li W, Ito S, Tanaka S, Matsumoto Y, Sato F, Toi M. Itou J, Li W, Ito S, Tanaka S, Matsumoto Y, Sato F, Toi M. Itou J, Li W, Ito S, Tanaka S, Matsumoto Y, Sato F, Toi M. Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif-containing 21. Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif-containing 21. Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif-containing 21. J Biological Chemostry, 27;293, 17, 6556-6564 J Biological Chemostry, 27;293, 17, 6556-6564 J Biological Chemostry, 27;293, 17, 6556-6564 2018/04 公開
Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Lu DR, Toi M. Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Lu DR, Toi M. Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Lu DR, Toi M. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. Int J Clin Oncol, doi: 10.1007/s10147-018-1353-9 Int J Clin Oncol, doi: 10.1007/s10147-018-1353-9 Int J Clin Oncol, doi: 10.1007/s10147-018-1353-9 2018/04 公開
Mackenzie L, Carey M, Suzuki E, Yoshimura M, Toi M, D'Este C, Sanson-Fisher R. Mackenzie L, Carey M, Suzuki E, Yoshimura M, Toi M, D'Este C, Sanson-Fisher R. Mackenzie L, Carey M, Suzuki E, Yoshimura M, Toi M, D'Este C, Sanson-Fisher R. A cross-sectional study of agreement between the Hospital Anxiety and Depression Scale and patient- and radiation oncologist-reported single-item assessment of depression and anxiety. A cross-sectional study of agreement between the Hospital Anxiety and Depression Scale and patient- and radiation oncologist-reported single-item assessment of depression and anxiety. A cross-sectional study of agreement between the Hospital Anxiety and Depression Scale and patient- and radiation oncologist-reported single-item assessment of depression and anxiety. Psychooncology, 16, doi: 10.1002/pon.4736. [Epub Psychooncology, 16, doi: 10.1002/pon.4736. [Epub Psychooncology, 16, doi: 10.1002/pon.4736. [Epub 2018/04 公開
Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst, 12, doi: 10.1093/jnci/djy018. [Ep J Natl Cancer Inst, 12, doi: 10.1093/jnci/djy018. [Ep J Natl Cancer Inst, 12, doi: 10.1093/jnci/djy018. [Ep 2018/04 公開
Kanao S, Kataoka M, Iima M, Ikeda DM, Toi M, Togashi K. Kanao S, Kataoka M, Iima M, Ikeda DM, Toi M, Togashi K. Kanao S, Kataoka M, Iima M, Ikeda DM, Toi M, Togashi K. Differentiating benign and malignant inflammatory breast lesions: Value of T2 weighted and diffusion weighted MR images. Differentiating benign and malignant inflammatory breast lesions: Value of T2 weighted and diffusion weighted MR images. Differentiating benign and malignant inflammatory breast lesions: Value of T2 weighted and diffusion weighted MR images. Magn Reson Imaging, 12;50, 38-44 doi: 10.1016/j.mri.2018.03. Magn Reson Imaging, 12;50, 38-44 doi: 10.1016/j.mri.2018.03. Magn Reson Imaging, 12;50, 38-44 doi: 10.1016/j.mri.2018.03. 2018/03 公開
Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators. Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators. Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators. Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. Clin Cancer Res, 12, doi: 10.1158/1078-0432.CCR-17- Clin Cancer Res, 12, doi: 10.1158/1078-0432.CCR-17- Clin Cancer Res, 12, doi: 10.1158/1078-0432.CCR-17- 2018/03 公開
戸井 雅和 戸井 雅和 Masuda N, Nishimura R, Takahashi M, Inoue K, Ohno S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Toi M. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. Cancer Sci, 109(3), 803-813 Cancer Sci, 109(3), 803-813 Cancer Sci, 109(3), 803-813 2018/02 公開
Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M. Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M. Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M. Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. ESMO Open, 14;3, 2, e000314. doi: 10.1136/esmoopen ESMO Open, 14;3, 2, e000314. doi: 10.1136/esmoopen ESMO Open, 14;3, 2, e000314. doi: 10.1136/esmoopen 2018/02 公開
Förnvik D, Kataoka M, Iima M, Ohashi A, Kanao S, Toi M, Togashi K. Förnvik D, Kataoka M, Iima M, Ohashi A, Kanao S, Toi M, Togashi K. Förnvik D, Kataoka M, Iima M, Ohashi A, Kanao S, Toi M, Togashi K. The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI. The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI. The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI. Eur Radiol, 19, doi: 10.1007/s00330-017-52-1846 Eur Radiol, 19, doi: 10.1007/s00330-017-52-1846 Eur Radiol, 19, doi: 10.1007/s00330-017-52-1846 2018/02 公開
Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T. Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T. Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. J Natl Cancer Inst, 1;110, 2, 141-148 J Natl Cancer Inst, 1;110, 2, 141-148 J Natl Cancer Inst, 1;110, 2, 141-148 2018/02 公開
Toi M, Masuda N, Lee SJ. Toi M, Masuda N, Lee SJ. Toi M, Masuda N, Lee SJ. Capecitabine for primary breast cancer. Capecitabine for primary breast cancer. Capecitabine for primary breast cancer. Oncotarget, 6;8, 67, 110739-110740 Oncotarget, 6;8, 67, 110739-110740 Oncotarget, 6;8, 67, 110739-110740 2017/12 公開
Kawaguchi K, Suzuki E, Nishie M, Kii I, Kataoka TR, Hirata M, Inoue M, Pu F, Iwaisako K, Tsuda M, Yamaguchi A, Haga H, Hagiwara M, Toi M. Kawaguchi K, Suzuki E, Nishie M, Kii I, Kataoka TR, Hirata M, Inoue M, Pu F, Iwaisako K, Tsuda M, Yamaguchi A, Haga H, Hagiwara M, Toi M. Kawaguchi K, Suzuki E, Nishie M, Kii I, Kataoka TR, Hirata M, Inoue M, Pu F, Iwaisako K, Tsuda M, Yamaguchi A, Haga H, Hagiwara M, Toi M. Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity. Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity. Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity. Cancer Immunol Immunother, 66, 9, 1131-1142 Cancer Immunol Immunother, 66, 9, 1131-1142 Cancer Immunol Immunother, 66, 9, 1131-1142 2017/09 英語 公開
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol, 1;28, 4, 754-760 Ann Oncol, 1;28, 4, 754-760 Ann Oncol, 1;28, 4, 754-760 2017/04 公開
Ikeda T, Sugie T, Shimizu A, Toi M Ikeda T, Sugie T, Shimizu A, Toi M Ikeda T, Sugie T, Shimizu A, Toi M Patterns of clinical practice for sentinel lymph node biopsy in women with node-negative breast cancer: the results of a national survey in Japan. Patterns of clinical practice for sentinel lymph node biopsy in women with node-negative breast cancer: the results of a national survey in Japan. Patterns of clinical practice for sentinel lymph node biopsy in women with node-negative breast cancer: the results of a national survey in Japan. Breast Cancer, 24, 2, 341-344 Breast Cancer, 24, 2, 341-344 Breast Cancer, 24, 2, 341-344 2017/03 英語 公開
Masakazu Toi, Yasufumi Asao, Yoshiaki Matsumoto, Hiroyuki Sekiguchi, Aya Yoshikawa, Masahiro Takada, Masako Kataoka, Takaaki Endo, Nobuko Kawaguchi, Masahiro Kawashima, Elham Fakhrejahani, Shotaro Kanao, Iku Yamaga, Yoshie Nakayama, Mariko Tokiwa, Masae Torii, Takayuki Yagi, Takaki Sakurai, Kaori Togashi, Tsuyoshi Shiina. Masakazu Toi, Yasufumi Asao, Yoshiaki Matsumoto, Hiroyuki Sekiguchi, Aya Yoshikawa, Masahiro Takada, Masako Kataoka, Takaaki Endo, Nobuko Kawaguchi, Masahiro Kawashima, Elham Fakhrejahani, Shotaro Kanao, Iku Yamaga, Yoshie Nakayama, Mariko Tokiwa, Masae Torii, Takayuki Yagi, Takaki Sakurai, Kaori Togashi, Tsuyoshi Shiina. Masakazu Toi, Yasufumi Asao, Yoshiaki Matsumoto, Hiroyuki Sekiguchi, Aya Yoshikawa, Masahiro Takada, Masako Kataoka, Takaaki Endo, Nobuko Kawaguchi, Masahiro Kawashima, Elham Fakhrejahani, Shotaro Kanao, Iku Yamaga, Yoshie Nakayama, Mariko Tokiwa, Masae Torii, Takayuki Yagi, Takaki Sakurai, Kaori Togashi, Tsuyoshi Shiina. Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector array Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector array Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector array Sci Rep., 7;7:41970. doi: 10.1038/srep41 , 7;7:41970. doi: 10.1038/srep41 Sci Rep., 7;7:41970. doi: 10.1038/srep41 2017/02 公開
Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. Int J Clin Oncol., 22, 1, 11-17 Int J Clin Oncol., 22, 1, 11-17 Int J Clin Oncol., 22, 1, 11-17 2017/02 公開
Itou J, Tanaka S, Li W, Iida A, Sehara-Fujisawa A, Sato F, Toi M. Itou J, Tanaka S, Li W, Iida A, Sehara-Fujisawa A, Sato F, Toi M. Itou J, Tanaka S, Li W, Iida A, Sehara-Fujisawa A, Sato F, Toi M. The Sal-like 4 - integrin α6β1 network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells. The Sal-like 4 - integrin α6β1 network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells. The Sal-like 4 - integrin α6β1 network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells. Biochim Biophys Acta., 1864, 1, 76-88 Biochim Biophys Acta., 1864, 1, 76-88 Biochim Biophys Acta., 1864, 1, 76-88 2017/01 公開
Hirata K, Yoshimura M, Inoue M, Yamauchi C, Ogura M, Toi M, Suzuki E, Takeuchi M, Takada M, Hiraoka M. Hirata K, Yoshimura M, Inoue M, Yamauchi C, Ogura M, Toi M, Suzuki E, Takeuchi M, Takada M, Hiraoka M. Hirata K, Yoshimura M, Inoue M, Yamauchi C, Ogura M, Toi M, Suzuki E, Takeuchi M, Takada M, Hiraoka M. Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation. Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation. Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation. J Radiat Res, 58, 1, 79-85 J Radiat Res, 58, 1, 79-85 J Radiat Res, 58, 1, 79-85 2017/01 公開
Kawaguchi K, Suzuki E, Yamaguchi A, Yamamoto M, Morita S, Toi M. Kawaguchi K, Suzuki E, Yamaguchi A, Yamamoto M, Morita S, Toi M. Kawaguchi K, Suzuki E, Yamaguchi A, Yamamoto M, Morita S, Toi M. Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. Breast Cancer, 24, 1, 111-120 Breast Cancer, 24, 1, 111-120 Breast Cancer, 24, 1, 111-120 2017/01 公開
Onishi N, Kataoka M, Kanao S, Kawai M, Iima M, Ohashi A, Toi M, Togashi K. Onishi N, Kataoka M, Kanao S, Kawai M, Iima M, Ohashi A, Toi M, Togashi K. Onishi N, Kataoka M, Kanao S, Kawai M, Iima M, Ohashi A, Toi M, Togashi K. A pilot study to determine the diagnostic criteria of spiculated masses for BI-RADS MRI category 5: when to perform re-biopsy after discordant pathologic result? A pilot study to determine the diagnostic criteria of spiculated masses for BI-RADS MRI category 5: when to perform re-biopsy after discordant pathologic result? A pilot study to determine the diagnostic criteria of spiculated masses for BI-RADS MRI category 5: when to perform re-biopsy after discordant pathologic result? Breast Cancer, 24, 1, 69-78 Breast Cancer, 24, 1, 69-78 Breast Cancer, 24, 1, 69-78 2017/01 公開
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. J Clin Oncol, 10;35, 2, 141-148 J Clin Oncol, 10;35, 2, 141-148 J Clin Oncol, 10;35, 2, 141-148 2017/01 公開
N. Masuda, S.-J. Lee, S. Ohtani, Y.-H. Im, E.-S. Lee, I. Yokota, K. Kuroi, S.-A. Im, B.-W. Park, S.-B. Kim, Y. Yanagita, S. Ohno, S. Takao, K. Aogi, H. Iwata, J. Jeong, A. Kim, K.-H. Park, H. Sasano, Y. Ohashi, and M. Toi N. Masuda, S.-J. Lee, S. Ohtani, Y.-H. Im, E.-S. Lee, I. Yokota, K. Kuroi, S.-A. Im, B.-W. Park, S.-B. Kim, Y. Yanagita, S. Ohno, S. Takao, K. Aogi, H. Iwata, J. Jeong, A. Kim, K.-H. Park, H. Sasano, Y. Ohashi, and M. Toi N. Masuda, S.-J. Lee, S. Ohtani, Y.-H. Im, E.-S. Lee, I. Yokota, K. Kuroi, S.-A. Im, B.-W. Park, S.-B. Kim, Y. Yanagita, S. Ohno, S. Takao, K. Aogi, H. Iwata, J. Jeong, A. Kim, K.-H. Park, H. Sasano, Y. Ohashi, and M. Toi Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy N Engl J Med, 1;376, 22, 2147-2159 N Engl J Med, 1;376, 22, 2147-2159 N Engl J Med, 1;376, 22, 2147-2159 2017/01 公開
Shi G, Yoshida Y, Yuki K, Nishimura T, Kawata Y, Kawashima M, Iwaisako K, Yoshikawa K, Kurebayashi J, Toi M, Noda M. Shi G, Yoshida Y, Yuki K, Nishimura T, Kawata Y, Kawashima M, Iwaisako K, Yoshikawa K, Kurebayashi J, Toi M, Noda M. Shi G, Yoshida Y, Yuki K, Nishimura T, Kawata Y, Kawashima M, Iwaisako K, Yoshikawa K, Kurebayashi J, Toi M, Noda M. Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity. Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity. Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity. Oncotarget, 13;7, 50, 82158-82169 Oncotarget, 13;7, 50, 82158-82169 Oncotarget, 13;7, 50, 82158-82169 2016/12 公開
Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M. Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M. Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. Breast Cancer Res., 19;18, 1, 129 Breast Cancer Res., 19;18, 1, 129 Breast Cancer Res., 19;18, 1, 129 2016/12 公開
Benson JR, Jatoi I, Toi M. Benson JR, Jatoi I, Toi M. Benson JR, Jatoi I, Toi M. Treatment of low-risk ductal carcinoma in situ: is nothing better than something? Treatment of low-risk ductal carcinoma in situ: is nothing better than something? Treatment of low-risk ductal carcinoma in situ: is nothing better than something? Lancet Oncol., 17, 10, e442-e451. Lancet Oncol., 17, 10, e442-e451. Lancet Oncol., 17, 10, e442-e451. 2016/10 公開
Jatoi I, Benson JR, Toi M. Jatoi I, Benson JR, Toi M. Jatoi I, Benson JR, Toi M. De-escalation of axillary surgery in early breast cancer. De-escalation of axillary surgery in early breast cancer. De-escalation of axillary surgery in early breast cancer. Lancet Oncol., 17, 10, e430-e441 Lancet Oncol., 17, 10, e430-e441 Lancet Oncol., 17, 10, e430-e441 2016/10 公開
Suzuki E, Mackenzie L, Sanson-Fisher R, Carey M, D'Este C, Asada H, Toi M. Suzuki E, Mackenzie L, Sanson-Fisher R, Carey M, D'Este C, Asada H, Toi M. Suzuki E, Mackenzie L, Sanson-Fisher R, Carey M, D'Este C, Asada H, Toi M. Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japa Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japa Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japa Int J Behav Med, 23, 4, 485-491 Int J Behav Med, 23, 4, 485-491 Int J Behav Med, 23, 4, 485-491 2016/08 英語 公開
Lee ES, Han W, Shin HC, Takada M, Ryu HS, Cho N, Kim MK, Kim J, Yoo TK, Moon HG, Toi M, Moon WK, Park IA, Noh DY. Lee ES, Han W, Shin HC, Takada M, Ryu HS, Cho N, Kim MK, Kim J, Yoo TK, Moon HG, Toi M, Moon WK, Park IA, Noh DY. Lee ES, Han W, Shin HC, Takada M, Ryu HS, Cho N, Kim MK, Kim J, Yoo TK, Moon HG, Toi M, Moon WK, Park IA, Noh DY. Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgery. Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgery. Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgery. Eur J Surg Oncol, 42, 8, 1169-1175 Eur J Surg Oncol, 42, 8, 1169-1175 Eur J Surg Oncol, 42, 8, 1169-1175 2016/08 公開
Ueno T, Utsumi J, Toi M, Shimizu K. Ueno T, Utsumi J, Toi M, Shimizu K. Ueno T, Utsumi J, Toi M, Shimizu K. Characteristic gene expression profiles of human fibroblasts and breast cancer cells in a newly developed bilateral coculture system. Characteristic gene expression profiles of human fibroblasts and breast cancer cells in a newly developed bilateral coculture system. Characteristic gene expression profiles of human fibroblasts and breast cancer cells in a newly developed bilateral coculture system. Biomed Res Int, 11 Biomed Res Int, 11 Biomed Res Int, 11 2016/06 公開
Li W, Itou J,Tanaka S, Nishimura T, Sato F, Toi M. Li W, Itou J,Tanaka S, Nishimura T, Sato F, Toi M. Li W, Itou J, Tanaka S, Nishimura T, Sato F, Toi M. A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells. A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells. A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells. Exp Cell Res, 1;343, 2, 177-189 Exp Cell Res, 1;343, 2, 177-189 Exp Cell Res, 1;343, 2, 177-189 2016/05 公開
Buyse M, Hurvitz SA, Andre F, Jiang Z, Burris HA, Toi M, Eiermann W, Lindsay MA, Slamon D. Buyse M, Hurvitz SA, Andre F, Jiang Z, Burris HA, Toi M, Eiermann W, Lindsay MA, Slamon D. Buyse M, Hurvitz SA, Andre F, Jiang Z, Burris HA, Toi M, Eiermann W, Lindsay MA, Slamon D. Statistical controversies in clinical research: statistical significance-too much of a good thing …. Statistical controversies in clinical research: statistical significance-too much of a good thing …. Statistical controversies in clinical research: statistical significance-too much of a good thing …. Ann Oncol, 27, 5, 760-762 Ann Oncol, 27, 5, 760-762 Ann Oncol, 27, 5, 760-762 2016/05 公開
Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. For choosing axillary treatment, and adjuvant hormonal treatment. For choosing axillary treatment, and adjuvant hormonal treatment. For choosing axillary treatment, and adjuvant hormonal treatment. Breast Cancer, 23, 2, 167-169 Breast Cancer, 23, 2, 167-169 Breast Cancer, 23, 2, 167-169 2016/03 英語 公開
Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, Sugimura H, Sugiyama Y, Toi M, Irimura T. Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, Sugimura H, Sugiyama Y, Toi M, Irimura T. Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, Sugimura H, Sugiyama Y, Toi M, Irimura T. Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. Cancer Sci, 107, 2, 189-202 Cancer Sci, 107, 2, 189-202 Cancer Sci, 107, 2, 189-202 2016/02 公開
Sato F, Saji S, Toi M. Sato F, Saji S, Toi M. Sato F, Saji S, Toi M. Genomic tumor evolution of breast cancer. Genomic tumor evolution of breast cancer. Genomic tumor evolution of breast cancer. Breast Cancer, 23, 1, 4-11 Breast Cancer, 23, 1, 4-11 Breast Cancer, 23, 1, 4-11 2016/01 英語 公開
Sugie T, Kinoshita T, Masuda N, Sawada T, Yamauchi A, Kuroi K, Taguchi T, Bando H, Yamashiro H, Lee T, Shinkura N, Kato H, Ikeda T, Yoshimura K, Ueyama H, Toi M. Sugie T, Kinoshita T, Masuda N, Sawada T, Yamauchi A, Kuroi K, Taguchi T, Bando H, Yamashiro H, Lee T, Shinkura N, Kato H, Ikeda T, Yoshimura K, Ueyama H, Toi M. Evaluation of the Clinical utility of the ICG fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer. Evaluation of the Clinical utility of the ICG fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer. Evaluation of the Clinical utility of the ICG fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer. Ann Surg Oncol, 23, 1, 44-50 Ann Surg Oncol, 23, 1, 44-50 Ann Surg Oncol, 23, 1, 44-50 2016/01 公開
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet, 3;386, 10001, 1353-1361 Lancet, 3;386, 10001, 1353-1361 Lancet, 3;386, 10001, 1353-1361 2016/01 公開
Kawaguchi-Sakita N, Kaneshiro-Nakagawa K, Kawashima M, Sugimoto M, Tokiwa M, Suzuki E, Kajihara S, Fujita Y, Iwamoto S, Tanaka K, Toi M Kawaguchi-Sakita N, Kaneshiro-Nakagawa K, Kawashima M, Sugimoto M, Tokiwa M, Suzuki E, Kajihara S, Fujita Y, Iwamoto S, Tanaka K, Toi M Serum immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. Serum immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. Serum immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. Biochem Biophys Res Commun, 22;469, 4, 1140-1145 Biochem Biophys Res Commun, 22;469, 4, 1140-1145 Biochem Biophys Res Commun, 22;469, 4, 1140-1145 2015/12 公開
Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. Personalization of loco-regional care for primary breast cancer patients (part 2). Personalization of loco-regional care for primary breast cancer patients (part 2). Personalization of loco-regional care for primary breast cancer patients (part 2). Future Oncol, 11, 9, 1301-1305 Future Oncol, 11, 9, 1301-1305 Future Oncol, 11, 9, 1301-1305 2015/11 公開
Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. Personalization of loco-regional care for primary breast cancer patients (part 1). Personalization of loco-regional care for primary breast cancer patients (part 1). Personalization of loco-regional care for primary breast cancer patients (part 1). Future Oncol, 11, 9, 1297-1300 Future Oncol, 11, 9, 1297-1300 Future Oncol, 11, 9, 1297-1300 2015/11 公開
Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F. Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F. Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. Breast Cancer., 22, 6, 586-596 Breast Cancer., 22, 6, 586-596 Breast Cancer., 22, 6, 586-596 2015/11 公開
Fakhrejahani E, Torii M, Kitai T, Kanao S, Asao Y, Hashizume Y, Mikami Y, Yamaga I, Kataoka M, Sugie T, Takada M, Haga H, Togashi K, Shiina T, Toi M. Fakhrejahani E, Torii M, Kitai T, Kanao S, Asao Y, Hashizume Y, Mikami Y, Yamaga I, Kataoka M, Sugie T, Takada M, Haga H, Togashi K, Shiina T, Toi M. Clinical report on the first prototype of a photoacoustic tomography system with dual illumination for breast cancer imaging. Clinical report on the first prototype of a photoacoustic tomography system with dual illumination for breast cancer imaging. Clinical report on the first prototype of a photoacoustic tomography system with dual illumination for breast cancer imaging. PLoS One, Oct 27;10, 10, e0139113 PLoS One, Oct 27;10, 10, e0139113 PLoS One, Oct 27;10, 10, e0139113 2015/10 公開
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet, 3;386, 10001, 1341-1352 Lancet, 3;386, 10001, 1341-1352 Lancet, 3;386, 10001, 1341-1352 2015/10 公開
Mukai H, Masuda N, Ishiguro H, Mitsuma A, Shibata T, Yamamura J, Toi M, Watabe A, Sarashina A, Uttenreuther-Fischer M, Ando Y. Mukai H, Masuda N, Ishiguro H, Mitsuma A, Shibata T, Yamamura J, Toi M, Watabe A, Sarashina A, Uttenreuther-Fischer M, Ando Y. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Cancer Chemother Pharmacol., 76, 4, 739-750 Cancer Chemother Pharmacol., 76, 4, 739-750 Cancer Chemother Pharmacol., 76, 4, 739-750 2015/10 公開
Suzuki E, Mackenzie L, Sanson-Fisher R, Carey M, D'Este C, Asada H, Toi M Suzuki E, Mackenzie L, Sanson-Fisher R, Carey M, D'Este C, Asada H, Toi M Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japan. Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japan. Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japan. Int J Behav Med Int J Behav Med Int J Behav Med 2015/08 公開
Sato F, Saji S, Toi M Sato F, Saji S, Toi M Genomic tumor evolution of breast cancer. Breast Cancer Genomic tumor evolution of breast cancer. Breast Cancer Genomic tumor evolution of breast cancer. Breast Cancer Breast Cancer, 22 Breast Cancer, 22 Breast Cancer, 22 2015/05 公開
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members. -Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. -Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. -Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol, 26, 8, 1533-1546 Ann Oncol, 26, 8, 1533-1546 Ann Oncol, 26, 8, 1533-1546 2015/05 公開
Toi M, Masuda N, Ishiguro H, Saji S, Ohno S, Chow LW Toi M, Masuda N, Ishiguro H, Saji S, Ohno S, Chow LW Toi M, Masuda N, Ishiguro H, Saji S, Ohno S, Chow LW Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting. Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting. Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting. Int J Biol Markers, Feb 7;30, 2 Int J Biol Markers, Feb 7;30, 2 Int J Biol Markers, Feb 7;30, 2 2015/02 公開
Suzuki E, Kataoka TR, Hirata M, Kawaguchi K, Nishie M, Haga H, Toi M. Suzuki E, Kataoka TR, Hirata M, Kawaguchi K, Nishie M, Haga H, Toi M. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. BMC Cancer, 6;15, 1, 39 BMC Cancer, 6;15, 1, 39 BMC Cancer, 6;15, 1, 39 2015/02 公開
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M. Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. Int J Clin Oncol, 20, 4, 723-724 Int J Clin Oncol, 20, 4, 723-724 Int J Clin Oncol, 20, 4, 723-724 2015/02 公開
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D. Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol, 16, 7, 816-829 Lancet Oncol, 16, 7, 816-829 Lancet Oncol, 16, 7, 816-829 2015/01 公開
Goto Y, Zeng L, Yeom CJ, Zhu Y, Morinibu A, Shinomiya K, Kobayashi M, Hirota K, Itasaka S, Yoshimura M, Tanimoto K, Torii M, Sowa T, Menju T, Sonobe M, Kakeya H, Toi M, Date H, Hammond EM, Hiraoka M, Harada H. Goto Y, Zeng L, Yeom CJ, Zhu Y, Morinibu A, Shinomiya K, Kobayashi M, Hirota K, Itasaka S, Yoshimura M, Tanimoto K, Torii M, Sowa T, Menju T, Sonobe M, Kakeya H, Toi M, Date H, Hammond EM, Hiraoka M, Harada H. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nat Commun. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nat Commun. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nat Commun. Nature Communications, 23, 6, 6153 Nature Communications, 23, 6, 6153 Nature Communications, 23, 6, 6153 2015/01 公開
Sugimoto M, Takada M, Toi M. Sugimoto M, Takada M, Toi M. Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients. Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients. Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients. Int J Biol Markers, 29, 4, e372-379 Int J Biol Markers, 29, 4, e372-379 Int J Biol Markers, 29, 4, e372-379 2014/12 英語 公開
Sumi E, Sugie T, Yoshimura K, Tada H, Ikeda T, Suzuki E, Tanaka Y, Teramukai S, Shimizu A, Toi M, Minato N. Sumi E, Sugie T, Yoshimura K, Tada H, Ikeda T, Suzuki E, Tanaka Y, Teramukai S, Shimizu A, Toi M, Minato N. Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. J Transl Med, 25, 12 J Transl Med, 25, 12 J Transl Med, 25, 12 2014/11 公開
Itou J, Tanaka S, Sato F, Akiyama R, Kawakami Y, Toi M Itou J, Tanaka S, Sato F, Akiyama R, Kawakami Y, Toi M Itou J, Tanaka S, Sato F, Akiyama R, Kawakami Y, Toi M An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer Biochim Biophys Acta., 1853, 1, 27-40 Biochim Biophys Acta., 1853, 1, 27-40 Biochim Biophys Acta., 1853, 1, 27-40 2014/10 公開
Fakhrejahani E, Asao Y, Toi M Fakhrejahani E, Asao Y, Toi M Fakhrejahani E, Asao Y, Toi M Tumor microvasculature characteristics studied by image analysis: Histologically-driven angiogenic profile. Tumor microvasculature characteristics studied by image analysis: Histologically-driven angiogenic profile. Tumor microvasculature characteristics studied by image analysis: Histologically-driven angiogenic profile. Int J Biol Markers, 29, 3, 204-207 Int J Biol Markers, 29, 3, 204-207 Int J Biol Markers, 29, 3, 204-207 2014/09 公開
Masuda N, Higaki K, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S, Toi M Masuda N, Higaki K, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S, Toi M Masuda N, Higaki K, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S, Toi M A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer Cancer Chemother Pharmacol, 74, 2, 229-238 Cancer Chemother Pharmacol, 74, 2, 229-238 Cancer Chemother Pharmacol, 74, 2, 229-238 2014/08 公開
Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer AJR Am J Roentgenol, 203, 2, 272-279 AJR Am J Roentgenol, 203, 2, 272-279 AJR Am J Roentgenol, 203, 2, 272-279 2014/08 公開
Sugimoto M, Takada M, Toi M Sugimoto M, Takada M, Toi M Sugimoto M, Takada M, Toi M Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients Int J Biol Markers Int J Biol Markers Int J Biol Markers 2014/07 公開
Mukai H, Noguchi S, Akiyama F, Inaji H, Iwase H, Horiguchi J, Kurebayashi J, Hirata K, Toi M, Kurosumi M, Kohno N, Nishimura R, Nakamura S, Imoto S, Iwase T, Endo T, Saeki T, Ogawa Y, Ito Y, Tokuda Y, Ikeda T Mukai H, Noguchi S, Akiyama F, Inaji H, Iwase H, Horiguchi J, Kurebayashi J, Hirata K, Toi M, Kurosumi M, Kohno N, Nishimura R, Nakamura S, Imoto S, Iwase T, Endo T, Saeki T, Ogawa Y, Ito Y, Tokuda Y, Ikeda T Mukai H, Noguchi S, Akiyama F, Inaji H, Iwase H, Horiguchi J, Kurebayashi J, Hirata K, Toi M, Kurosumi M, Kohno N, Nishimura R, Nakamura S, Imoto S, Iwase T, Endo T, Saeki T, Ogawa Y, Ito Y, Tokuda Y, Ikeda T 2013 clinical practice guidelines (The Japanese Breast Cancer Society) 2013 clinical practice guidelines (The Japanese Breast Cancer Society) 2013 clinical practice guidelines (The Japanese Breast Cancer Society) history, policy and mission. Breast Cancer history, policy and mission. Breast Cancer history, policy and mission. Breast Cancer 2014/07 公開
M. Takada; H. Ishiguro; S. Nagai; S. Ohtani; H. Kawabata; Y. Yanagita; Y. Hozumi; C. Shimizu; S. Takao; N. Sato; Y. Kosaka; Y. Sagara; H. Iwata; S. Ohno; K. Kuroi; N. Masuda; H. Yamashiro; M. Sugimoto; M. Kondo; Y. Naito; H. Sasano; T. Inamoto; S. Morita; M. Toi M. Takada; H. Ishiguro; S. Nagai; S. Ohtani; H. Kawabata; Y. Yanagita; Y. Hozumi; C. Shimizu; S. Takao; N. Sato; Y. Kosaka; Y. Sagara; H. Iwata; S. Ohno; K. Kuroi; N. Masuda; H. Yamashiro; M. Sugimoto; M. Kondo; Y. Naito; H. Sasano; T. Inamoto; S. Morita; M. Toi M. Takada; H. Ishiguro; S. Nagai; S. Ohtani; H. Kawabata; Y. Yanagita; Y. Hozumi; C. Shimizu; S. Takao; N. Sato; Y. Kosaka; Y. Sagara; H. Iwata; S. Ohno; K. Kuroi; N. Masuda; H. Yamashiro; M. Sugimoto; M. Kondo; Y. Naito; H. Sasano; T. Inamoto; S. Morita; M. Toi Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study) Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study) Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study) Breast Cancer Research and Treatment, 145, 1, 143-153 Breast Cancer Research and Treatment, 145, 1, 143-153 Breast Cancer Research and Treatment, 145, 1, 143-153 2014/05 英語 公開
F. André; R. O'Regan; M. Ozguroglu; M. Toi; B. Xu; G. Jerusalem; N. Masuda; S. Wilks; F. Arena; C. Isaacs; Y.-S. Yap; Z. Papai; I. Lang; A. Armstrong; G. Lerzo; M. White; K. Shen; J. Litton; D. Chen; Y. Zhang; S. Ali; T. Taran; L. Gianni F. André; R. O'Regan; M. Ozguroglu; M. Toi; B. Xu; G. Jerusalem; N. Masuda; S. Wilks; F. Arena; C. Isaacs; Y.-S. Yap; Z. Papai; I. Lang; A. Armstrong; G. Lerzo; M. White; K. Shen; J. Litton; D. Chen; Y. Zhang; S. Ali; T. Taran; L. Gianni F. André; R. O'Regan; M. Ozguroglu; M. Toi; B. Xu; G. Jerusalem; N. Masuda; S. Wilks; F. Arena; C. Isaacs; Y.-S. Yap; Z. Papai; I. Lang; A. Armstrong; G. Lerzo; M. White; K. Shen; J. Litton; D. Chen; Y. Zhang; S. Ali; T. Taran; L. Gianni Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial The Lancet Oncology, 15, 6, 580-591 The Lancet Oncology, 15, 6, 580-591 The Lancet Oncology, 15, 6, 580-591 2014/04 英語 公開
N. Onishi; S. Kanao; M. Kataoka; M. Iima; R. Sakaguchi; M. Kawai; T.R. Kataoka; Y. Mikami; M. Toi; K. Togashi N. Onishi; S. Kanao; M. Kataoka; M. Iima; R. Sakaguchi; M. Kawai; T.R. Kataoka; Y. Mikami; M. Toi; K. Togashi N. Onishi; S. Kanao; M. Kataoka; M. Iima; R. Sakaguchi; M. Kawai; T.R. Kataoka; Y. Mikami; M. Toi; K. Togashi Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma Journal of Magnetic Resonance Imaging Journal of Magnetic Resonance Imaging Journal of Magnetic Resonance Imaging 2014/03 英語 公開
Fakhrejahani E, Toi M Fakhrejahani E, Toi M Fakhrejahani E, Toi M Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials Jpn J Clin Oncol, 44, 3, 197-207 Jpn J Clin Oncol, 44, 3, 197-207 Jpn J Clin Oncol, 44, 3, 197-207 2014/03 公開
K. Kuroi; M. Toi; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; N. Sato; H. Tsuda; M. Kurosumi; F. Akiyama K. Kuroi; M. Toi; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; N. Sato; H. Tsuda; M. Kurosumi; F. Akiyama K. Kuroi; M. Toi; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; N. Sato; H. Tsuda; M. Kurosumi; F. Akiyama Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG Breast Cancer, 1-10 Breast Cancer, 1-10 Breast Cancer, 1-10 2014/02 英語 公開
W. Tsuji; S. Teramukai; M. Ueno; M. Toi; T. Inamoto W. Tsuji; S. Teramukai; M. Ueno; M. Toi; T. Inamoto W. Tsuji; S. Teramukai; M. Ueno; M. Toi; T. Inamoto Prognostic factors for survival after first recurrence in breast cancer: A retrospective analysis of 252 recurrent cases at a single institution Prognostic factors for survival after first recurrence in breast cancer: A retrospective analysis of 252 recurrent cases at a single institution Prognostic factors for survival after first recurrence in breast cancer: A retrospective analysis of 252 recurrent cases at a single institution Breast Cancer, 21, 1, 86-95 Breast Cancer, 21, 1, 86-95 Breast Cancer, 21, 1, 86-95 2014/01 英語 公開
M. Toi; T. Saeki; H. Iwata; K. Inoue; Y. Tokuda; Y. Sato; Y. Ito; K. Aogi; Y. Takatsuka; H. Arioka M. Toi; T. Saeki; H. Iwata; K. Inoue; Y. Tokuda; Y. Sato; Y. Ito; K. Aogi; Y. Takatsuka; H. Arioka M. Toi; T. Saeki; H. Iwata; K. Inoue; Y. Tokuda; Y. Sato; Y. Ito; K. Aogi; Y. Takatsuka; H. Arioka A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance Breast Cancer, 21, 1, 20-27 Breast Cancer, 21, 1, 20-27 Breast Cancer, 21, 1, 20-27 2014 英語 公開
T. Kitai; M. Torii; T. Sugie; S. Kanao; Y. Mikami; T. Shiina; M. Toi T. Kitai; M. Torii; T. Sugie; S. Kanao; Y. Mikami; T. Shiina; M. Toi T. Kitai; M. Torii; T. Sugie; S. Kanao; Y. Mikami; T. Shiina; M. Toi Photoacoustic mammography: Initial clinical results Photoacoustic mammography: Initial clinical results Photoacoustic mammography: Initial clinical results Breast Cancer, 21, 2, 146-153 Breast Cancer, 21, 2, 146-153 Breast Cancer, 21, 2, 146-153 2014 英語 公開
A.-A. Lertkhachonsuk; C.H. Yip; T. Khuhaprema; D.-S. Chen; M. Plummer; S.H. Jee; M. Toi; S. Wilailak A.-A. Lertkhachonsuk; C.H. Yip; T. Khuhaprema; D.-S. Chen; M. Plummer; S.H. Jee; M. Toi; S. Wilailak A.-A. Lertkhachonsuk; C.H. Yip; T. Khuhaprema; D.-S. Chen; M. Plummer; S.H. Jee; M. Toi; S. Wilailak Cancer prevention in asia: Resource-stratified guidelines from the asian oncology summit 2013 Cancer prevention in asia: Resource-stratified guidelines from the asian oncology summit 2013 Cancer prevention in asia: Resource-stratified guidelines from the asian oncology summit 2013 The Lancet Oncology, 14, 12, E497-E507 The Lancet Oncology, 14, 12, E497-E507 The Lancet Oncology, 14, 12, E497-E507 2013/11 英語 公開
M. Kawashima; N. Iwamoto; N. Kawaguchi-Sakita; M. Sugimoto; T. Ueno; Y. Mikami; K. Terasawa; T.-A. Sato; K. Tanaka; K. Shimizu; M. Toi M. Kawashima; N. Iwamoto; N. Kawaguchi-Sakita; M. Sugimoto; T. Ueno; Y. Mikami; K. Terasawa; T.-A. Sato; K. Tanaka; K. Shimizu; M. Toi M. Kawashima; N. Iwamoto; N. Kawaguchi-Sakita; M. Sugimoto; T. Ueno; Y. Mikami; K. Terasawa; T.-A. Sato; K. Tanaka; K. Shimizu; M. Toi High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer Cancer Science, 104, 10, 1372-1379 Cancer Science, 104, 10, 1372-1379 Cancer Science, 104, 10, 1372-1379 2013/10 英語 公開
J. Itou; Y. Matsumoto; K. Yoshikawa; M. Toi J. Itou; Y. Matsumoto; K. Yoshikawa; M. Toi J. Itou; Y. Matsumoto; K. Yoshikawa; M. Toi Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer FEBS Letters, 587, 18, 3115-3121 FEBS Letters, 587, 18, 3115-3121 FEBS Letters, 587, 18, 3115-3121 2013/09/17 英語 公開
A. Goldhirsch; E.P. Winer; A.S. Coates; R.D. Gelber; M. Piccart-Gebhart; B. Thürlimann; H.-J. Senn; K.S. Albain; F. André; J. Bergh; H. Bonnefoi; D. Bretel-Morales; H. Burstein; F. Cardoso; M. Castiglione-Gertsch; A.S. Coates; M. Colleoni; A. Costa; G. Curigliano; N.E. Davidson; A.D. Leo; B. Ejlertsen; J.F. Forbes; R.D. Gelber; M. Gnant; A. Goldhirsch; P. Goodwin; P.E. Goss; J.R. Harris; D.F. Hayes; C.A. Hudis; J.N. Ingle; J. Jassem; Z. Jiang; P. Karlsson; S. Loibl; M. Morrow; M. Namer; C.K. Osborne; A.H. Partridge; F. Penault-Llorca; C.M. Perou; M.J. Piccart-Gebhart; K.I. Pritchard; E.J.T. Rutgers; F. Sedlmayer; V. Semiglazov; Z.-M. Shao; I. Smith; B. Thürlimann; M. Toi; A. Tutt; M. Untch; G. Viale; T. Watanabe; N. Wilcken; E.P. Winer; W.C. Wood A. Goldhirsch; E.P. Winer; A.S. Coates; R.D. Gelber; M. Piccart-Gebhart; B. Thürlimann; H.-J. Senn; K.S. Albain; F. André; J. Bergh; H. Bonnefoi; D. Bretel-Morales; H. Burstein; F. Cardoso; M. Castiglione-Gertsch; A.S. Coates; M. Colleoni; A. Costa; G. Curigliano; N.E. Davidson; A.D. Leo; B. Ejlertsen; J.F. Forbes; R.D. Gelber; M. Gnant; A. Goldhirsch; P. Goodwin; P.E. Goss; J.R. Harris; D.F. Hayes; C.A. Hudis; J.N. Ingle; J. Jassem; Z. Jiang; P. Karlsson; S. Loibl; M. Morrow; M. Namer; C.K. Osborne; A.H. Partridge; F. Penault-Llorca; C.M. Perou; M.J. Piccart-Gebhart; K.I. Pritchard; E.J.T. Rutgers; F. Sedlmayer; V. Semiglazov; Z.-M. Shao; I. Smith; B. Thürlimann; M. Toi; A. Tutt; M. Untch; G. Viale; T. Watanabe; N. Wilcken; E.P. Winer; W.C. Wood A. Goldhirsch; E.P. Winer; A.S. Coates; R.D. Gelber; M. Piccart-Gebhart; B. Thürlimann; H.-J. Senn; K.S. Albain; F. André; J. Bergh; H. Bonnefoi; D. Bretel-Morales; H. Burstein; F. Cardoso; M. Castiglione-Gertsch; A.S. Coates; M. Colleoni; A. Costa; G. Curigliano; N.E. Davidson; A.D. Leo; B. Ejlertsen; J.F. Forbes; R.D. Gelber; M. Gnant; A. Goldhirsch; P. Goodwin; P.E. Goss; J.R. Harris; D.F. Hayes; C.A. Hudis; J.N. Ingle; J. Jassem; Z. Jiang; P. Karlsson; S. Loibl; M. Morrow; M. Namer; C.K. Osborne; A.H. Partridge; F. Penault-Llorca; C.M. Perou; M.J. Piccart-Gebhart; K.I. Pritchard; E.J.T. Rutgers; F. Sedlmayer; V. Semiglazov; Z.-M. Shao; I. Smith; B. Thürlimann; M. Toi; A. Tutt; M. Untch; G. Viale; T. Watanabe; N. Wilcken; E.P. Winer; W.C. Wood Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013 Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013 Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013 Annals of Oncology, 24, 9, 2206-2223 Annals of Oncology, 24, 9, 2206-2223 Annals of Oncology, 24, 9, 2206-2223 2013/09 英語 公開
H. Ishiguro; M. Toi H. Ishiguro; M. Toi H. Ishiguro; M. Toi Colony-stimulating factors for febrile neutropenia [5] Colony-stimulating factors for febrile neutropenia [5] Colony-stimulating factors for febrile neutropenia [5] New England Journal of Medicine, 369, 3, 284-284 New England Journal of Medicine, 369, 3, 284-284 New England Journal of Medicine, 369, 3, 284-284 2013/07/18 英語 公開
T. Sugie; T. Sawada; N. Tagaya; T. Kinoshita; K. Yamagami; H. Suwa; T. Ikeda; K. Yoshimura; M. Niimi; A. Shimizu; M. Toi T. Sugie; T. Sawada; N. Tagaya; T. Kinoshita; K. Yamagami; H. Suwa; T. Ikeda; K. Yoshimura; M. Niimi; A. Shimizu; M. Toi T. Sugie; T. Sawada; N. Tagaya; T. Kinoshita; K. Yamagami; H. Suwa; T. Ikeda; K. Yoshimura; M. Niimi; A. Shimizu; M. Toi Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer Annals of Surgical Oncology, 20, 7, 2213-2218 Annals of Surgical Oncology, 20, 7, 2213-2218 Annals of Surgical Oncology, 20, 7, 2213-2218 2013/07 英語 公開
M. Komuro; K. Suzuki; M. Kanebako; T. Kawahara; T. Otoi; K. Kitazato; T. Inagi; K. Makino; M. Toi; H. Terada M. Komuro; K. Suzuki; M. Kanebako; T. Kawahara; T. Otoi; K. Kitazato; T. Inagi; K. Makino; M. Toi; H. Terada M. Komuro; K. Suzuki; M. Kanebako; T. Kawahara; T. Otoi; K. Kitazato; T. Inagi; K. Makino; M. Toi; H. Terada Novel iontophoretic administration method for local therapy of breast cancer Novel iontophoretic administration method for local therapy of breast cancer Novel iontophoretic administration method for local therapy of breast cancer Journal of Controlled Release, 168, 3, 298-306 Journal of Controlled Release, 168, 3, 298-306 Journal of Controlled Release, 168, 3, 298-306 2013/06/28 英語 公開
A.S.M. Idrees; T. Sugie; C. Inoue; K. Murata-Hirai; H. Okamura; C.T. Morita; N. Minato; M. Toi; Y. Tanaka A.S.M. Idrees; T. Sugie; C. Inoue; K. Murata-Hirai; H. Okamura; C.T. Morita; N. Minato; M. Toi; Y. Tanaka A.S.M. Idrees; T. Sugie; C. Inoue; K. Murata-Hirai; H. Okamura; C.T. Morita; N. Minato; M. Toi; Y. Tanaka Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid Cancer Science, 104, 5, 536-542 Cancer Science, 104, 5, 536-542 Cancer Science, 104, 5, 536-542 2013/05 日本語 公開
H. Ishiguro; K. Kawaguchi; T. Nishimura; M. Toi H. Ishiguro; K. Kawaguchi; T. Nishimura; M. Toi H. Ishiguro; K. Kawaguchi; T. Nishimura; M. Toi Antipsychotics-containing regimen as an alternative to standard antiemetics for delayed nausea induced by highly emetogenic chemotherapy Antipsychotics-containing regimen as an alternative to standard antiemetics for delayed nausea induced by highly emetogenic chemotherapy Antipsychotics-containing regimen as an alternative to standard antiemetics for delayed nausea induced by highly emetogenic chemotherapy Journal of Clinical Oncology, 31, 10, 1377-1378 Journal of Clinical Oncology, 31, 10, 1377-1378 Journal of Clinical Oncology, 31, 10, 1377-1378 2013/04/01 英語 公開
W. Li; S. Saji; F. Sato; M. Noda; M. Toi W. Li; S. Saji; F. Sato; M. Noda; M. Toi W. Li; S. Saji; F. Sato; M. Noda; M. Toi Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects International Journal of Biological Markers, 28, 2, 117-130 International Journal of Biological Markers, 28, 2, 117-130 International Journal of Biological Markers, 28, 2, 117-130 2013/04 日本語 公開
L.W. Chow; S.Y. Tung; T.-Y. Ng; S.-A. Im; M.-H. Lee; A.Y. Yip; M. Toi; S. Glück L.W. Chow; S.Y. Tung; T.-Y. Ng; S.-A. Im; M.-H. Lee; A.Y. Yip; M. Toi; S. Glück L.W. Chow; S.Y. Tung; T.-Y. Ng; S.-A. Im; M.-H. Lee; A.Y. Yip; M. Toi; S. Glück Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: The OOTR-N001 study Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: The OOTR-N001 study Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: The OOTR-N001 study Expert Opinion on Investigational Drugs, 22, 3, 299-307 Expert Opinion on Investigational Drugs, 22, 3, 299-307 Expert Opinion on Investigational Drugs, 22, 3, 299-307 2013/03 英語 公開
W. Tsuji; T. Inamoto; R. Ito; N. Morimoto; Y. Tabata; M. Toi W. Tsuji; T. Inamoto; R. Ito; N. Morimoto; Y. Tabata; M. Toi W. Tsuji; T. Inamoto; R. Ito; N. Morimoto; Y. Tabata; M. Toi Simple and longstanding adipose tissue engineering in rabbits Simple and longstanding adipose tissue engineering in rabbits Simple and longstanding adipose tissue engineering in rabbits Journal of Artificial Organs, 16, 1, 110-114 Journal of Artificial Organs, 16, 1, 110-114 Journal of Artificial Organs, 16, 1, 110-114 2013/03 英語 公開
T. Sugie; K. Murata-Hirai; M. Iwasaki; C.T. Morita; W. Li; H. Okamura; N. Minato; M. Toi; Y. Tanaka T. Sugie; K. Murata-Hirai; M. Iwasaki; C.T. Morita; W. Li; H. Okamura; N. Minato; M. Toi; Y. Tanaka T. Sugie; K. Murata-Hirai; M. Iwasaki; C.T. Morita; W. Li; H. Okamura; N. Minato; M. Toi; Y. Tanaka Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: Effect of IL-18 on helper NK cells Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: Effect of IL-18 on helper NK cells Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: Effect of IL-18 on helper NK cells Cancer Immunology, Immunotherapy, 62, 4, 677-687 Cancer Immunology, Immunotherapy, 62, 4, 677-687 Cancer Immunology, Immunotherapy, 62, 4, 677-687 2013 日本語 公開
Mikami, Yoshiki;Ueno, Takayuki;Yoshimura, Kenichi;Tsuda, Hitoshi;Kurosumi, Masafumi;Masuda, Shinobu;Horii, Rie;Toi, Masakazu;Sasano, Hironobu Mikami, Yoshiki;Ueno, Takayuki;Yoshimura, Kenichi;Tsuda, Hitoshi;Kurosumi, Masafumi;Masuda, Shinobu;Horii, Rie;Toi, Masakazu;Sasano, Hironobu Mikami, Yoshiki;Ueno, Takayuki;Yoshimura, Kenichi;Tsuda, Hitoshi;Kurosumi, Masafumi;Masuda, Shinobu;Horii, Rie;Toi, Masakazu;Sasano, Hironobu Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer science Cancer science Cancer science 2013 英語 公開
Tsuji, Wakako;Ishiguro, Hiroshi;Tanaka, Sunao;Takeuchi, Megumi;Ueno, Takayuki;Toi, Masakazu Tsuji, Wakako;Ishiguro, Hiroshi;Tanaka, Sunao;Takeuchi, Megumi;Ueno, Takayuki;Toi, Masakazu Tsuji, Wakako;Ishiguro, Hiroshi;Tanaka, Sunao;Takeuchi, Megumi;Ueno, Takayuki;Toi, Masakazu Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients. Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients. Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients. International journal of clinical oncology International journal of clinical oncology International journal of clinical oncology 2013 英語 公開
Ueno, Takayuki;Masuda, Norikazu;Yamanaka, Takeharu;Saji, Shigehira;Kuroi, Katsumasa;Sato, Nobuaki;Takei, Hiroyuki;Yamamoto, Yutaka;Ohno, Shinji;Yamashita, Hiroko;Hisamatsu, Kazufumi;Aogi, Kenjiro;Iwata, Hiroji;Sasano, Hironobu;Toi, Masakazu Ueno, Takayuki;Masuda, Norikazu;Yamanaka, Takeharu;Saji, Shigehira;Kuroi, Katsumasa;Sato, Nobuaki;Takei, Hiroyuki;Yamamoto, Yutaka;Ohno, Shinji;Yamashita, Hiroko;Hisamatsu, Kazufumi;Aogi, Kenjiro;Iwata, Hiroji;Sasano, Hironobu;Toi, Masakazu Ueno, Takayuki;Masuda, Norikazu;Yamanaka, Takeharu;Saji, Shigehira;Kuroi, Katsumasa;Sato, Nobuaki;Takei, Hiroyuki;Yamamoto, Yutaka;Ohno, Shinji;Yamashita, Hiroko;Hisamatsu, Kazufumi;Aogi, Kenjiro;Iwata, Hiroji;Sasano, Hironobu;Toi, Masakazu Evaluating the 21-gene assay Recurrence Score(®) as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. Evaluating the 21-gene assay Recurrence Score(®) as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. Evaluating the 21-gene assay Recurrence Score(®) as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. International journal of clinical oncology International journal of clinical oncology International journal of clinical oncology 2013 日本語 公開
M. Chan; L. Wang; N. Chanplakorn; K. Tamaki; T. Ueno; M. Toi; W. Loo; L.W.C. Chow; T. Suzuki; H. Sasano M. Chan; L. Wang; N. Chanplakorn; K. Tamaki; T. Ueno; M. Toi; W. Loo; L.W.C. Chow; T. Suzuki; H. Sasano M. Chan; L. Wang; N. Chanplakorn; K. Tamaki; T. Ueno; M. Toi; W. Loo; L.W.C. Chow; T. Suzuki; H. Sasano Author\\'s response Author\\'s response Author\\'s response Expert Opinion on Therapeutic Targets, 17, 1, 106- Expert Opinion on Therapeutic Targets, 17, 1, 106- Expert Opinion on Therapeutic Targets, 17, 1, 106- 2013 英語 公開
B. Zheng; R. Ishikawa; J. Takamatsu; K. Ikeuchi; T. Endo; K. Sato; T. Ueno; T. Sugie; M. Toi; S. Kanao; K. Togashi B. Zheng; R. Ishikawa; J. Takamatsu; K. Ikeuchi; T. Endo; K. Sato; T. Ueno; T. Sugie; M. Toi; S. Kanao; K. Togashi B. Zheng; R. Ishikawa; J. Takamatsu; K. Ikeuchi; T. Endo; K. Sato; T. Ueno; T. Sugie; M. Toi; S. Kanao; K. Togashi Breast MR Image fusion by deformable implicit polynomial (DIP) Breast MR Image fusion by deformable implicit polynomial (DIP) Breast MR Image fusion by deformable implicit polynomial (DIP) IPSJ Transactions on Computer Vision and Applications, 5, 99-103 IPSJ Transactions on Computer Vision and Applications, 5, 99-103 IPSJ Transactions on Computer Vision and Applications, 5, 99-103 2013 英語 公開
Y. Suzuki; T. Saeki; K. Aogi; M. Toi; H. Fujii; K. Inoue; T. Watanabe; Y. Fujiwara; Y. Ito; Y. Takatsuka; H. Iwata; H. Arioka; Y. Tokuda Y. Suzuki; T. Saeki; K. Aogi; M. Toi; H. Fujii; K. Inoue; T. Watanabe; Y. Fujiwara; Y. Ito; Y. Takatsuka; H. Iwata; H. Arioka; Y. Tokuda Y. Suzuki; T. Saeki; K. Aogi; M. Toi; H. Fujii; K. Inoue; T. Watanabe; Y. Fujiwara; Y. Ito; Y. Takatsuka; H. Iwata; H. Arioka; Y. Tokuda A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane International Journal of Clinical Oncology, 18, 4, 590-597 International Journal of Clinical Oncology, 18, 4, 590-597 International Journal of Clinical Oncology, 18, 4, 590-597 2013 英語 公開
D. Cameron; J. Brown; R. Dent; C. Jackisch; J. Mackey; X. Pivot; G.G. Steger; T.M. Suter; M. Toi; M. Parmar; R. Laeufle; Y.-H. Im; G. Romieu; V. Harvey; O. Lipatov; T. Pienkowski; P. Cottu; A. Chan; S.-A. Im; P.S. Hall; L. Bubuteishvili-Pacaud; V. Henschel; R.J. Deurloo; C. Pallaud; R. Bell D. Cameron; J. Brown; R. Dent; C. Jackisch; J. Mackey; X. Pivot; G.G. Steger; T.M. Suter; M. Toi; M. Parmar; R. Laeufle; Y.-H. Im; G. Romieu; V. Harvey; O. Lipatov; T. Pienkowski; P. Cottu; A. Chan; S.-A. Im; P.S. Hall; L. Bubuteishvili-Pacaud; V. Henschel; R.J. Deurloo; C. Pallaud; R. Bell D. Cameron; J. Brown; R. Dent; C. Jackisch; J. Mackey; X. Pivot; G.G. Steger; T.M. Suter; M. Toi; M. Parmar; R. Laeufle; Y.-H. Im; G. Romieu; V. Harvey; O. Lipatov; T. Pienkowski; P. Cottu; A. Chan; S.-A. Im; P.S. Hall; L. Bubuteishvili-Pacaud; V. Henschel; R.J. Deurloo; C. Pallaud; R. Bell Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial The Lancet Oncology, 14, 10, 933-942 The Lancet Oncology, 14, 10, 933-942 The Lancet Oncology, 14, 10, 933-942 2013 英語 公開
R. Kumar; A. Horvath; R. Mazumder; M. Toi; F. Sato; M.R. Pillai; L. Costa; M. Carmo-Fonseca; S. Knapp; A. Dutt; S. Gupta; R. Badwe R. Kumar; A. Horvath; R. Mazumder; M. Toi; F. Sato; M.R. Pillai; L. Costa; M. Carmo-Fonseca; S. Knapp; A. Dutt; S. Gupta; R. Badwe R. Kumar; A. Horvath; R. Mazumder; M. Toi; F. Sato; M.R. Pillai; L. Costa; M. Carmo-Fonseca; S. Knapp; A. Dutt; S. Gupta; R. Badwe The Global Cancer Genomics Consortium\\'s Second Annual Symposium: Genomics Medicine in Cancer Research The Global Cancer Genomics Consortium\\'s Second Annual Symposium: Genomics Medicine in Cancer Research The Global Cancer Genomics Consortium\\'s Second Annual Symposium: Genomics Medicine in Cancer Research Genes and Cancer, 4, 5-6, 196-200 Genes and Cancer, 4, 5-6, 196-200 Genes and Cancer, 4, 5-6, 196-200 2013 英語 公開
C. Kaga; A. Takagi; M. Kano; S. Kado; I. Kato; M. Sakai; K. Miyazaki; M. Nanno; F. Ishikawa; Y. Ohashi; M. Toi C. Kaga; A. Takagi; M. Kano; S. Kado; I. Kato; M. Sakai; K. Miyazaki; M. Nanno; F. Ishikawa; Y. Ohashi; M. Toi C. Kaga; A. Takagi; M. Kano; S. Kado; I. Kato; M. Sakai; K. Miyazaki; M. Nanno; F. Ishikawa; Y. Ohashi; M. Toi Lactobacillus casei Shirota enhances the preventive efficacy of soymilk in chemically induced breast cancer Lactobacillus casei Shirota enhances the preventive efficacy of soymilk in chemically induced breast cancer Lactobacillus casei Shirota enhances the preventive efficacy of soymilk in chemically induced breast cancer Cancer Science, 104, 11, 1508-1514 Cancer Science, 104, 11, 1508-1514 Cancer Science, 104, 11, 1508-1514 2013 英語 公開
M. Toi; S. Hirota; A. Tomotaki; N. Sato; Y. Hozumi; K. Anan; T. Nagashima; Y. Tokuda; N. Masuda; S. Ohsumi; S. Ohno; M. Takahashi; H. Hayashi; S. Yamamoto; Y. Ohashi M. Toi; S. Hirota; A. Tomotaki; N. Sato; Y. Hozumi; K. Anan; T. Nagashima; Y. Tokuda; N. Masuda; S. Ohsumi; S. Ohno; M. Takahashi; H. Hayashi; S. Yamamoto; Y. Ohashi M. Toi; S. Hirota; A. Tomotaki; N. Sato; Y. Hozumi; K. Anan; T. Nagashima; Y. Tokuda; N. Masuda; S. Ohsumi; S. Ohno; M. Takahashi; H. Hayashi; S. Yamamoto; Y. Ohashi Probiotic beverage with soy isoflavone consumption for breast cancer prevention: A case-control study Probiotic beverage with soy isoflavone consumption for breast cancer prevention: A case-control study Probiotic beverage with soy isoflavone consumption for breast cancer prevention: A case-control study Current Nutrition and Food Science, 9, 3, 194-200 Current Nutrition and Food Science, 9, 3, 194-200 Current Nutrition and Food Science, 9, 3, 194-200 2013 英語 公開
H. Yamashiro; M. Takada; E. Nakatani; S. Imai; A. Yamauchi; S. Tsuyuki; Y. Matsutani; S. Sakata; Y. Wada; R. Okamura; T. Harada; F. Tanaka; Y. Moriguchi; H. Kato; S. Higashide; N. Kan; H. Yoshibayashi; H. Suwa; T. Okino; I. Nakayama; Y. Ichinose; K. Yamagami; T. Hashimoto; T. Inamoto; M. Toi H. Yamashiro; M. Takada; E. Nakatani; S. Imai; A. Yamauchi; S. Tsuyuki; Y. Matsutani; S. Sakata; Y. Wada; R. Okamura; T. Harada; F. Tanaka; Y. Moriguchi; H. Kato; S. Higashide; N. Kan; H. Yoshibayashi; H. Suwa; T. Okino; I. Nakayama; Y. Ichinose; K. Yamagami; T. Hashimoto; T. Inamoto; M. Toi H. Yamashiro; M. Takada; E. Nakatani; S. Imai; A. Yamauchi; S. Tsuyuki; Y. Matsutani; S. Sakata; Y. Wada; R. Okamura; T. Harada; F. Tanaka; Y. Moriguchi; H. Kato; S. Higashide; N. Kan; H. Yoshibayashi; H. Suwa; T. Okino; I. Nakayama; Y. Ichinose; K. Yamagami; T. Hashimoto; T. Inamoto; M. Toi Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan International Journal of Clinical Oncology, 1-11 International Journal of Clinical Oncology, 1-11 International Journal of Clinical Oncology, 1-11 2013 英語 公開
S. Ohno; L.W.C. Chow; N. Sato; N. Masuda; H. Sasano; F. Takahashi; H. Bando; H. Iwata; T. Morimoto; S. Kamigaki; T. Nakayama; S. Nakamura; K. Kuroi; K. Aogi; M. Kashiwaba; H. Yamashita; K. Hisamatsu; Y. Ito; Y. Yamamoto; T. Ueno; E. Fakhrejahani; N. Yoshida; M. Toi S. Ohno; L.W.C. Chow; N. Sato; N. Masuda; H. Sasano; F. Takahashi; H. Bando; H. Iwata; T. Morimoto; S. Kamigaki; T. Nakayama; S. Nakamura; K. Kuroi; K. Aogi; M. Kashiwaba; H. Yamashita; K. Hisamatsu; Y. Ito; Y. Yamamoto; T. Ueno; E. Fakhrejahani; N. Yoshida; M. Toi S. Ohno; L.W.C. Chow; N. Sato; N. Masuda; H. Sasano; F. Takahashi; H. Bando; H. Iwata; T. Morimoto; S. Kamigaki; T. Nakayama; S. Nakamura; K. Kuroi; K. Aogi; M. Kashiwaba; H. Yamashita; K. Hisamatsu; Y. Ito; Y. Yamamoto; T. Ueno; E. Fakhrejahani; N. Yoshida; M. Toi Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: Exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuva Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: Exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuva Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: Exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuva Breast Cancer Research and Treatment, 142, 1, 69-80 Breast Cancer Research and Treatment, 142, 1, 69-80 Breast Cancer Research and Treatment, 142, 1, 69-80 2013 英語 公開
K. Kuroi; M. Toi; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; N. Sato; H. Tsuda; M. Kurosumi; F. Akiyama K. Kuroi; M. Toi; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; N. Sato; H. Tsuda; M. Kurosumi; F. Akiyama K. Kuroi; M. Toi; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; N. Sato; H. Tsuda; M. Kurosumi; F. Akiyama Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG Breast Cancer, 1-10 Breast Cancer, 1-10 Breast Cancer, 1-10 2013 英語 公開
S. Ohno; K. Kuroi; M. Toi S. Ohno; K. Kuroi; M. Toi S. Ohno; K. Kuroi; M. Toi An overview of the Japan Breast Cancer Research Group (JBCRG) activities An overview of the Japan Breast Cancer Research Group (JBCRG) activities An overview of the Japan Breast Cancer Research Group (JBCRG) activities Breast Cancer, 20, 4, 291-295 Breast Cancer, 20, 4, 291-295 Breast Cancer, 20, 4, 291-295 2013 英語 公開
S. Hamada; S. Hinotsu; H. Ishiguro; M. Toi; K. Kawakami S. Hamada; S. Hinotsu; H. Ishiguro; M. Toi; K. Kawakami S. Hamada; S. Hinotsu; H. Ishiguro; M. Toi; K. Kawakami Cross-national comparison of medical costs shared by payers and patients: A study of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees Cross-national comparison of medical costs shared by payers and patients: A study of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees Cross-national comparison of medical costs shared by payers and patients: A study of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees Breast Care, 8, 4, 282-288 Breast Care, 8, 4, 282-288 Breast Care, 8, 4, 282-288 2013 英語 公開
M. Toi; J.R. Benson; E.P. Winer; J.F. Forbes; G. Von Minckwitz; M. Golshan; J.F.R. Robertson; H. Sasano; B.F. Cole; L.W.C. Chow; M.D. Pegram; W. Han; C.-S. Huang; T. Ikeda; S. Kanao; E.-S. Lee; S. Noguchi; S. Ohno; A.H. Partridge; R. Rouzier; M. Tozaki; T. Sugie; A. Yamauchi; T. Inamoto M. Toi; J.R. Benson; E.P. Winer; J.F. Forbes; G. Von Minckwitz; M. Golshan; J.F.R. Robertson; H. Sasano; B.F. Cole; L.W.C. Chow; M.D. Pegram; W. Han; C.-S. Huang; T. Ikeda; S. Kanao; E.-S. Lee; S. Noguchi; S. Ohno; A.H. Partridge; R. Rouzier; M. Tozaki; T. Sugie; A. Yamauchi; T. Inamoto M. Toi; J.R. Benson; E.P. Winer; J.F. Forbes; G. Von Minckwitz; M. Golshan; J.F.R. Robertson; H. Sasano; B.F. Cole; L.W.C. Chow; M.D. Pegram; W. Han; C.-S. Huang; T. Ikeda; S. Kanao; E.-S. Lee; S. Noguchi; S. Ohno; A.H. Partridge; R. Rouzier; M. Tozaki; T. Sugie; A. Yamauchi; T. Inamoto Preoperative systemic therapy in locoregional management of early breast cancer: Highlights from the Kyoto Breast Cancer Consensus Conference Preoperative systemic therapy in locoregional management of early breast cancer: Highlights from the Kyoto Breast Cancer Consensus Conference Preoperative systemic therapy in locoregional management of early breast cancer: Highlights from the Kyoto Breast Cancer Consensus Conference Breast Cancer Research and Treatment, 136, 3, 919-926 Breast Cancer Research and Treatment, 136, 3, 919-926 Breast Cancer Research and Treatment, 136, 3, 919-926 2012/12 英語 公開
S. Tanaka; T. Ueno; F. Sato; Y. Chigusa; N. Kawaguchi-Sakita; M. Kawashima; N. Fujisawa; K. Yoshimura; S. Teramukai; H. Fujiwara; M. Fujita; M. Toi S. Tanaka; T. Ueno; F. Sato; Y. Chigusa; N. Kawaguchi-Sakita; M. Kawashima; N. Fujisawa; K. Yoshimura; S. Teramukai; H. Fujiwara; M. Fujita; M. Toi S. Tanaka; T. Ueno; F. Sato; Y. Chigusa; N. Kawaguchi-Sakita; M. Kawashima; N. Fujisawa; K. Yoshimura; S. Teramukai; H. Fujiwara; M. Fujita; M. Toi Alterations of circulating endothelial cell and endothelial progenitor cell counts around the ovulation Alterations of circulating endothelial cell and endothelial progenitor cell counts around the ovulation Alterations of circulating endothelial cell and endothelial progenitor cell counts around the ovulation Journal of Clinical Endocrinology and Metabolism, 97, 11, 4182-4192 Journal of Clinical Endocrinology and Metabolism, 97, 11, 4182-4192 Journal of Clinical Endocrinology and Metabolism, 97, 11, 4182-4192 2012/11 英語 公開
K. Takeda; S. Kanao; T. Okada; M. Kataoka; T. Ueno; M. Toi; H. Ishiguro; Y. Mikami; K. Togashi K. Takeda; S. Kanao; T. Okada; M. Kataoka; T. Ueno; M. Toi; H. Ishiguro; Y. Mikami; K. Togashi K. Takeda; S. Kanao; T. Okada; M. Kataoka; T. Ueno; M. Toi; H. Ishiguro; Y. Mikami; K. Togashi Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy European Journal of Radiology, 81, 10, 2627-2631 European Journal of Radiology, 81, 10, 2627-2631 European Journal of Radiology, 81, 10, 2627-2631 2012/10 英語 公開
M. Iima; Y. Nakamoto; S. Kanao; T. Sugie; T. Ueno; M. Kawada; Y. Mikami; M. Toi; K. Togashi M. Iima; Y. Nakamoto; S. Kanao; T. Sugie; T. Ueno; M. Kawada; Y. Mikami; M. Toi; K. Togashi M. Iima; Y. Nakamoto; S. Kanao; T. Sugie; T. Ueno; M. Kawada; Y. Mikami; M. Toi; K. Togashi Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation Journal of Nuclear Medicine, 53, 10, 1534-1542 Journal of Nuclear Medicine, 53, 10, 1534-1542 Journal of Nuclear Medicine, 53, 10, 1534-1542 2012/10 英語 公開
M.S.M. Chan; L. Wang; S.J.A. Felizola; T. Ueno; M. Toi; W. Loo; L.W.C. Chow; T. Suzuki; H. Sasano M.S.M. Chan; L. Wang; S.J.A. Felizola; T. Ueno; M. Toi; W. Loo; L.W.C. Chow; T. Suzuki; H. Sasano M.S.M. Chan; L. Wang; S.J.A. Felizola; T. Ueno; M. Toi; W. Loo; L.W.C. Chow; T. Suzuki; H. Sasano Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients - an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pat Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients - an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pat Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients - an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pat International Journal of Biological Markers, 27, 4, E295-E304 International Journal of Biological Markers, 27, 4, E295-E304 International Journal of Biological Markers, 27, 4, E295-E304 2012/10 英語 公開
K. Takeda; S. Kanao; T. Okada; T. Ueno; M. Toi; H. Ishiguro; Y. Mikami; S. Tanaka; K. Togashi K. Takeda; S. Kanao; T. Okada; T. Ueno; M. Toi; H. Ishiguro; Y. Mikami; S. Tanaka; K. Togashi K. Takeda; S. Kanao; T. Okada; T. Ueno; M. Toi; H. Ishiguro; Y. Mikami; S. Tanaka; K. Togashi MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy European Journal of Radiology, 81, 9, 2148-2153 European Journal of Radiology, 81, 9, 2148-2153 European Journal of Radiology, 81, 9, 2148-2153 2012/09 英語 公開
M. Takada; M. Sugimoto; S. Ohno; K. Kuroi; N. Sato; H. Bando; N. Masuda; H. Iwata; M. Kondo; H. Sasano; L.W.C. Chow; T. Inamoto; Y. Naito; M. Tomita; M. Toi M. Takada; M. Sugimoto; S. Ohno; K. Kuroi; N. Sato; H. Bando; N. Masuda; H. Iwata; M. Kondo; H. Sasano; L.W.C. Chow; T. Inamoto; Y. Naito; M. Tomita; M. Toi M. Takada; M. Sugimoto; S. Ohno; K. Kuroi; N. Sato; H. Bando; N. Masuda; H. Iwata; M. Kondo; H. Sasano; L.W.C. Chow; T. Inamoto; Y. Naito; M. Tomita; M. Toi Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique Breast Cancer Research and Treatment, 134, 2, 661-670 Breast Cancer Research and Treatment, 134, 2, 661-670 Breast Cancer Research and Treatment, 134, 2, 661-670 2012/07 英語 公開
M. Takada; M. Sugimoto; Y. Naito; H.-G. Moon; W. Han; D.-Y. Noh; M. Kondo; K. Kuroi; H. Sasano; T. Inamoto; M. Tomita; M. Toi M. Takada; M. Sugimoto; Y. Naito; H.-G. Moon; W. Han; D.-Y. Noh; M. Kondo; K. Kuroi; H. Sasano; T. Inamoto; M. Tomita; M. Toi M. Takada; M. Sugimoto; Y. Naito; H.-G. Moon; W. Han; D.-Y. Noh; M. Kondo; K. Kuroi; H. Sasano; T. Inamoto; M. Tomita; M. Toi Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model BMC Medical Informatics and Decision Making, 12 BMC Medical Informatics and Decision Making, 12 BMC Medical Informatics and Decision Making, 12 2012/06/13 英語 公開
M. Kondo; S.-L. Hoshi; H. Ishiguro; M. Toi M. Kondo; S.-L. Hoshi; H. Ishiguro; M. Toi M. Kondo; S.-L. Hoshi; H. Ishiguro; M. Toi Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan Breast Cancer Research and Treatment, 133, 2, 759-768 Breast Cancer Research and Treatment, 133, 2, 759-768 Breast Cancer Research and Treatment, 133, 2, 759-768 2012/06 日本語 公開
C. Barrios; J.F. Forbes; W. Jonat; P. Conte; W. Gradishar; A. Buzdar; K. Gelmon; M. Gnant; J. Bonneterre; M. Toi; C. Hudis; J.F.R. Robertson C. Barrios; J.F. Forbes; W. Jonat; P. Conte; W. Gradishar; A. Buzdar; K. Gelmon; M. Gnant; J. Bonneterre; M. Toi; C. Hudis; J.F.R. Robertson C. Barrios; J.F. Forbes; W. Jonat; P. Conte; W. Gradishar; A. Buzdar; K. Gelmon; M. Gnant; J. Bonneterre; M. Toi; C. Hudis; J.F.R. Robertson The sequential use of endocrine treatment for advanced breast cancer: Where are we? The sequential use of endocrine treatment for advanced breast cancer: Where are we? The sequential use of endocrine treatment for advanced breast cancer: Where are we? Annals of Oncology, 23, 6, 1378-1386 Annals of Oncology, 23, 6, 1378-1386 Annals of Oncology, 23, 6, 1378-1386 2012/06 英語 公開
G. Gasparini; F. Torino; T. Ueno; S. Cascinu; T. Troiani; A. Ballestrero; R. Berardi; J. Shishido; A. Yoshizawa; Y. Mori; S. Nagayama; P. Morosini; M. Toi G. Gasparini; F. Torino; T. Ueno; S. Cascinu; T. Troiani; A. Ballestrero; R. Berardi; J. Shishido; A. Yoshizawa; Y. Mori; S. Nagayama; P. Morosini; M. Toi G. Gasparini; F. Torino; T. Ueno; S. Cascinu; T. Troiani; A. Ballestrero; R. Berardi; J. Shishido; A. Yoshizawa; Y. Mori; S. Nagayama; P. Morosini; M. Toi A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer Angiogenesis, 15, 1, 141-150 Angiogenesis, 15, 1, 141-150 Angiogenesis, 15, 1, 141-150 2012/03 英語 公開
T. Ichikawa; F. Sato; K. Terasawa; S. Tsuchiya; M. Toi; G. Tsujimoto; K. Shimizu T. Ichikawa; F. Sato; K. Terasawa; S. Tsuchiya; M. Toi; G. Tsujimoto; K. Shimizu T. Ichikawa; F. Sato; K. Terasawa; S. Tsuchiya; M. Toi; G. Tsujimoto; K. Shimizu Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells PLoS ONE, 7, 2 PLoS ONE, 7, 2 PLoS ONE, 7, 2 2012/02/27 英語 公開
M. Takada; S. Saji; N. Masuda; K. Kuroi; N. Sato; H. Takei; Y. Yamamoto; S. Ohno; H. Yamashita; K. Hisamatsu; K. Aogi; H. Iwata; T. Ueno; H. Sasano; M. Toi M. Takada; S. Saji; N. Masuda; K. Kuroi; N. Sato; H. Takei; Y. Yamamoto; S. Ohno; H. Yamashita; K. Hisamatsu; K. Aogi; H. Iwata; T. Ueno; H. Sasano; M. Toi M. Takada; S. Saji; N. Masuda; K. Kuroi; N. Sato; H. Takei; Y. Yamamoto; S. Ohno; H. Yamashita; K. Hisamatsu; K. Aogi; H. Iwata; T. Ueno; H. Sasano; M. Toi Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer Breast, 21, 1, 40-45 Breast, 21, 1, 40-45 Breast, 21, 1, 40-45 2012 英語 公開
E. Fakhrejahani; M. Toi E. Fakhrejahani; M. Toi E. Fakhrejahani; M. Toi Tumor angiogenesis: Pericytes and maturation are not to be ignored Tumor angiogenesis: Pericytes and maturation are not to be ignored Tumor angiogenesis: Pericytes and maturation are not to be ignored Journal of Oncology Journal of Oncology Journal of Oncology 2012 英語 公開
R. Ito; N. Morimoto; P.H. Liem; Y. Nakamura; K. Kawai; T. Taira; W. Tsuji; M. Toi; S. Suzuki R. Ito; N. Morimoto; P.H. Liem; Y. Nakamura; K. Kawai; T. Taira; W. Tsuji; M. Toi; S. Suzuki R. Ito; N. Morimoto; P.H. Liem; Y. Nakamura; K. Kawai; T. Taira; W. Tsuji; M. Toi; S. Suzuki Adipogenesis using human adipose tissue-derived stromal cells combined with a collagen/gelatin sponge sustaining release of basic fibroblast growth factor Adipogenesis using human adipose tissue-derived stromal cells combined with a collagen/gelatin sponge sustaining release of basic fibroblast growth factor Adipogenesis using human adipose tissue-derived stromal cells combined with a collagen/gelatin sponge sustaining release of basic fibroblast growth factor Journal of Tissue Engineering and Regenerative Medicine Journal of Tissue Engineering and Regenerative Medicine Journal of Tissue Engineering and Regenerative Medicine 2012 英語 公開
Y.-S. Ren; N.-S. Qian; Y. Tang; Y.-H. Liao; Y.-L. Yang; K.-F. Dou; M. Toi Y.-S. Ren; N.-S. Qian; Y. Tang; Y.-H. Liao; Y.-L. Yang; K.-F. Dou; M. Toi Y.-S. Ren; N.-S. Qian; Y. Tang; Y.-H. Liao; Y.-L. Yang; K.-F. Dou; M. Toi Sodium channel Nav1.6 is up-regulated in the dorsal root ganglia in a mouse model of type 2 diabetes Sodium channel Nav1.6 is up-regulated in the dorsal root ganglia in a mouse model of type 2 diabetes Sodium channel Nav1.6 is up-regulated in the dorsal root ganglia in a mouse model of type 2 diabetes Brain Research Bulletin, 87, 2-3, 244-249 Brain Research Bulletin, 87, 2-3, 244-249 Brain Research Bulletin, 87, 2-3, 244-249 2012 英語 公開
T. Ueno; M. Emi; H. Sato; N. Ito; M. Muta; K. Kuroi; M. Toi T. Ueno; M. Emi; H. Sato; N. Ito; M. Muta; K. Kuroi; M. Toi T. Ueno; M. Emi; H. Sato; N. Ito; M. Muta; K. Kuroi; M. Toi Genome-wide copy number analysis in primary breast cancer Genome-wide copy number analysis in primary breast cancer Genome-wide copy number analysis in primary breast cancer Expert Opinion on Therapeutic Targets, 16, SUPPL. 1, S31-S35 Expert Opinion on Therapeutic Targets, 16, SUPPL. 1, S31-S35 Expert Opinion on Therapeutic Targets, 16, SUPPL. 1, S31-S35 2012 英語 公開
M.S. Chan; L. Wang; N. Chanplakorn; K. Tamaki; T. Ueno; M. Toi; W.T. Loo; L.W. Chow; T. Suzuki; H. Sasano M.S. Chan; L. Wang; N. Chanplakorn; K. Tamaki; T. Ueno; M. Toi; W.T. Loo; L.W. Chow; T. Suzuki; H. Sasano M.S. Chan; L. Wang; N. Chanplakorn; K. Tamaki; T. Ueno; M. Toi; W.T. Loo; L.W. Chow; T. Suzuki; H. Sasano Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy Expert Opinion on Therapeutic Targets, 16, SUPPL. 1, S69-S78 Expert Opinion on Therapeutic Targets, 16, SUPPL. 1, S69-S78 Expert Opinion on Therapeutic Targets, 16, SUPPL. 1, S69-S78 2012 英語 公開
J. Eswaran; S. Gupta; A. Dutt; M. Toi; M.R. Pillai; L. Costa; S. Knapp; R. Badwe; R. Kumar J. Eswaran; S. Gupta; A. Dutt; M. Toi; M.R. Pillai; L. Costa; S. Knapp; R. Badwe; R. Kumar J. Eswaran; S. Gupta; A. Dutt; M. Toi; M.R. Pillai; L. Costa; S. Knapp; R. Badwe; R. Kumar The Global Cancer Genomics Consortium: Interfacing genomics and cancer medicine The Global Cancer Genomics Consortium: Interfacing genomics and cancer medicine The Global Cancer Genomics Consortium: Interfacing genomics and cancer medicine Cancer Research, 72, 15, 3720-3724 Cancer Research, 72, 15, 3720-3724 Cancer Research, 72, 15, 3720-3724 2012 英語 公開
H. Ishiguro; S. Takashima; K. Yoshimura; I. Yano; T. Yamamoto; M. Niimi; H. Yamashiro; T. Ueno; M. Takeuchi; T. Sugie; K. Yanagihara; M. Toi; M. Fukushima H. Ishiguro; S. Takashima; K. Yoshimura; I. Yano; T. Yamamoto; M. Niimi; H. Yamashiro; T. Ueno; M. Takeuchi; T. Sugie; K. Yanagihara; M. Toi; M. Fukushima H. Ishiguro; S. Takashima; K. Yoshimura; I. Yano; T. Yamamoto; M. Niimi; H. Yamashiro; T. Ueno; M. Takeuchi; T. Sugie; K. Yanagihara; M. Toi; M. Fukushima Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients Supportive Care in Cancer, 20, 9, 2017-2024 Supportive Care in Cancer, 20, 9, 2017-2024 Supportive Care in Cancer, 20, 9, 2017-2024 2012 英語 公開
Y. Tang; X. Zeng; F. He; Y. Liao; N. Qian; M. Toi Y. Tang; X. Zeng; F. He; Y. Liao; N. Qian; M. Toi Y. Tang; X. Zeng; F. He; Y. Liao; N. Qian; M. Toi Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer Medical Oncology, 29, 2, 977-984 Medical Oncology, 29, 2, 977-984 Medical Oncology, 29, 2, 977-984 2012 英語 公開
M. Takeuchi; T. Sugie; K. Abdelazeem; H. Kato; N. Shinkura; M. Takada; H. Yamashiro; T. Ueno; M. Toi M. Takeuchi; T. Sugie; K. Abdelazeem; H. Kato; N. Shinkura; M. Takada; H. Yamashiro; T. Ueno; M. Toi M. Takeuchi; T. Sugie; K. Abdelazeem; H. Kato; N. Shinkura; M. Takada; H. Yamashiro; T. Ueno; M. Toi Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer Breast Journal, 18, 6, 535-541 Breast Journal, 18, 6, 535-541 Breast Journal, 18, 6, 535-541 2012 英語 公開
K. Imami; N. Sugiyama; H. Imamura; M. Wakabayashi; M. Tomita; M. Taniguchi; T. Ueno; M. Toi; Y. Ishihama K. Imami; N. Sugiyama; H. Imamura; M. Wakabayashi; M. Tomita; M. Taniguchi; T. Ueno; M. Toi; Y. Ishihama K. Imami; N. Sugiyama; H. Imamura; M. Wakabayashi; M. Tomita; M. Taniguchi; T. Ueno; M. Toi; Y. Ishihama Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways Molecular and Cellular Proteomics, 11, 12, 1741-1757 Molecular and Cellular Proteomics, 11, 12, 1741-1757 Molecular and Cellular Proteomics, 11, 12, 1741-1757 2012 英語 公開
L.W. Chow; M. Toi L.W. Chow; M. Toi L.W. Chow; M. Toi The clinical trials of the organisation for oncology and translational research (ootr) The clinical trials of the organisation for oncology and translational research (ootr) The clinical trials of the organisation for oncology and translational research (ootr) International Journal of Biological Markers, 27, 4, e353-e356 International Journal of Biological Markers, 27, 4, e353-e356 International Journal of Biological Markers, 27, 4, e353-e356 2012 英語 公開
N. Masuda; M. Toi; K. Kuroi N. Masuda; M. Toi; K. Kuroi N. Masuda; M. Toi; K. Kuroi [Current activities and perspective of JBCRG (Japan Breast Cancer Research Group)]. [Current activities and perspective of JBCRG (Japan Breast Cancer Research Group)]. [Current activities and perspective of JBCRG (Japan Breast Cancer Research Group)]. Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 763-772 Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 763-772 Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 763-772 2012 英語 公開
T. Kitai; M. Toi T. Kitai; M. Toi T. Kitai; M. Toi [Photoacoustic mammography for the diagnosis of breast cancer]. [Photoacoustic mammography for the diagnosis of breast cancer]. [Photoacoustic mammography for the diagnosis of breast cancer]. Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 326-330 Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 326-330 Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 326-330 2012 英語 公開
Y. Mitsudo; M. Takada; M. Toi Y. Mitsudo; M. Takada; M. Toi Y. Mitsudo; M. Takada; M. Toi [Multidisciplinary treatment of chemotherapy and surgical therapy]. [Multidisciplinary treatment of chemotherapy and surgical therapy]. [Multidisciplinary treatment of chemotherapy and surgical therapy]. Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 571-575 Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 571-575 Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 571-575 2012 英語 公開
E. Suzuki; M. Toi E. Suzuki; M. Toi E. Suzuki; M. Toi [Targeting therapy perspectives]. [Targeting therapy perspectives]. [Targeting therapy perspectives]. Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 620-626 Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 620-626 Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 620-626 2012 英語 公開
H. Ishiguro; M. Toi H. Ishiguro; M. Toi H. Ishiguro; M. Toi Pharmacokinetics and pharmacogenomics of selective estrogen receptor modulators in breast cancer patients Pharmacokinetics and pharmacogenomics of selective estrogen receptor modulators in breast cancer patients Pharmacokinetics and pharmacogenomics of selective estrogen receptor modulators in breast cancer patients Current Topics in Pharmacology, 16, 1, 53-58 Current Topics in Pharmacology, 16, 1, 53-58 Current Topics in Pharmacology, 16, 1, 53-58 2012 英語 公開
H. Ishiguro; M. Toi H. Ishiguro; M. Toi H. Ishiguro; M. Toi How to dose cytotoxic chemotherapeutic drugs How to dose cytotoxic chemotherapeutic drugs How to dose cytotoxic chemotherapeutic drugs Current Topics in Pharmacology, 16, 1, 67-81 Current Topics in Pharmacology, 16, 1, 67-81 Current Topics in Pharmacology, 16, 1, 67-81 2012 英語 公開
H. Ishiguro; S. Saji; M. Toi H. Ishiguro; S. Saji; M. Toi H. Ishiguro; S. Saji; M. Toi [Clinical pharmacology of targeted drug for breast cancer]. [Clinical pharmacology of targeted drug for breast cancer]. [Clinical pharmacology of targeted drug for breast cancer]. Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 8, 443-446 Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 8, 443-446 Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 8, 443-446 2012 英語 公開
M. Kanai; H. Ishiguro; Y. Mori; T. Kitano; T. Nishimura; S. Matsumoto; K. Yanagihara; T. Chiba; M. Toi M. Kanai; H. Ishiguro; Y. Mori; T. Kitano; T. Nishimura; S. Matsumoto; K. Yanagihara; T. Chiba; M. Toi M. Kanai; H. Ishiguro; Y. Mori; T. Kitano; T. Nishimura; S. Matsumoto; K. Yanagihara; T. Chiba; M. Toi Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer British Journal of Cancer, 105, 11, 1693-1696 British Journal of Cancer, 105, 11, 1693-1696 British Journal of Cancer, 105, 11, 1693-1696 2011/11/22 英語 公開
K. Kawaguchi; H. Ishiguro; S. Morita; S. Nakamura; S. Ohno; N. Masuda; H. Iwata; K. Aogi; K. Kuroi; M. Toi K. Kawaguchi; H. Ishiguro; S. Morita; S. Nakamura; S. Ohno; N. Masuda; H. Iwata; K. Aogi; K. Kuroi; M. Toi K. Kawaguchi; H. Ishiguro; S. Morita; S. Nakamura; S. Ohno; N. Masuda; H. Iwata; K. Aogi; K. Kuroi; M. Toi Correlation between docetaxel-induced skin toxicity and the use of steroids and H <sub>2</sub> blockers: A multi-institution survey Correlation between docetaxel-induced skin toxicity and the use of steroids and H <sub>2</sub> blockers: A multi-institution survey Correlation between docetaxel-induced skin toxicity and the use of steroids and H <sub>2</sub> blockers: A multi-institution survey Breast Cancer Research and Treatment, 130, 2, 627-634 Breast Cancer Research and Treatment, 130, 2, 627-634 Breast Cancer Research and Treatment, 130, 2, 627-634 2011/11 英語 公開
H.S. Han; I.M. Reis; W. Zhao; K. Kuroi; M. Toi; E. Suzuki; R. Syme; L. Chow; A.Y.S. Yip; S. Glück H.S. Han; I.M. Reis; W. Zhao; K. Kuroi; M. Toi; E. Suzuki; R. Syme; L. Chow; A.Y.S. Yip; S. Glück H.S. Han; I.M. Reis; W. Zhao; K. Kuroi; M. Toi; E. Suzuki; R. Syme; L. Chow; A.Y.S. Yip; S. Glück Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer European Journal of Cancer, 47, 17, 2537-2545 European Journal of Cancer, 47, 17, 2537-2545 European Journal of Cancer, 47, 17, 2537-2545 2011/11 英語 公開
A.M. Ali; T. Ueno; S. Tanaka; M. Takada; H. Ishiguro; A.Z. Abdellah; M. Toi A.M. Ali; T. Ueno; S. Tanaka; M. Takada; H. Ishiguro; A.Z. Abdellah; M. Toi A.M. Ali; T. Ueno; S. Tanaka; M. Takada; H. Ishiguro; A.Z. Abdellah; M. Toi Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients European Journal of Cancer, 47, 15, 2265-2272 European Journal of Cancer, 47, 15, 2265-2272 European Journal of Cancer, 47, 15, 2265-2272 2011/10 英語 公開
N. Qian; T. Ueno; N. Kawaguchi-Sakita; M. Kawashima; N. Yoshida; Y. Mikami; T. Wakasa; M. Shintaku; S. Tsuyuki; T. Inamoto; M. Toi N. Qian; T. Ueno; N. Kawaguchi-Sakita; M. Kawashima; N. Yoshida; Y. Mikami; T. Wakasa; M. Shintaku; S. Tsuyuki; T. Inamoto; M. Toi N. Qian; T. Ueno; N. Kawaguchi-Sakita; M. Kawashima; N. Yoshida; Y. Mikami; T. Wakasa; M. Shintaku; S. Tsuyuki; T. Inamoto; M. Toi Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients Cancer Science, 102, 8, 1590-1596 Cancer Science, 102, 8, 1590-1596 Cancer Science, 102, 8, 1590-1596 2011/08 英語 公開
M. Kondo; S.-L. Hoshi; T. Yamanaka; H. Ishiguro; M. Toi M. Kondo; S.-L. Hoshi; T. Yamanaka; H. Ishiguro; M. Toi M. Kondo; S.-L. Hoshi; T. Yamanaka; H. Ishiguro; M. Toi Economic evaluation of the 21-gene signature (Oncotype DX <sup>®</sup>) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03) Economic evaluation of the 21-gene signature (Oncotype DX <sup>®</sup>) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03) Economic evaluation of the 21-gene signature (Oncotype DX <sup>®</sup>) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03) Breast Cancer Research and Treatment, 127, 3, 739-749 Breast Cancer Research and Treatment, 127, 3, 739-749 Breast Cancer Research and Treatment, 127, 3, 739-749 2011/06 日本語 公開
K. Aogi; M. Yoshida; Y. Sagara; S. Kamigaki; M. Okazaki; J. Funai; T. Fujimoto; M. Toi; T. Saeki; S. Takashima K. Aogi; M. Yoshida; Y. Sagara; S. Kamigaki; M. Okazaki; J. Funai; T. Fujimoto; M. Toi; T. Saeki; S. Takashima K. Aogi; M. Yoshida; Y. Sagara; S. Kamigaki; M. Okazaki; J. Funai; T. Fujimoto; M. Toi; T. Saeki; S. Takashima The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype Cancer Chemotherapy and Pharmacology, 67, 5, 1007-1015 Cancer Chemotherapy and Pharmacology, 67, 5, 1007-1015 Cancer Chemotherapy and Pharmacology, 67, 5, 1007-1015 2011/05 英語 公開
L.W.C. Chow; A.Y.S. Yip; W.P. Chu; W.T.Y. Loo; M. Toi L.W.C. Chow; A.Y.S. Yip; W.P. Chu; W.T.Y. Loo; M. Toi L.W.C. Chow; A.Y.S. Yip; W.P. Chu; W.T.Y. Loo; M. Toi Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: Sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: Sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: Sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial Journal of Steroid Biochemistry and Molecular Biology, 125, 1-2, 112-119 Journal of Steroid Biochemistry and Molecular Biology, 125, 1-2, 112-119 Journal of Steroid Biochemistry and Molecular Biology, 125, 1-2, 112-119 2011/05 英語 公開
M. Toi; S. Saji; N. Masuda; K. Kuroi; N. Sato; H. Takei; Y. Yamamoto; S. Ohno; H. Yamashita; K. Hisamatsu; K. Aogi; H. Iwata; M. Takada; T. Ueno; S. Saji; N. Chanplakorn; T. Suzuki; H. Sasano M. Toi; S. Saji; N. Masuda; K. Kuroi; N. Sato; H. Takei; Y. Yamamoto; S. Ohno; H. Yamashita; K. Hisamatsu; K. Aogi; H. Iwata; M. Takada; T. Ueno; S. Saji; N. Chanplakorn; T. Suzuki; H. Sasano M. Toi; S. Saji; N. Masuda; K. Kuroi; N. Sato; H. Takei; Y. Yamamoto; S. Ohno; H. Yamashita; K. Hisamatsu; K. Aogi; H. Iwata; M. Takada; T. Ueno; S. Saji; N. Chanplakorn; T. Suzuki; H. Sasano Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24weeks of aromatase inhibition Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24weeks of aromatase inhibition Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24weeks of aromatase inhibition Cancer Science, 102, 4, 858-865 Cancer Science, 102, 4, 858-865 Cancer Science, 102, 4, 858-865 2011/04 英語 公開
M. Honda; S. Saji; S.-I. Horiguchi; E. Suzuki; T. Aruga; K. Horiguchi; D. Kitagawa; S. Sekine; N. Funata; M. Toi; K. Kuroi M. Honda; S. Saji; S.-I. Horiguchi; E. Suzuki; T. Aruga; K. Horiguchi; D. Kitagawa; S. Sekine; N. Funata; M. Toi; K. Kuroi M. Honda; S. Saji; S.-I. Horiguchi; E. Suzuki; T. Aruga; K. Horiguchi; D. Kitagawa; S. Sekine; N. Funata; M. Toi; K. Kuroi Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast Surgery Today, 41, 3, 328-332 Surgery Today, 41, 3, 328-332 Surgery Today, 41, 3, 328-332 2011/03 英語 公開
M. Takada; H. Terunuma; X. Deng; M.Z. Dewan; S. Saji; K. Kuroi; N. Yamamoto; M. Toi M. Takada; H. Terunuma; X. Deng; M.Z. Dewan; S. Saji; K. Kuroi; N. Yamamoto; M. Toi M. Takada; H. Terunuma; X. Deng; M.Z. Dewan; S. Saji; K. Kuroi; N. Yamamoto; M. Toi Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach Breast Cancer, 18, 1, 64-67 Breast Cancer, 18, 1, 64-67 Breast Cancer, 18, 1, 64-67 2011/01 英語 公開
Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS. Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS. Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS. Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto Consensus Conference. Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto Consensus Conference. Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto Consensus Conference. Ann Surg Oncol 2011 Mar 23. [Epub] Ann Surg Oncol 2011 Mar 23. [Epub] Ann Surg Oncol 2011 Mar 23. [Epub] 2011 英語 公開
M. Iwasaki; Y. Tanaka; H. Kobayashi; K. Murata-Hirai; H. Miyabe; T. Sugie; M. Toi; N. Minato M. Iwasaki; Y. Tanaka; H. Kobayashi; K. Murata-Hirai; H. Miyabe; T. Sugie; M. Toi; N. Minato M. Iwasaki; Y. Tanaka; H. Kobayashi; K. Murata-Hirai; H. Miyabe; T. Sugie; M. Toi; N. Minato Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens European Journal of Immunology, 41, 2, 345-355 European Journal of Immunology, 41, 2, 345-355 European Journal of Immunology, 41, 2, 345-355 2011 日本語 公開
H. Takuwa; T. Ueno; H. Ishiguro; Y. Mikami; S. Kanao; M. Takada; T. Sugie; M. Toi H. Takuwa; T. Ueno; H. Ishiguro; Y. Mikami; S. Kanao; M. Takada; T. Sugie; M. Toi H. Takuwa; T. Ueno; H. Ishiguro; Y. Mikami; S. Kanao; M. Takada; T. Sugie; M. Toi A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy Breast Cancer, 1-4 Breast Cancer, 1-4 Breast Cancer, 1-4 2011 英語 公開
Y. Tang; F. Xu; K. Tao; N. Qian; M. Toi Y. Tang; F. Xu; K. Tao; N. Qian; M. Toi Y. Tang; F. Xu; K. Tao; N. Qian; M. Toi Clinical applications of sentinel lymph node biopsy in Ductal carcinoma in situ of the breast: A dilemma Clinical applications of sentinel lymph node biopsy in Ductal carcinoma in situ of the breast: A dilemma Clinical applications of sentinel lymph node biopsy in Ductal carcinoma in situ of the breast: A dilemma Tohoku Journal of Experimental Medicine, 224, 1, 1-5 Tohoku Journal of Experimental Medicine, 224, 1, 1-5 Tohoku Journal of Experimental Medicine, 224, 1, 1-5 2011 英語 公開
M. Toi; W. Yasui; H. Ito; E. Tahara M. Toi; W. Yasui; H. Ito; E. Tahara M. Toi; W. Yasui; H. Ito; E. Tahara Recent progress in carcinogenesis, progression and therapy of breast cancer: The 20th Hiroshima Cancer seminar-the 4th three universities\\' Consortium International Symposium, october 2010 Recent progress in carcinogenesis, progression and therapy of breast cancer: The 20th Hiroshima Cancer seminar-the 4th three universities\\' Consortium International Symposium, october 2010 Recent progress in carcinogenesis, progression and therapy of breast cancer: The 20th Hiroshima Cancer seminar-the 4th three universities\\' Consortium International Symposium, october 2010 Japanese Journal of Clinical Oncology, 41, 7, 924-930 Japanese Journal of Clinical Oncology, 41, 7, 924-930 Japanese Journal of Clinical Oncology, 41, 7, 924-930 2011 英語 公開
H. Iwata; N. Sato; N. Masuda; S. Nakamura; N. Yamamoto; K. Kuroi; M. Kurosumi; H. Tsuda; F. Akiyama; Y. Ohashi; M. Toi H. Iwata; N. Sato; N. Masuda; S. Nakamura; N. Yamamoto; K. Kuroi; M. Kurosumi; H. Tsuda; F. Akiyama; Y. Ohashi; M. Toi H. Iwata; N. Sato; N. Masuda; S. Nakamura; N. Yamamoto; K. Kuroi; M. Kurosumi; H. Tsuda; F. Akiyama; Y. Ohashi; M. Toi Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer Japanese Journal of Clinical Oncology, 41, 7, 867-875 Japanese Journal of Clinical Oncology, 41, 7, 867-875 Japanese Journal of Clinical Oncology, 41, 7, 867-875 2011 英語 公開
Y. Tang; Y. Liao; N. Kawaguchi-Sakita; V. Raut; E. Fakhrejahani; N. Qian; M. Toi Y. Tang; Y. Liao; N. Kawaguchi-Sakita; V. Raut; E. Fakhrejahani; N. Qian; M. Toi Y. Tang; Y. Liao; N. Kawaguchi-Sakita; V. Raut; E. Fakhrejahani; N. Qian; M. Toi Sinisan, a traditional Chinese medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats Sinisan, a traditional Chinese medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats Sinisan, a traditional Chinese medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats Journal of Hepato-Biliary-Pancreatic Sciences, 18, 4, 551-558 Journal of Hepato-Biliary-Pancreatic Sciences, 18, 4, 551-558 Journal of Hepato-Biliary-Pancreatic Sciences, 18, 4, 551-558 2011 英語 公開
M. Toi; E.P. Winer; T. Inamoto; J.R. Benson; J.F. Forbes; M. Mitsumori; J.F.R. Robertson; H. Sasano; G. Von Minckwitz; A. Yamauchi; V.S. Klimberg M. Toi; E.P. Winer; T. Inamoto; J.R. Benson; J.F. Forbes; M. Mitsumori; J.F.R. Robertson; H. Sasano; G. Von Minckwitz; A. Yamauchi; V.S. Klimberg M. Toi; E.P. Winer; T. Inamoto; J.R. Benson; J.F. Forbes; M. Mitsumori; J.F.R. Robertson; H. Sasano; G. Von Minckwitz; A. Yamauchi; V.S. Klimberg Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto consensus conference Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto consensus conference Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto consensus conference Annals of Surgical Oncology, 18, 10, 2885-2892 Annals of Surgical Oncology, 18, 10, 2885-2892 Annals of Surgical Oncology, 18, 10, 2885-2892 2011 英語 公開
福谷和彦,染田恭宏,卓雅一,浅尾恭史,小林秀一,八木隆行,山川誠,椎名 毅,杉江知治,戸井雅和 福谷和彦,染田恭宏,卓雅一,浅尾恭史,小林秀一,八木隆行,山川誠,椎名 毅,杉江知治,戸井雅和 福谷和彦,染田恭宏,卓雅一,浅尾恭史,小林秀一,八木隆行,山川誠,椎名 毅,杉江知治,戸井雅和 高深度イメージングを目指した両面照射型光音響イメージングシステムの評価 高深度イメージングを目指した両面照射型光音響イメージングシステムの評価 高深度イメージングを目指した両面照射型光音響イメージングシステムの評価 2011 BIOS(SPIE Photonic West) (2011.1.24) 2011 BIOS(SPIE Photonic West) (2011.1.24) 2011 BIOS(SPIE Photonic West) (2011.1.24) 2011 日本語 公開
M. Takada; M. Toi M. Takada; M. Toi M. Takada; M. Toi Surgery for breast cancer - From radical mastectomy to breast-conserving surgery Surgery for breast cancer - From radical mastectomy to breast-conserving surgery Surgery for breast cancer - From radical mastectomy to breast-conserving surgery Japanese Journal of Cancer and Chemotherapy, 38, 2, 173-178 Japanese Journal of Cancer and Chemotherapy, 38, 2, 173-178 Japanese Journal of Cancer and Chemotherapy, 38, 2, 173-178 2011 日本語 公開
A. Tomotaki; S. Hirota; Y. Ohashi; A. Teramoto; M. Yokobori; M. Toi A. Tomotaki; S. Hirota; Y. Ohashi; A. Teramoto; M. Yokobori; M. Toi A. Tomotaki; S. Hirota; Y. Ohashi; A. Teramoto; M. Yokobori; M. Toi Participant proportion of population controls and matching for cases and controls: Lactic acid bacterium and breast cancer in the case-control study Participant proportion of population controls and matching for cases and controls: Lactic acid bacterium and breast cancer in the case-control study Participant proportion of population controls and matching for cases and controls: Lactic acid bacterium and breast cancer in the case-control study Japanese Pharmacology and Therapeutics, 39, SUPPL. 2, S211-SS221 Japanese Pharmacology and Therapeutics, 39, SUPPL. 2, S211-SS221 Japanese Pharmacology and Therapeutics, 39, SUPPL. 2, S211-SS221 2011 英語 公開
C.C.P. Yiu; N. Chanplakorn; M.S.M. Chan; W.T.Y. Loo; L.W.C. Chow; M. Toi; S. Hironobu C.C.P. Yiu; N. Chanplakorn; M.S.M. Chan; W.T.Y. Loo; L.W.C. Chow; M. Toi; S. Hironobu C.C.P. Yiu; N. Chanplakorn; M.S.M. Chan; W.T.Y. Loo; L.W.C. Chow; M. Toi; S. Hironobu Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients Anticancer Research, 30, 9, 3465-3472 Anticancer Research, 30, 9, 3465-3472 Anticancer Research, 30, 9, 3465-3472 2010/09 英語 公開
L. Chen; A. Endler; K. Uchida; S.-I. Horiguchi; Y. Morizane; O. Iijima; M. Toi; F. Shibasaki L. Chen; A. Endler; K. Uchida; S.-I. Horiguchi; Y. Morizane; O. Iijima; M. Toi; F. Shibasaki L. Chen; A. Endler; K. Uchida; S.-I. Horiguchi; Y. Morizane; O. Iijima; M. Toi; F. Shibasaki Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2α expression Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2α expression Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2α expression Circulation, 122, 9, 910-919 Circulation, 122, 9, 910-919 Circulation, 122, 9, 910-919 2010/08/31 英語 公開
M. Procter; T.M. Suter; E. De Azambuja; U. Dafni; V. Van Dooren; S. Muehlbauer; M.A. Climent; E. Rechberger; W.T.-W. Liu; M. Toi; R.C. Coombes; D. Dodwell; O. Pagani; J. Madrid; M. Hall; S.-C. Chen; C. Focan; M. Muschol; D.J. Van Veldhuisen; M.J. Piccart-Gebhart M. Procter; T.M. Suter; E. De Azambuja; U. Dafni; V. Van Dooren; S. Muehlbauer; M.A. Climent; E. Rechberger; W.T.-W. Liu; M. Toi; R.C. Coombes; D. Dodwell; O. Pagani; J. Madrid; M. Hall; S.-C. Chen; C. Focan; M. Muschol; D.J. Van Veldhuisen; M.J. Piccart-Gebhart M. Procter; T.M. Suter; E. De Azambuja; U. Dafni; V. Van Dooren; S. Muehlbauer; M.A. Climent; E. Rechberger; W.T.-W. Liu; M. Toi; R.C. Coombes; D. Dodwell; O. Pagani; J. Madrid; M. Hall; S.-C. Chen; C. Focan; M. Muschol; D.J. Van Veldhuisen; M.J. Piccart-Gebhart Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial Journal of Clinical Oncology, 28, 21, 3422-3428 Journal of Clinical Oncology, 28, 21, 3422-3428 Journal of Clinical Oncology, 28, 21, 3422-3428 2010/07/20 英語 公開
M. Toi; H. Iwata; T. Yamanaka; N. Masuda; S. Ohno; S. Nakamura; T. Nakayama; M. Kashiwaba; S. Kamigaki; K. Kuroi; T. Ueno; K. Aogi M. Toi; H. Iwata; T. Yamanaka; N. Masuda; S. Ohno; S. Nakamura; T. Nakayama; M. Kashiwaba; S. Kamigaki; K. Kuroi; T. Ueno; K. Aogi M. Toi; H. Iwata; T. Yamanaka; N. Masuda; S. Ohno; S. Nakamura; T. Nakayama; M. Kashiwaba; S. Kamigaki; K. Kuroi; T. Ueno; K. Aogi Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population Cancer, 116, 13, 3112-3118 Cancer, 116, 13, 3112-3118 Cancer, 116, 13, 3112-3118 2010/07/01 英語 公開
D. Kitagawa; S. Saji; S.-I. Horiguchi; Y. Satoh; K. Horiguchi; M. Toi; N. Funata; K. Kuroi D. Kitagawa; S. Saji; S.-I. Horiguchi; Y. Satoh; K. Horiguchi; M. Toi; N. Funata; K. Kuroi D. Kitagawa; S. Saji; S.-I. Horiguchi; Y. Satoh; K. Horiguchi; M. Toi; N. Funata; K. Kuroi Alternation of estrogen receptor and progesterone receptor expression in primary breast cancer patients treated with neoadjuvant chemotherapy Alternation of estrogen receptor and progesterone receptor expression in primary breast cancer patients treated with neoadjuvant chemotherapy Alternation of estrogen receptor and progesterone receptor expression in primary breast cancer patients treated with neoadjuvant chemotherapy Breast Journal, 16, 4, 435-436 Breast Journal, 16, 4, 435-436 Breast Journal, 16, 4, 435-436 2010/07 英語 公開
S. Nakamura; H. Yagata; S. Ohno; H. Yamaguchi; H. Iwata; N. Tsunoda; Y. Ito; N. Tokudome; M. Toi; K. Kuroi; E. Suzuki S. Nakamura; H. Yagata; S. Ohno; H. Yamaguchi; H. Iwata; N. Tsunoda; Y. Ito; N. Tokudome; M. Toi; K. Kuroi; E. Suzuki S. Nakamura; H. Yagata; S. Ohno; H. Yamaguchi; H. Iwata; N. Tsunoda; Y. Ito; N. Tokudome; M. Toi; K. Kuroi; E. Suzuki Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer Breast Cancer, 17, 3, 199-204 Breast Cancer, 17, 3, 199-204 Breast Cancer, 17, 3, 199-204 2010/07 英語 公開
N. Chanplakorn; P. Chanplakorn; T. Suzuki; K. Ono; M.S.M. Chan; Y. Miki; S. Saji; T. Ueno; M. Toi; H. Sasano N. Chanplakorn; P. Chanplakorn; T. Suzuki; K. Ono; M.S.M. Chan; Y. Miki; S. Saji; T. Ueno; M. Toi; H. Sasano N. Chanplakorn; P. Chanplakorn; T. Suzuki; K. Ono; M.S.M. Chan; Y. Miki; S. Saji; T. Ueno; M. Toi; H. Sasano Increased estrogen sulfatase (STS) and 17βhydroxysteroid dehydrogenase type l(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients Increased estrogen sulfatase (STS) and 17βhydroxysteroid dehydrogenase type l(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients Increased estrogen sulfatase (STS) and 17βhydroxysteroid dehydrogenase type l(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients Breast Cancer Research and Treatment, 120, 3, 639-648 Breast Cancer Research and Treatment, 120, 3, 639-648 Breast Cancer Research and Treatment, 120, 3, 639-648 2010/04 英語 公開
H. Ishiguro; M. Kondo; S.-L. Hoshi; M. Takada; S. Nakamura; S. Teramukai; K. Yanagihara; M. Toi H. Ishiguro; M. Kondo; S.-L. Hoshi; M. Takada; S. Nakamura; S. Teramukai; K. Yanagihara; M. Toi H. Ishiguro; M. Kondo; S.-L. Hoshi; M. Takada; S. Nakamura; S. Teramukai; K. Yanagihara; M. Toi Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan Clinical Therapeutics, 32, 2, 311-326 Clinical Therapeutics, 32, 2, 311-326 Clinical Therapeutics, 32, 2, 311-326 2010/02 英語 公開
Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H. Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H. Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat 2010 Feb 12. [Epub] Breast Cancer Res Treat 2010 Feb 12. [Epub] Breast Cancer Res Treat 2010 Feb 12. [Epub] 2010 英語 公開
M. Toi; J. Sperinde; W. Huang; S. Saji; J. Winslow; X. Jin; Y. Tan; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; K. Aogi; S. Morita; C. Petropoulos; M. Bates M. Toi; J. Sperinde; W. Huang; S. Saji; J. Winslow; X. Jin; Y. Tan; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; K. Aogi; S. Morita; C. Petropoulos; M. Bates M. Toi; J. Sperinde; W. Huang; S. Saji; J. Winslow; X. Jin; Y. Tan; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; K. Aogi; S. Morita; C. Petropoulos; M. Bates Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer BMC Cancer, 10 BMC Cancer, 10 BMC Cancer, 10 2010 英語 公開
M. Toi; Y. Ohashi; A. Seow; T. Moriya; G. Tse; H. Sasano; B.W. Park; L.W. Chow; A.V. Laudico; C.H. Yip; E. Ueno; H. Ishiguro; H. Bando M. Toi; Y. Ohashi; A. Seow; T. Moriya; G. Tse; H. Sasano; B.W. Park; L.W. Chow; A.V. Laudico; C.H. Yip; E. Ueno; H. Ishiguro; H. Bando M. Toi; Y. Ohashi; A. Seow; T. Moriya; G. Tse; H. Sasano; B.W. Park; L.W. Chow; A.V. Laudico; C.H. Yip; E. Ueno; H. Ishiguro; H. Bando The breast cancer working group presentation was divided into three sections: The epidemiology, pathology and treatment of breast cancer The breast cancer working group presentation was divided into three sections: The epidemiology, pathology and treatment of breast cancer The breast cancer working group presentation was divided into three sections: The epidemiology, pathology and treatment of breast cancer Japanese Journal of Clinical Oncology, 40, SUPPL. 1, i13-i18 Japanese Journal of Clinical Oncology, 40, SUPPL. 1, i13-i18 Japanese Journal of Clinical Oncology, 40, SUPPL. 1, i13-i18 2010 英語 公開
Y. Kimura; W. Tsuji; H. Yamashiro; M. Toi; T. Inamoto; Y. Tabata Y. Kimura; W. Tsuji; H. Yamashiro; M. Toi; T. Inamoto; Y. Tabata Y. Kimura; W. Tsuji; H. Yamashiro; M. Toi; T. Inamoto; Y. Tabata In situ adipogenesis in fat tissue augmented by collagen scaffold with gelatin microspheres containing basic fibroblast growth factor In situ adipogenesis in fat tissue augmented by collagen scaffold with gelatin microspheres containing basic fibroblast growth factor In situ adipogenesis in fat tissue augmented by collagen scaffold with gelatin microspheres containing basic fibroblast growth factor Journal of Tissue Engineering and Regenerative Medicine, 4, 1, 55-61 Journal of Tissue Engineering and Regenerative Medicine, 4, 1, 55-61 Journal of Tissue Engineering and Regenerative Medicine, 4, 1, 55-61 2010 英語 公開
L.W.C. Chow; M. Toi L.W.C. Chow; M. Toi L.W.C. Chow; M. Toi Combat against cancer with science and medicine Combat against cancer with science and medicine Combat against cancer with science and medicine Expert Opinion on Investigational Drugs, 19, SUPPL. 1, S3-S4 Expert Opinion on Investigational Drugs, 19, SUPPL. 1, S3-S4 Expert Opinion on Investigational Drugs, 19, SUPPL. 1, S3-S4 2010 英語 公開
M. Kimura; T. Tominaga; Y. Takatsuka; M. Toi; R. Abe; H. Koyama; S. Takashima; Y. Nomura; S. Miura; I. Kimijima; H. Tashiro; Y. Ohashi M. Kimura; T. Tominaga; Y. Takatsuka; M. Toi; R. Abe; H. Koyama; S. Takashima; Y. Nomura; S. Miura; I. Kimijima; H. Tashiro; Y. Ohashi M. Kimura; T. Tominaga; Y. Takatsuka; M. Toi; R. Abe; H. Koyama; S. Takashima; Y. Nomura; S. Miura; I. Kimijima; H. Tashiro; Y. Ohashi Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan Breast Cancer, 17, 3, 190-198 Breast Cancer, 17, 3, 190-198 Breast Cancer, 17, 3, 190-198 2010 英語 公開
T. Shimbo; T. Fukui; C. Ishioka; K. Okamoto; T. Okamoto; S. Kameoka; A. Sato; M. Toi; K. Matsui; T. Mayumi; S. Saji; M. Miyazaki; Y. Takatsuka; K. Hirata T. Shimbo; T. Fukui; C. Ishioka; K. Okamoto; T. Okamoto; S. Kameoka; A. Sato; M. Toi; K. Matsui; T. Mayumi; S. Saji; M. Miyazaki; Y. Takatsuka; K. Hirata T. Shimbo; T. Fukui; C. Ishioka; K. Okamoto; T. Okamoto; S. Kameoka; A. Sato; M. Toi; K. Matsui; T. Mayumi; S. Saji; M. Miyazaki; Y. Takatsuka; K. Hirata Quality of guideline development assessed by the evaluation committee of the japan society of clinical oncology Quality of guideline development assessed by the evaluation committee of the japan society of clinical oncology Quality of guideline development assessed by the evaluation committee of the japan society of clinical oncology International Journal of Clinical Oncology, 15, 3, 227-233 International Journal of Clinical Oncology, 15, 3, 227-233 International Journal of Clinical Oncology, 15, 3, 227-233 2010 英語 公開
Y. Kumagai; M. Toi; K. Kawada; T. Kawano Y. Kumagai; M. Toi; K. Kawada; T. Kawano Y. Kumagai; M. Toi; K. Kawada; T. Kawano Angiogenesis in superficial esophageal squamous cell carcinoma: Magnifying endoscopic observation and molecular analysis Angiogenesis in superficial esophageal squamous cell carcinoma: Magnifying endoscopic observation and molecular analysis Angiogenesis in superficial esophageal squamous cell carcinoma: Magnifying endoscopic observation and molecular analysis Digestive Endoscopy, 22, 4, 259-267 Digestive Endoscopy, 22, 4, 259-267 Digestive Endoscopy, 22, 4, 259-267 2010 英語 公開
T. Sugie; K.A. Kassim; M. Takeuchi; T. Hashimoto; K. Yamagami; Y. Masai; M. Toi T. Sugie; K.A. Kassim; M. Takeuchi; T. Hashimoto; K. Yamagami; Y. Masai; M. Toi T. Sugie; K.A. Kassim; M. Takeuchi; T. Hashimoto; K. Yamagami; Y. Masai; M. Toi A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast Cancer A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast Cancer A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast Cancer Cancers, 2, 2, 713-720 Cancers, 2, 2, 713-720 Cancers, 2, 2, 713-720 2010 英語 公開
Y. Matsumura; H. Yamashiro; M. Toi Y. Matsumura; H. Yamashiro; M. Toi Y. Matsumura; H. Yamashiro; M. Toi Trastuzumab for cancer treatment: Present role and future perspective Trastuzumab for cancer treatment: Present role and future perspective Trastuzumab for cancer treatment: Present role and future perspective Biotherapy, 24, 2, 178-182 Biotherapy, 24, 2, 178-182 Biotherapy, 24, 2, 178-182 2010 日本語 公開
K. Horiguchi; M. Toi; S.-I. Horiguchi; M. Sugimoto; Y. Naito; Y. Hayashi; T. Ueno; S. Ohno; N. Funata; K. Kuroi; M. Tomita; Y. Eishi K. Horiguchi; M. Toi; S.-I. Horiguchi; M. Sugimoto; Y. Naito; Y. Hayashi; T. Ueno; S. Ohno; N. Funata; K. Kuroi; M. Tomita; Y. Eishi K. Horiguchi; M. Toi; S.-I. Horiguchi; M. Sugimoto; Y. Naito; Y. Hayashi; T. Ueno; S. Ohno; N. Funata; K. Kuroi; M. Tomita; Y. Eishi Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients Journal of Medical and Dental Sciences, 57, 2, 165-175 Journal of Medical and Dental Sciences, 57, 2, 165-175 Journal of Medical and Dental Sciences, 57, 2, 165-175 2010 英語 公開
S.-I. Horiguchi; T. Hishima; Y. Hayashi; Y. Shiozawa; K. Horiguchi; K. Kuroi; M. Toi; N. Funata; Y. Eishi S.-I. Horiguchi; T. Hishima; Y. Hayashi; Y. Shiozawa; K. Horiguchi; K. Kuroi; M. Toi; N. Funata; Y. Eishi S.-I. Horiguchi; T. Hishima; Y. Hayashi; Y. Shiozawa; K. Horiguchi; K. Kuroi; M. Toi; N. Funata; Y. Eishi HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma Journal of Medical and Dental Sciences, 57, 2, 155-163 Journal of Medical and Dental Sciences, 57, 2, 155-163 Journal of Medical and Dental Sciences, 57, 2, 155-163 2010 英語 公開
H. Yamashiro; M. Toi H. Yamashiro; M. Toi H. Yamashiro; M. Toi [Molecular targeted therapy for breast cancer treatment, challenge to cure]. [Molecular targeted therapy for breast cancer treatment, challenge to cure]. [Molecular targeted therapy for breast cancer treatment, challenge to cure]. Nippon rinsho. Japanese journal of clinical medicine, 68, 10, 1854-1858 Nippon rinsho. Japanese journal of clinical medicine, 68, 10, 1854-1858 Nippon rinsho. Japanese journal of clinical medicine, 68, 10, 1854-1858 2010 英語 公開
W. Tsuji; H. Yamashiro; M. Toi W. Tsuji; H. Yamashiro; M. Toi W. Tsuji; H. Yamashiro; M. Toi [Basic fibroblast growth factor (FGF-2)]. [Basic fibroblast growth factor (FGF-2)]. [Basic fibroblast growth factor (FGF-2)]. Nippon rinsho. Japanese journal of clinical medicine, 68 Suppl 7, 118-120 Nippon rinsho. Japanese journal of clinical medicine, 68 Suppl 7, 118-120 Nippon rinsho. Japanese journal of clinical medicine, 68 Suppl 7, 118-120 2010 英語 公開
M. Toi M. Toi M. Toi [Current organ topics: chemotherapy of breast cancer]. [Current organ topics: chemotherapy of breast cancer]. [Current organ topics: chemotherapy of breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 37, 13, 2844- Gan to kagaku ryoho. Cancer & chemotherapy, 37, 13, 2844- Gan to kagaku ryoho. Cancer & chemotherapy, 37, 13, 2844- 2010 英語 公開
M. Toi; H. Iwata; Y. Fujiwara; Y. Ito; S. Nakamura; Y. Tokuda; T. Taguchi; Y. Rai; K. Aogi; T. Arai; J. Watanabe; T. Wakamatsu; K. Katsura; C.E. Ellis; R.C. Gagnon; K.E. Allen; Y. Sasaki; S. Takashima M. Toi; H. Iwata; Y. Fujiwara; Y. Ito; S. Nakamura; Y. Tokuda; T. Taguchi; Y. Rai; K. Aogi; T. Arai; J. Watanabe; T. Wakamatsu; K. Katsura; C.E. Ellis; R.C. Gagnon; K.E. Allen; Y. Sasaki; S. Takashima M. Toi; H. Iwata; Y. Fujiwara; Y. Ito; S. Nakamura; Y. Tokuda; T. Taguchi; Y. Rai; K. Aogi; T. Arai; J. Watanabe; T. Wakamatsu; K. Katsura; C.E. Ellis; R.C. Gagnon; K.E. Allen; Y. Sasaki; S. Takashima Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: Efficacy, safety, and biomarker results from Japanese patients phase II studies Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: Efficacy, safety, and biomarker results from Japanese patients phase II studies Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: Efficacy, safety, and biomarker results from Japanese patients phase II studies British Journal of Cancer, 101, 10, 1676-1682 British Journal of Cancer, 101, 10, 1676-1682 British Journal of Cancer, 101, 10, 1676-1682 2009/11/10 英語 公開
M. Kondo; S.-L. Hoshi; M. Toi M. Kondo; S.-L. Hoshi; M. Toi M. Kondo; S.-L. Hoshi; M. Toi Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan British Journal of Cancer, 100, 2, 281-290 British Journal of Cancer, 100, 2, 281-290 British Journal of Cancer, 100, 2, 281-290 2009/01/22 英語 公開
W. Tsuji; T. Inamoto; H. Yamashiro; T. Ueno; H. Kato; Y. Kimura; Y. Tabata; M. Toi W. Tsuji; T. Inamoto; H. Yamashiro; T. Ueno; H. Kato; Y. Kimura; Y. Tabata; M. Toi W. Tsuji; T. Inamoto; H. Yamashiro; T. Ueno; H. Kato; Y. Kimura; Y. Tabata; M. Toi Adipogenesis induced by human adipose tissue-derived stem cells Adipogenesis induced by human adipose tissue-derived stem cells Adipogenesis induced by human adipose tissue-derived stem cells Tissue Engineering - Part A, 15, 1, 83-93 Tissue Engineering - Part A, 15, 1, 83-93 Tissue Engineering - Part A, 15, 1, 83-93 2009/01 英語 公開
F. Chen; T. Fujinaga; K. Sato; M. Sonobe; T. Shoji; H. Sakai; R. Miyahara; T. Bando; K. Okubo; T. Hirata; M. Toi; H. Date F. Chen; T. Fujinaga; K. Sato; M. Sonobe; T. Shoji; H. Sakai; R. Miyahara; T. Bando; K. Okubo; T. Hirata; M. Toi; H. Date F. Chen; T. Fujinaga; K. Sato; M. Sonobe; T. Shoji; H. Sakai; R. Miyahara; T. Bando; K. Okubo; T. Hirata; M. Toi; H. Date Clinical features of surgical resection for pulmonary metastasis from breast cancer Clinical features of surgical resection for pulmonary metastasis from breast cancer Clinical features of surgical resection for pulmonary metastasis from breast cancer European Journal of Surgical Oncology, 35, 4, 393-397 European Journal of Surgical Oncology, 35, 4, 393-397 European Journal of Surgical Oncology, 35, 4, 393-397 2009 英語 公開
T. Aruga; E. Suzuki; S. Saji; S.-I. Horiguchi; K. Horiguchi; S. Sekine; D. Kitagawa; N. Funata; M. Toi; K. Sugihara; K. Kuroi T. Aruga; E. Suzuki; S. Saji; S.-I. Horiguchi; K. Horiguchi; S. Sekine; D. Kitagawa; N. Funata; M. Toi; K. Sugihara; K. Kuroi T. Aruga; E. Suzuki; S. Saji; S.-I. Horiguchi; K. Horiguchi; S. Sekine; D. Kitagawa; N. Funata; M. Toi; K. Sugihara; K. Kuroi A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer Oncology Reports, 22, 2, 273-278 Oncology Reports, 22, 2, 273-278 Oncology Reports, 22, 2, 273-278 2009 英語 公開
M. Toi; H. Yamashiro; W. Tsuji M. Toi; H. Yamashiro; W. Tsuji M. Toi; H. Yamashiro; W. Tsuji Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer Breast Cancer, 16, 3, 207-218 Breast Cancer, 16, 3, 207-218 Breast Cancer, 16, 3, 207-218 2009 英語 公開
S. Noguchi; M. Toi S. Noguchi; M. Toi S. Noguchi; M. Toi From standardization to personalization in breast cancer treatment From standardization to personalization in breast cancer treatment From standardization to personalization in breast cancer treatment Breast Cancer, 16, 4, 241-242 Breast Cancer, 16, 4, 241-242 Breast Cancer, 16, 4, 241-242 2009 英語 公開
A.M. Ali; M. Toi; T. Ueno A.M. Ali; M. Toi; T. Ueno A.M. Ali; M. Toi; T. Ueno Anti-angiogenic cancer therapy updates Anti-angiogenic cancer therapy updates Anti-angiogenic cancer therapy updates Current Molecular Medicine, 9, 8, 954-966 Current Molecular Medicine, 9, 8, 954-966 Current Molecular Medicine, 9, 8, 954-966 2009 英語 公開
M. Kondo; S.-L. Hoshi; M. Toi M. Kondo; S.-L. Hoshi; M. Toi M. Kondo; S.-L. Hoshi; M. Toi Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan Japanese Journal of Clinical Oncology, 39, 11, 767-770 Japanese Journal of Clinical Oncology, 39, 11, 767-770 Japanese Journal of Clinical Oncology, 39, 11, 767-770 2009 英語 公開
Md.Z. Dewan; M. Takada; H. Terunuma; X. Deng; S. Ahmed; N. Yamamoto; M. Toi Md.Z. Dewan; M. Takada; H. Terunuma; X. Deng; S. Ahmed; N. Yamamoto; M. Toi Md.Z. Dewan; M. Takada; H. Terunuma; X. Deng; S. Ahmed; N. Yamamoto; M. Toi Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients Biomedicine and Pharmacotherapy, 63, 9, 703-706 Biomedicine and Pharmacotherapy, 63, 9, 703-706 Biomedicine and Pharmacotherapy, 63, 9, 703-706 2009 英語 公開
M. Muta; T. Yanagawa; Y. Sai; S. Saji; E. Suzuki; T. Aruga; K. Kuroi; G. Matsumoto; M. Toi; E. Nakashima M. Muta; T. Yanagawa; Y. Sai; S. Saji; E. Suzuki; T. Aruga; K. Kuroi; G. Matsumoto; M. Toi; E. Nakashima M. Muta; T. Yanagawa; Y. Sai; S. Saji; E. Suzuki; T. Aruga; K. Kuroi; G. Matsumoto; M. Toi; E. Nakashima Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells Oncology, 77, 3-4, 182-191 Oncology, 77, 3-4, 182-191 Oncology, 77, 3-4, 182-191 2009 英語 公開
T. Sugie; Y. Tanaka; M. Toi T. Sugie; Y. Tanaka; M. Toi T. Sugie; Y. Tanaka; M. Toi New development in breast cancer therapy. III. Zoledronic acid and anti-tumor immunity in breast cancer New development in breast cancer therapy. III. Zoledronic acid and anti-tumor immunity in breast cancer New development in breast cancer therapy. III. Zoledronic acid and anti-tumor immunity in breast cancer Gan to kagaku ryoho. Cancer & chemotherapy, 36, 13, 2555-2559 Gan to kagaku ryoho. Cancer & chemotherapy, 36, 13, 2555-2559 Gan to kagaku ryoho. Cancer & chemotherapy, 36, 13, 2555-2559 2009 英語 公開
M. Toi; H. Sasano; M.J. Ellis M. Toi; H. Sasano; M.J. Ellis M. Toi; H. Sasano; M.J. Ellis Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer Japanese Journal of Cancer and Chemotherapy, 36, 6, 1035-1042 Japanese Journal of Cancer and Chemotherapy, 36, 6, 1035-1042 Japanese Journal of Cancer and Chemotherapy, 36, 6, 1035-1042 2009 日本語 公開
H. Yamashiro; M. Toi H. Yamashiro; M. Toi H. Yamashiro; M. Toi Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway Japanese Journal of Cancer and Chemotherapy, 36, 7, 1067-1071 Japanese Journal of Cancer and Chemotherapy, 36, 7, 1067-1071 Japanese Journal of Cancer and Chemotherapy, 36, 7, 1067-1071 2009 日本語 公開
T. Ueno; M. Toi T. Ueno; M. Toi T. Ueno; M. Toi Biomarker Biomarker Biomarker Japanese Journal of Cancer and Chemotherapy, 36, 1, 15-20 Japanese Journal of Cancer and Chemotherapy, 36, 1, 15-20 Japanese Journal of Cancer and Chemotherapy, 36, 1, 15-20 2009 英語 公開
H. Ishiguro; I. Yano; M. Toi H. Ishiguro; I. Yano; M. Toi H. Ishiguro; I. Yano; M. Toi Important drug interactions for clinical oncologists Important drug interactions for clinical oncologists Important drug interactions for clinical oncologists Frontiers in Drug Design and Discovery, 4, 1, 97-121 Frontiers in Drug Design and Discovery, 4, 1, 97-121 Frontiers in Drug Design and Discovery, 4, 1, 97-121 2009 英語 公開
H. Ishiguro; I. Yano; M. Toi H. Ishiguro; I. Yano; M. Toi H. Ishiguro; I. Yano; M. Toi Pharmacogenomic considerations in breast cancer management Pharmacogenomic considerations in breast cancer management Pharmacogenomic considerations in breast cancer management Frontiers in Drug Design and Discovery, 4, 1, 122-134 Frontiers in Drug Design and Discovery, 4, 1, 122-134 Frontiers in Drug Design and Discovery, 4, 1, 122-134 2009 英語 公開
Kimura Y., Tsuji W., Yamashiro H., Toi M., Inamoto T., Tabata Y. Kimura Y., Tsuji W., Yamashiro H., Toi M., Inamoto T., Tabata Y. Kimura Y., Tsuji W., Yamashiro H., Toi M., Inamoto T., Tabata Y. In Situ adipose tissue regeneration augmented by collagen scaffold combined with gelatin microspheres containing basic fibroblast growth factor. In Situ adipose tissue regeneration augmented by collagen scaffold combined with gelatin microspheres containing basic fibroblast growth factor. In Situ adipose tissue regeneration augmented by collagen scaffold combined with gelatin microspheres containing basic fibroblast growth factor. The 2nd World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS-WC2009) (2009.08.31-09. 03 Seoul, Korea) The 2nd World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS-WC2009) (2009.08.31-09. 03 Seoul, Korea) The 2nd World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS-WC2009) (2009.08.31-09. 03 Seoul, Korea) 2009 英語 公開
M. Toi M. Toi M. Toi Long-term outcomes of aromatase inhibition for breast cancer Long-term outcomes of aromatase inhibition for breast cancer Long-term outcomes of aromatase inhibition for breast cancer The Lancet Oncology, 9, 1, 8-10 The Lancet Oncology, 9, 1, 8-10 The Lancet Oncology, 9, 1, 8-10 2008 英語 公開
S. Saji; M. Toi; S. Morita; H. Iwata; Y. Ito; S. Ohno; T. Kobayashi; Y. Hozumi; J. Sakamoto S. Saji; M. Toi; S. Morita; H. Iwata; Y. Ito; S. Ohno; T. Kobayashi; Y. Hozumi; J. Sakamoto S. Saji; M. Toi; S. Morita; H. Iwata; Y. Ito; S. Ohno; T. Kobayashi; Y. Hozumi; J. Sakamoto Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer Oncology, 72, 5-6, 330-337 Oncology, 72, 5-6, 330-337 Oncology, 72, 5-6, 330-337 2008 英語 公開
T. Ueno; G. Elmberger; T.E. Weaver; M. Toi; S. Linder T. Ueno; G. Elmberger; T.E. Weaver; M. Toi; S. Linder T. Ueno; G. Elmberger; T.E. Weaver; M. Toi; S. Linder The aspartic protease napsin a suppresses tumor growth independent of its catalytic activity The aspartic protease napsin a suppresses tumor growth independent of its catalytic activity The aspartic protease napsin a suppresses tumor growth independent of its catalytic activity Laboratory Investigation, 88, 3, 256-263 Laboratory Investigation, 88, 3, 256-263 Laboratory Investigation, 88, 3, 256-263 2008 英語 公開
H. Yamashiro; M. Toi H. Yamashiro; M. Toi H. Yamashiro; M. Toi Update of evidence in chemotherapy for breast cancer Update of evidence in chemotherapy for breast cancer Update of evidence in chemotherapy for breast cancer International Journal of Clinical Oncology, 13, 1, 3-7 International Journal of Clinical Oncology, 13, 1, 3-7 International Journal of Clinical Oncology, 13, 1, 3-7 2008 英語 公開
L.W.-C. Chow; A.Y.-S. Yip; W.T.-Y. Loo; M. Toi L.W.-C. Chow; A.Y.-S. Yip; W.T.-Y. Loo; M. Toi L.W.-C. Chow; A.Y.-S. Yip; W.T.-Y. Loo; M. Toi Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer Cancer Letters, 262, 2, 232-238 Cancer Letters, 262, 2, 232-238 Cancer Letters, 262, 2, 232-238 2008 英語 公開
H. Ishiguro; T. Kitano; H. Yoshibayashi; M. Toi; T. Ueno; H. Yasuda; K. Yanagihara; C.L. Garbo; M. Fukushima H. Ishiguro; T. Kitano; H. Yoshibayashi; M. Toi; T. Ueno; H. Yasuda; K. Yanagihara; C.L. Garbo; M. Fukushima H. Ishiguro; T. Kitano; H. Yoshibayashi; M. Toi; T. Ueno; H. Yasuda; K. Yanagihara; C.L. Garbo; M. Fukushima Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim Annals of Oncology, 19, 5, 1019- Annals of Oncology, 19, 5, 1019- Annals of Oncology, 19, 5, 1019- 2008 英語 公開
S. Noguchi; M. Toi S. Noguchi; M. Toi S. Noguchi; M. Toi Molecular target therapy: Basics and clinical application Molecular target therapy: Basics and clinical application Molecular target therapy: Basics and clinical application Breast Cancer, 15, 1, 47-48 Breast Cancer, 15, 1, 47-48 Breast Cancer, 15, 1, 47-48 2008 英語 公開
H. Yagata; S. Nakamura; M. Toi; H. Bando; S. Ohno; A. Kataoka H. Yagata; S. Nakamura; M. Toi; H. Bando; S. Ohno; A. Kataoka H. Yagata; S. Nakamura; M. Toi; H. Bando; S. Ohno; A. Kataoka Evaluation of circulating tumor cells in patients with breast cancer: Multi-institutional clinical trial in Japan Evaluation of circulating tumor cells in patients with breast cancer: Multi-institutional clinical trial in Japan Evaluation of circulating tumor cells in patients with breast cancer: Multi-institutional clinical trial in Japan International Journal of Clinical Oncology, 13, 3, 252-256 International Journal of Clinical Oncology, 13, 3, 252-256 International Journal of Clinical Oncology, 13, 3, 252-256 2008 英語 公開
M. Toi; S. Nakamura; K. Kuroi; H. Iwata; S. Ohno; N. Masuda; M. Kusama; K. Yamazaki; K. Hisamatsu; Y. Sato; M. Kashiwaba; H. Kaise; M. Kurosumi; H. Tsuda; F. Akiyama; Y. Ohashi; Y. Takatsuka M. Toi; S. Nakamura; K. Kuroi; H. Iwata; S. Ohno; N. Masuda; M. Kusama; K. Yamazaki; K. Hisamatsu; Y. Sato; M. Kashiwaba; H. Kaise; M. Kurosumi; H. Tsuda; F. Akiyama; Y. Ohashi; Y. Takatsuka M. Toi; S. Nakamura; K. Kuroi; H. Iwata; S. Ohno; N. Masuda; M. Kusama; K. Yamazaki; K. Hisamatsu; Y. Sato; M. Kashiwaba; H. Kaise; M. Kurosumi; H. Tsuda; F. Akiyama; Y. Ohashi; Y. Takatsuka Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival Breast Cancer Research and Treatment, 110, 3, 531-539 Breast Cancer Research and Treatment, 110, 3, 531-539 Breast Cancer Research and Treatment, 110, 3, 531-539 2008 英語 公開
L.W.-C. Chow; A.Y.-S. Yip; W.T.-Y. Loo; C.-K. Lam; M. Toi L.W.-C. Chow; A.Y.-S. Yip; W.T.-Y. Loo; C.-K. Lam; M. Toi L.W.-C. Chow; A.Y.-S. Yip; W.T.-Y. Loo; C.-K. Lam; M. Toi Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer Journal of Steroid Biochemistry and Molecular Biology, 111, 1-2, 13-17 Journal of Steroid Biochemistry and Molecular Biology, 111, 1-2, 13-17 Journal of Steroid Biochemistry and Molecular Biology, 111, 1-2, 13-17 2008 英語 公開
N. Tokudome; Y. Ito; K. Hatake; M. Toi; M. Sano; H. Iwata; Y. Sato; T. Saeki; K. Aogi; S. Takashima N. Tokudome; Y. Ito; K. Hatake; M. Toi; M. Sano; H. Iwata; Y. Sato; T. Saeki; K. Aogi; S. Takashima N. Tokudome; Y. Ito; K. Hatake; M. Toi; M. Sano; H. Iwata; Y. Sato; T. Saeki; K. Aogi; S. Takashima Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II and pharmacokinetic study in Japan Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II and pharmacokinetic study in Japan Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II and pharmacokinetic study in Japan Anti-Cancer Drugs, 19, 7, 753-759 Anti-Cancer Drugs, 19, 7, 753-759 Anti-Cancer Drugs, 19, 7, 753-759 2008 英語 公開
M. Kondo; S.L. Hoshi; H. Ishiguro; H. Yoshibayashi; M. Toi M. Kondo; S.L. Hoshi; H. Ishiguro; H. Yoshibayashi; M. Toi M. Kondo; S.L. Hoshi; H. Ishiguro; H. Yoshibayashi; M. Toi Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan Breast Cancer Research and Treatment, 112, 1, 175-187 Breast Cancer Research and Treatment, 112, 1, 175-187 Breast Cancer Research and Treatment, 112, 1, 175-187 2008 英語 公開
M. Toi M. Toi M. Toi Novel targeting therapy concept for breast cancer treatment Novel targeting therapy concept for breast cancer treatment Novel targeting therapy concept for breast cancer treatment Folia Pharmacologica Japonica, 132, 3, 177-179 Folia Pharmacologica Japonica, 132, 3, 177-179 Folia Pharmacologica Japonica, 132, 3, 177-179 2008 英語 公開
T. Kiba; T. Inamoto; T. Nishimura; M. Ueno; K. Yanagihara; S. Teramukai; H. Kato; M. Toi; M. Fukushima T. Kiba; T. Inamoto; T. Nishimura; M. Ueno; K. Yanagihara; S. Teramukai; H. Kato; M. Toi; M. Fukushima T. Kiba; T. Inamoto; T. Nishimura; M. Ueno; K. Yanagihara; S. Teramukai; H. Kato; M. Toi; M. Fukushima The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery BMC Cancer, 8 BMC Cancer, 8 BMC Cancer, 8 2008 英語 公開
N. Honma; S. Saji; R. Kurabayashi; J. Aida; T. Arai; R. Horii; F. Akiyama; T. Iwase; N. Harada; M. Younes; M. Toi; K. Takubo; G. Sakamoto N. Honma; S. Saji; R. Kurabayashi; J. Aida; T. Arai; R. Horii; F. Akiyama; T. Iwase; N. Harada; M. Younes; M. Toi; K. Takubo; G. Sakamoto N. Honma; S. Saji; R. Kurabayashi; J. Aida; T. Arai; R. Horii; F. Akiyama; T. Iwase; N. Harada; M. Younes; M. Toi; K. Takubo; G. Sakamoto Oestrogen receptor-β1 but not oestrogen receptor-βcx is of prognostic value in apocrine carcinoma of the breast Oestrogen receptor-β1 but not oestrogen receptor-βcx is of prognostic value in apocrine carcinoma of the breast Oestrogen receptor-β1 but not oestrogen receptor-βcx is of prognostic value in apocrine carcinoma of the breast APMIS, 116, 10, 923-930 APMIS, 116, 10, 923-930 APMIS, 116, 10, 923-930 2008 英語 公開
H. Yoshibayashi; H. Ishiguro; M. Takada; M. Takeuchi; H. Yamashiro; T. Ueno; H. Kato; K. Yoshikawa; S. Kanao; C. Yamauchi; Y. Mikami; M. Toi H. Yoshibayashi; H. Ishiguro; M. Takada; M. Takeuchi; H. Yamashiro; T. Ueno; H. Kato; K. Yoshikawa; S. Kanao; C. Yamauchi; Y. Mikami; M. Toi H. Yoshibayashi; H. Ishiguro; M. Takada; M. Takeuchi; H. Yamashiro; T. Ueno; H. Kato; K. Yoshikawa; S. Kanao; C. Yamauchi; Y. Mikami; M. Toi A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide Gan to kagaku ryoho. Cancer & chemotherapy, 35, 6, 987-990 Gan to kagaku ryoho. Cancer & chemotherapy, 35, 6, 987-990 Gan to kagaku ryoho. Cancer & chemotherapy, 35, 6, 987-990 2008 日本語 公開
M. Takada; H. Ishiguro; M. Toi M. Takada; H. Ishiguro; M. Toi M. Takada; H. Ishiguro; M. Toi Treatment for breast cancer and endocrine neoplasm Treatment for breast cancer and endocrine neoplasm Treatment for breast cancer and endocrine neoplasm Gan to kagaku ryoho. Cancer & chemotherapy, 35, 13, 2344-2350 Gan to kagaku ryoho. Cancer & chemotherapy, 35, 13, 2344-2350 Gan to kagaku ryoho. Cancer & chemotherapy, 35, 13, 2344-2350 2008 英語 公開
T. Oikawa; C. Onozawa; S. Kuranuki; Y. Igarashi; M. Sato; H. Ashino; M. Shimamura; M. Toi; S. Kurakata T. Oikawa; C. Onozawa; S. Kuranuki; Y. Igarashi; M. Sato; H. Ashino; M. Shimamura; M. Toi; S. Kurakata T. Oikawa; C. Onozawa; S. Kuranuki; Y. Igarashi; M. Sato; H. Ashino; M. Shimamura; M. Toi; S. Kurakata Dipalmitoylation of radicicol results in improved efficacy against tumor growth and angiogenesis in vivo Dipalmitoylation of radicicol results in improved efficacy against tumor growth and angiogenesis in vivo Dipalmitoylation of radicicol results in improved efficacy against tumor growth and angiogenesis in vivo Cancer Science, 98, 2, 219-225 Cancer Science, 98, 2, 219-225 Cancer Science, 98, 2, 219-225 2007 英語 公開
T. Yamaguchi; H. Bando; T. Mori; K. Takahashi; H. Matsumoto; M. Yasutome; H.A. Weich; M. Toi T. Yamaguchi; H. Bando; T. Mori; K. Takahashi; H. Matsumoto; M. Yasutome; H.A. Weich; M. Toi T. Yamaguchi; H. Bando; T. Mori; K. Takahashi; H. Matsumoto; M. Yasutome; H.A. Weich; M. Toi Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis Cancer Science, 98, 3, 405-410 Cancer Science, 98, 3, 405-410 Cancer Science, 98, 3, 405-410 2007 英語 公開
T. Saeki; T. Nomizu; M. Toi; Y. Ito; S. Noguchi; T. Kobayashi; T. Asaga; H. Minami; N. Yamamoto; K. Aogi; T. Ikeda; Y. Ohashi; W. Sato; T. Tsuruo T. Saeki; T. Nomizu; M. Toi; Y. Ito; S. Noguchi; T. Kobayashi; T. Asaga; H. Minami; N. Yamamoto; K. Aogi; T. Ikeda; Y. Ohashi; W. Sato; T. Tsuruo T. Saeki; T. Nomizu; M. Toi; Y. Ito; S. Noguchi; T. Kobayashi; T. Asaga; H. Minami; N. Yamamoto; K. Aogi; T. Ikeda; Y. Ohashi; W. Sato; T. Tsuruo Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer Journal of Clinical Oncology, 25, 4, 411-417 Journal of Clinical Oncology, 25, 4, 411-417 Journal of Clinical Oncology, 25, 4, 411-417 2007 英語 公開
E. Suzuki; R. Niwa; S. Saji; M. Muta; M. Hirose; S. Iida; Y. Shiotsu; M. Satoh; K. Shitara; M. Kondo; M. Toi E. Suzuki; R. Niwa; S. Saji; M. Muta; M. Hirose; S. Iida; Y. Shiotsu; M. Satoh; K. Shitara; M. Kondo; M. Toi E. Suzuki; R. Niwa; S. Saji; M. Muta; M. Hirose; S. Iida; Y. Shiotsu; M. Satoh; K. Shitara; M. Kondo; M. Toi A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients Clinical Cancer Research, 13, 6, 1875-1882 Clinical Cancer Research, 13, 6, 1875-1882 Clinical Cancer Research, 13, 6, 1875-1882 2007 英語 公開
E. Suzuki; M. Toi E. Suzuki; M. Toi E. Suzuki; M. Toi Improving the efficacy of trastuzumab in breast cancer Improving the efficacy of trastuzumab in breast cancer Improving the efficacy of trastuzumab in breast cancer Cancer Science, 98, 6, 767-771 Cancer Science, 98, 6, 767-771 Cancer Science, 98, 6, 767-771 2007 英語 公開
M. Toi M. Toi M. Toi What does DNA methylation surrogate? What does DNA methylation surrogate? What does DNA methylation surrogate? Digestion, 75, 1, 53- Digestion, 75, 1, 53- Digestion, 75, 1, 53- 2007 英語 公開
M.H. Olofsson; T. Ueno; Y. Pan; R. Xu; F. Cai; H. Van Der Kuip; T.E. Muerdter; M. Sonnenberg; W.E. Aulitzky; S. Schwarz; E. Andersson; M.C. Shoshan; A.M. Havelka; M. Toi; S. Linder M.H. Olofsson; T. Ueno; Y. Pan; R. Xu; F. Cai; H. Van Der Kuip; T.E. Muerdter; M. Sonnenberg; W.E. Aulitzky; S. Schwarz; E. Andersson; M.C. Shoshan; A.M. Havelka; M. Toi; S. Linder M.H. Olofsson; T. Ueno; Y. Pan; R. Xu; F. Cai; H. Van Der Kuip; T.E. Muerdter; M. Sonnenberg; W.E. Aulitzky; S. Schwarz; E. Andersson; M.C. Shoshan; A.M. Havelka; M. Toi; S. Linder Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy Clinical Cancer Research, 13, 11, 3198-3206 Clinical Cancer Research, 13, 11, 3198-3206 Clinical Cancer Research, 13, 11, 3198-3206 2007 英語 公開
Md.Z. Dewan; H. Terunuma; M. Takada; Y. Tanaka; H. Abe; T. Sata; M. Toi; N. Yamamoto Md.Z. Dewan; H. Terunuma; M. Takada; Y. Tanaka; H. Abe; T. Sata; M. Toi; N. Yamamoto Md.Z. Dewan; H. Terunuma; M. Takada; Y. Tanaka; H. Abe; T. Sata; M. Toi; N. Yamamoto Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo Breast Cancer Research and Treatment, 104, 3, 267-275 Breast Cancer Research and Treatment, 104, 3, 267-275 Breast Cancer Research and Treatment, 104, 3, 267-275 2007 英語 公開
D. Kitagawa; M. Toi D. Kitagawa; M. Toi D. Kitagawa; M. Toi Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer Nippon rinsho. Japanese journal of clinical medicine, 65 Suppl 6, 396-401 Nippon rinsho. Japanese journal of clinical medicine, 65 Suppl 6, 396-401 Nippon rinsho. Japanese journal of clinical medicine, 65 Suppl 6, 396-401 2007 英語 公開
H. Yamashiro; M. Toi H. Yamashiro; M. Toi H. Yamashiro; M. Toi Herceptin (trastuzumab) Herceptin (trastuzumab) Herceptin (trastuzumab) Gan to kagaku ryoho. Cancer & chemotherapy, 34, 8, 1173-1176 Gan to kagaku ryoho. Cancer & chemotherapy, 34, 8, 1173-1176 Gan to kagaku ryoho. Cancer & chemotherapy, 34, 8, 1173-1176 2007 日本語 公開
M. Toi M. Toi M. Toi Lapatinib: A viewpoint Lapatinib: A viewpoint Lapatinib: A viewpoint Drugs, 67, 14, 2109- Drugs, 67, 14, 2109- Drugs, 67, 14, 2109- 2007 英語 公開
M. Toi; T. Ikeda; F. Akiyama; M. Kurosumi; H. Tsuda; G. Sakamoto; O. Abe M. Toi; T. Ikeda; F. Akiyama; M. Kurosumi; H. Tsuda; G. Sakamoto; O. Abe M. Toi; T. Ikeda; F. Akiyama; M. Kurosumi; H. Tsuda; G. Sakamoto; O. Abe Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy International Journal of Oncology, 31, 4, 899-906 International Journal of Oncology, 31, 4, 899-906 International Journal of Oncology, 31, 4, 899-906 2007 英語 公開
S. Morita; M. Toi; S. Saji; H. Iwata; S. Ohno; Y. Ito; T. Kobayashi; Y. Hozumi; J. Sakamoto S. Morita; M. Toi; S. Saji; H. Iwata; S. Ohno; Y. Ito; T. Kobayashi; Y. Hozumi; J. Sakamoto S. Morita; M. Toi; S. Saji; H. Iwata; S. Ohno; Y. Ito; T. Kobayashi; Y. Hozumi; J. Sakamoto Practical application of the continual reassessment method to a phase I dose-finding trial in advanced breast cancer Practical application of the continual reassessment method to a phase I dose-finding trial in advanced breast cancer Practical application of the continual reassessment method to a phase I dose-finding trial in advanced breast cancer Drug Information Journal, 41, 6, 691-700 Drug Information Journal, 41, 6, 691-700 Drug Information Journal, 41, 6, 691-700 2007 英語 公開
N. Masuda; M. Toi; Y. Takatsuka; S. Nakamura; H. Iwata; S. Ohno; K. Kuroi; M. Kusama; K. Hisamatsu; K. Yamazaki; S. Eisei; Y. Sato; H. Kaise; M. Kashiwaba; H. Iwase; M. Kurosumi; H. Tsuda; F. Akiyama N. Masuda; M. Toi; Y. Takatsuka; S. Nakamura; H. Iwata; S. Ohno; K. Kuroi; M. Kusama; K. Hisamatsu; K. Yamazaki; S. Eisei; Y. Sato; H. Kaise; M. Kashiwaba; H. Iwase; M. Kurosumi; H. Tsuda; F. Akiyama N. Masuda; M. Toi; Y. Takatsuka; S. Nakamura; H. Iwata; S. Ohno; K. Kuroi; M. Kusama; K. Hisamatsu; K. Yamazaki; S. Eisei; Y. Sato; H. Kaise; M. Kashiwaba; H. Iwase; M. Kurosumi; H. Tsuda; F. Akiyama Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01) Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01) Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01) Gan to kagaku ryoho. Cancer & chemotherapy, 34, 10, 1609-1615 Gan to kagaku ryoho. Cancer & chemotherapy, 34, 10, 1609-1615 Gan to kagaku ryoho. Cancer & chemotherapy, 34, 10, 1609-1615 2007 英語 公開
M. Takada; M. Toi M. Takada; M. Toi M. Takada; M. Toi Primary systemic chemotherapy for breast cancer Primary systemic chemotherapy for breast cancer Primary systemic chemotherapy for breast cancer Gan to kagaku ryoho. Cancer & chemotherapy, 34, 11, 1730-1734 Gan to kagaku ryoho. Cancer & chemotherapy, 34, 11, 1730-1734 Gan to kagaku ryoho. Cancer & chemotherapy, 34, 11, 1730-1734 2007 日本語 公開
M.Z. Dewan; J.-N. Uchihara; K. Terashima; M. Honda; T. Sata; M. Ito; N. Fujii; K. Uozumi; K. Tsukasaki; M. Tomonaga; Y. Kubuki; A. Okayama; M. Toi; N. Mori; N. Yamamoto M.Z. Dewan; J.-N. Uchihara; K. Terashima; M. Honda; T. Sata; M. Ito; N. Fujii; K. Uozumi; K. Tsukasaki; M. Tomonaga; Y. Kubuki; A. Okayama; M. Toi; N. Mori; N. Yamamoto M.Z. Dewan; J.-N. Uchihara; K. Terashima; M. Honda; T. Sata; M. Ito; N. Fujii; K. Uozumi; K. Tsukasaki; M. Tomonaga; Y. Kubuki; A. Okayama; M. Toi; N. Mori; N. Yamamoto Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir Blood, 107, 2, 716-724 Blood, 107, 2, 716-724 Blood, 107, 2, 716-724 2006 英語 公開
M. Muta; G. Matsumoto; E. Nakashima; M. Toi M. Muta; G. Matsumoto; E. Nakashima; M. Toi M. Muta; G. Matsumoto; E. Nakashima; M. Toi Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: Importance of monocyte chemoattractant protein-1 modulation Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: Importance of monocyte chemoattractant protein-1 modulation Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: Importance of monocyte chemoattractant protein-1 modulation Clinical Cancer Research, 12, 1, 264-272 Clinical Cancer Research, 12, 1, 264-272 Clinical Cancer Research, 12, 1, 264-272 2006 英語 公開
M. Kondo; M. Toi M. Kondo; M. Toi M. Kondo; M. Toi Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan Expert Review of Anticancer Therapy, 6, 2, 197-204 Expert Review of Anticancer Therapy, 6, 2, 197-204 Expert Review of Anticancer Therapy, 6, 2, 197-204 2006 英語 公開
T. Suzuki; M. Toi; S. Saji; K. Horiguchi; T. Aruga; E. Suzuki; S. Horiguchi; N. Funata; K. Karasawa; N. Kamata T. Suzuki; M. Toi; S. Saji; K. Horiguchi; T. Aruga; E. Suzuki; S. Horiguchi; N. Funata; K. Karasawa; N. Kamata T. Suzuki; M. Toi; S. Saji; K. Horiguchi; T. Aruga; E. Suzuki; S. Horiguchi; N. Funata; K. Karasawa; N. Kamata Early breast cancer Early breast cancer Early breast cancer International Journal of Clinical Oncology, 11, 2, 108-119 International Journal of Clinical Oncology, 11, 2, 108-119 International Journal of Clinical Oncology, 11, 2, 108-119 2006 英語 公開
T. Saeki; T. Kimura; M. Toi; T. Taguchi T. Saeki; T. Kimura; M. Toi; T. Taguchi T. Saeki; T. Kimura; M. Toi; T. Taguchi A pilot phase II study of capecitabine in advanced or recurrent breast cancer. A pilot phase II study of capecitabine in advanced or recurrent breast cancer. A pilot phase II study of capecitabine in advanced or recurrent breast cancer. Breast cancer (Tokyo, Japan), 13, 1, 49-57 Breast cancer (Tokyo, Japan), 13, 1, 49-57 Breast cancer (Tokyo, Japan), 13, 1, 49-57 2006 英語 公開
K. Kuroi; M. Toi; H. Tsuda; M. Kurosumi; F. Akiyama K. Kuroi; M. Toi; H. Tsuda; M. Kurosumi; F. Akiyama K. Kuroi; M. Toi; H. Tsuda; M. Kurosumi; F. Akiyama Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast cancer (Tokyo, Japan), 13, 1, 38-48 Breast cancer (Tokyo, Japan), 13, 1, 38-48 Breast cancer (Tokyo, Japan), 13, 1, 38-48 2006 英語 公開
M.Z. Dewan; S. Ahmed; Y. Iwasaki; K. Ohba; M. Toi; N. Yamamoto M.Z. Dewan; S. Ahmed; Y. Iwasaki; K. Ohba; M. Toi; N. Yamamoto M.Z. Dewan; S. Ahmed; Y. Iwasaki; K. Ohba; M. Toi; N. Yamamoto Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer Biomedicine and Pharmacotherapy, 60, 6, 273-276 Biomedicine and Pharmacotherapy, 60, 6, 273-276 Biomedicine and Pharmacotherapy, 60, 6, 273-276 2006 英語 公開
T. Ueno; L.W.C. Chow; M. Toi T. Ueno; L.W.C. Chow; M. Toi T. Ueno; L.W.C. Chow; M. Toi Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients Biomedicine and Pharmacotherapy, 60, 6, 277-279 Biomedicine and Pharmacotherapy, 60, 6, 277-279 Biomedicine and Pharmacotherapy, 60, 6, 277-279 2006 英語 公開
Md.Z. Dewan; H. Terunuma; M. Toi; Y. Tanaka; H. Katano; X. Deng; H. Abe; T. Nakasone; N. Mori; T. Sata; N. Yamamoto Md.Z. Dewan; H. Terunuma; M. Toi; Y. Tanaka; H. Katano; X. Deng; H. Abe; T. Nakasone; N. Mori; T. Sata; N. Yamamoto Md.Z. Dewan; H. Terunuma; M. Toi; Y. Tanaka; H. Katano; X. Deng; H. Abe; T. Nakasone; N. Mori; T. Sata; N. Yamamoto Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells Cancer Science, 97, 12, 1381-1387 Cancer Science, 97, 12, 1381-1387 Cancer Science, 97, 12, 1381-1387 2006 英語 公開
Y. Asami; H. Kakeya; G. Okada; M. Toi; H. Osada Y. Asami; H. Kakeya; G. Okada; M. Toi; H. Osada Y. Asami; H. Kakeya; G. Okada; M. Toi; H. Osada RK-95113, a new angiogenesis inhibitor produced by Aspergillus fumigatus RK-95113, a new angiogenesis inhibitor produced by Aspergillus fumigatus RK-95113, a new angiogenesis inhibitor produced by Aspergillus fumigatus Journal of Antibiotics, 59, 11, 724-728 Journal of Antibiotics, 59, 11, 724-728 Journal of Antibiotics, 59, 11, 724-728 2006 英語 公開
H. Bando; H.A. Weich; S. Horiguchi; N. Funata; T. Ogawa; M. Toi H. Bando; H.A. Weich; S. Horiguchi; N. Funata; T. Ogawa; M. Toi H. Bando; H.A. Weich; S. Horiguchi; N. Funata; T. Ogawa; M. Toi The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: A study with 193 cases The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: A study with 193 cases The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: A study with 193 cases Oncology Reports, 15, 3, 653-659 Oncology Reports, 15, 3, 653-659 Oncology Reports, 15, 3, 653-659 2006 英語 公開
E. Suzuki; M. Toi E. Suzuki; M. Toi E. Suzuki; M. Toi Neoadjuvant Chemotherapy in breast cancer Neoadjuvant Chemotherapy in breast cancer Neoadjuvant Chemotherapy in breast cancer Nippon rinsho. Japanese journal of clinical medicine, 64, 3, 536-539 Nippon rinsho. Japanese journal of clinical medicine, 64, 3, 536-539 Nippon rinsho. Japanese journal of clinical medicine, 64, 3, 536-539 2006 英語 公開
M. Toi; Y. Iino M. Toi; Y. Iino M. Toi; Y. Iino Who benefits from hormone therapy? Who benefits from hormone therapy? Who benefits from hormone therapy? Breast cancer (Tokyo, Japan), 13, 2, 117-122 Breast cancer (Tokyo, Japan), 13, 2, 117-122 Breast cancer (Tokyo, Japan), 13, 2, 117-122 2006 英語 公開
G. Matsumoto; J.-I. Namekawa; M. Muta; T. Nakamura; H. Bando; K. Tohyama; M. Toi; K. Umezawa G. Matsumoto; J.-I. Namekawa; M. Muta; T. Nakamura; H. Bando; K. Tohyama; M. Toi; K. Umezawa G. Matsumoto; J.-I. Namekawa; M. Muta; T. Nakamura; H. Bando; K. Tohyama; M. Toi; K. Umezawa Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo Clinical Cancer Research, 11, 3, 1287-1293 Clinical Cancer Research, 11, 3, 1287-1293 Clinical Cancer Research, 11, 3, 1287-1293 2005 英語 公開
M. Yasuno; T. Mori; M. Koike; K. Takahashi; M. Toi; T. Takizawa; S. Shimizu; T. Yamaguchi; H. Matsumoto M. Yasuno; T. Mori; M. Koike; K. Takahashi; M. Toi; T. Takizawa; S. Shimizu; T. Yamaguchi; H. Matsumoto M. Yasuno; T. Mori; M. Koike; K. Takahashi; M. Toi; T. Takizawa; S. Shimizu; T. Yamaguchi; H. Matsumoto Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma Oncology Reports, 13, 3, 405-412 Oncology Reports, 13, 3, 405-412 Oncology Reports, 13, 3, 405-412 2005 英語 公開
I. Okubo; M. Kondo; M. Toi; T. Ochiai; S. Miki I. Okubo; M. Kondo; M. Toi; T. Ochiai; S. Miki I. Okubo; M. Kondo; M. Toi; T. Ochiai; S. Miki Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan. Gan to kagaku ryoho. Cancer & chemotherapy, 32, 3, 351-363 Gan to kagaku ryoho. Cancer & chemotherapy, 32, 3, 351-363 Gan to kagaku ryoho. Cancer & chemotherapy, 32, 3, 351-363 2005 英語 公開
H. Bando; M. Toi H. Bando; M. Toi H. Bando; M. Toi VEGF (vascular endothelial growth factor) VEGF (vascular endothelial growth factor) VEGF (vascular endothelial growth factor) Nippon rinsho. Japanese journal of clinical medicine., 63 Suppl 8, 99-102 Nippon rinsho. Japanese journal of clinical medicine., 63 Suppl 8, 99-102 Nippon rinsho. Japanese journal of clinical medicine., 63 Suppl 8, 99-102 2005 英語 公開
G. Matsumoto; M. Muta; K. Umezawa; T. Suzuki; K. Misumi; K. Tsuruta; A. Okamoto; M. Toi G. Matsumoto; M. Muta; K. Umezawa; T. Suzuki; K. Misumi; K. Tsuruta; A. Okamoto; M. Toi G. Matsumoto; M. Muta; K. Umezawa; T. Suzuki; K. Misumi; K. Tsuruta; A. Okamoto; M. Toi Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-κB inhibitor Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-κB inhibitor Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-κB inhibitor International Journal of Oncology, 27, 5, 1247-1255 International Journal of Oncology, 27, 5, 1247-1255 International Journal of Oncology, 27, 5, 1247-1255 2005 英語 公開
M. Toi; M. Atiqur Rahman; H. Bando; L.W.C. Chow M. Toi; M. Atiqur Rahman; H. Bando; L.W.C. Chow M. Toi; M. Atiqur Rahman; H. Bando; L.W.C. Chow Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment Lancet Oncology, 6, 3, 158-166 Lancet Oncology, 6, 3, 158-166 Lancet Oncology, 6, 3, 158-166 2005 英語 公開
H. Bando; H.A. Weich; M. Brokelmann; S. Horiguchi; N. Funata; T. Ogawa; M. Toi H. Bando; H.A. Weich; M. Brokelmann; S. Horiguchi; N. Funata; T. Ogawa; M. Toi H. Bando; H.A. Weich; M. Brokelmann; S. Horiguchi; N. Funata; T. Ogawa; M. Toi Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer British Journal of Cancer, 92, 3, 553-561 British Journal of Cancer, 92, 3, 553-561 British Journal of Cancer, 92, 3, 553-561 2005 英語 公開
C. Nakanishi; M. Toi C. Nakanishi; M. Toi C. Nakanishi; M. Toi Nuclear factor-κB inhibitors as sensitizers to anticancer drugs Nuclear factor-κB inhibitors as sensitizers to anticancer drugs Nuclear factor-κB inhibitors as sensitizers to anticancer drugs Nature Reviews Cancer, 5, 4, 297-309 Nature Reviews Cancer, 5, 4, 297-309 Nature Reviews Cancer, 5, 4, 297-309 2005 英語 公開
T. Saeki; S. Takashima; M. Terashima; A. Satoh; M. Toi; A. Osaki; T. Toge; S. Ohno; N. Nomura; Y. Fukuyama; W. Koizumi; T. Taguchi T. Saeki; S. Takashima; M. Terashima; A. Satoh; M. Toi; A. Osaki; T. Toge; S. Ohno; N. Nomura; Y. Fukuyama; W. Koizumi; T. Taguchi T. Saeki; S. Takashima; M. Terashima; A. Satoh; M. Toi; A. Osaki; T. Toge; S. Ohno; N. Nomura; Y. Fukuyama; W. Koizumi; T. Taguchi A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors International Journal of Clinical Oncology, 10, 1, 51-57 International Journal of Clinical Oncology, 10, 1, 51-57 International Journal of Clinical Oncology, 10, 1, 51-57 2005 英語 公開
K. Hiramatsu; K. Takahashi; T. Yamaguchi; H. Matsumoto; H. Miyamoto; S. Tanaka; C. Tanaka; Y. Tamamori; M. Imajo; M. Kawaguchi; M. Toi; T. Mori; M. Kawakita K. Hiramatsu; K. Takahashi; T. Yamaguchi; H. Matsumoto; H. Miyamoto; S. Tanaka; C. Tanaka; Y. Tamamori; M. Imajo; M. Kawaguchi; M. Toi; T. Mori; M. Kawakita K. Hiramatsu; K. Takahashi; T. Yamaguchi; H. Matsumoto; H. Miyamoto; S. Tanaka; C. Tanaka; Y. Tamamori; M. Imajo; M. Kawaguchi; M. Toi; T. Mori; M. Kawakita N <sup>1</sup>,N <sup>12</sup>-diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers N <sup>1</sup>,N <sup>12</sup>-diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers N <sup>1</sup>,N <sup>12</sup>-diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers Clinical Cancer Research, 11, 8, 2986-2990 Clinical Cancer Research, 11, 8, 2986-2990 Clinical Cancer Research, 11, 8, 2986-2990 2005 英語 公開
S. Saji; M. Kawakami; S.-I. Hayashi; N. Yoshida; M. Hirose; S.-I. Horiguchi; A. Itoh; N. Funata; S.L. Schreiber; M. Yoshida; M. Toi S. Saji; M. Kawakami; S.-I. Hayashi; N. Yoshida; M. Hirose; S.-I. Horiguchi; A. Itoh; N. Funata; S.L. Schreiber; M. Yoshida; M. Toi S. Saji; M. Kawakami; S.-I. Hayashi; N. Yoshida; M. Hirose; S.-I. Horiguchi; A. Itoh; N. Funata; S.L. Schreiber; M. Yoshida; M. Toi Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer Oncogene, 24, 28, 4531-4539 Oncogene, 24, 28, 4531-4539 Oncogene, 24, 28, 4531-4539 2005 英語 公開
M. Toi; T. Saeki; K. Aogi; M. Sano; K. Hatake; T. Asaga; Y. Tokuda; S. Mitsuyama; M. Kimura; T. Kobayashi; M. Tamura; T. Tabei; E. Shin; R. Nishimura; S. Ohno; S. Takashima M. Toi; T. Saeki; K. Aogi; M. Sano; K. Hatake; T. Asaga; Y. Tokuda; S. Mitsuyama; M. Kimura; T. Kobayashi; M. Tamura; T. Tabei; E. Shin; R. Nishimura; S. Ohno; S. Takashima M. Toi; T. Saeki; K. Aogi; M. Sano; K. Hatake; T. Asaga; Y. Tokuda; S. Mitsuyama; M. Kimura; T. Kobayashi; M. Tamura; T. Tabei; E. Shin; R. Nishimura; S. Ohno; S. Takashima Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes Japanese Journal of Clinical Oncology, 35, 6, 310-315 Japanese Journal of Clinical Oncology, 35, 6, 310-315 Japanese Journal of Clinical Oncology, 35, 6, 310-315 2005 英語 公開
M. Toi; Y. Takebayashi; L.W. Chow M. Toi; Y. Takebayashi; L.W. Chow M. Toi; Y. Takebayashi; L.W. Chow Translational research in breast cancer Translational research in breast cancer Translational research in breast cancer Breast Cancer, 12, 2, 86-90 Breast Cancer, 12, 2, 86-90 Breast Cancer, 12, 2, 86-90 2005 英語 公開
H. Iwata; S. Nakamura; M. Toi; E. Shin; N. Masuda; S. Ohno; Y. Takatsuka; K. Hisamatsu; K. Yamazaki; M. Kusama; H. Kaise; Y. Sato; K. Kuroi; F. Akiyama; H. Tsuda; M. Kurosumi H. Iwata; S. Nakamura; M. Toi; E. Shin; N. Masuda; S. Ohno; Y. Takatsuka; K. Hisamatsu; K. Yamazaki; M. Kusama; H. Kaise; Y. Sato; K. Kuroi; F. Akiyama; H. Tsuda; M. Kurosumi H. Iwata; S. Nakamura; M. Toi; E. Shin; N. Masuda; S. Ohno; Y. Takatsuka; K. Hisamatsu; K. Yamazaki; M. Kusama; H. Kaise; Y. Sato; K. Kuroi; F. Akiyama; H. Tsuda; M. Kurosumi Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage Breast carcinoma Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage Breast carcinoma Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage Breast carcinoma Breast Cancer, 12, 2, 99-103 Breast Cancer, 12, 2, 99-103 Breast Cancer, 12, 2, 99-103 2005 英語 公開
G. Gasparini; R. Longo; M. Toi; N. Ferrara G. Gasparini; R. Longo; M. Toi; N. Ferrara G. Gasparini; R. Longo; M. Toi; N. Ferrara Angiogenic inhibitors: A new therapeutic strategy in oncology Angiogenic inhibitors: A new therapeutic strategy in oncology Angiogenic inhibitors: A new therapeutic strategy in oncology Nature Clinical Practice Oncology, 2, 11, 562-577 Nature Clinical Practice Oncology, 2, 11, 562-577 Nature Clinical Practice Oncology, 2, 11, 562-577 2005 英語 公開
S. Saji; M. Hirose; M. Toi S. Saji; M. Hirose; M. Toi S. Saji; M. Hirose; M. Toi Clinical significance of estrogen receptor β in breast cancer Clinical significance of estrogen receptor β in breast cancer Clinical significance of estrogen receptor β in breast cancer Cancer Chemotherapy and Pharmacology, 56, SUPPL. 7, s21-s26 Cancer Chemotherapy and Pharmacology, 56, SUPPL. 7, s21-s26 Cancer Chemotherapy and Pharmacology, 56, SUPPL. 7, s21-s26 2005 英語 公開
M. Toi; K. Horiguchi; H. Bando; S. Saji; L.W.C. Chow M. Toi; K. Horiguchi; H. Bando; S. Saji; L.W.C. Chow M. Toi; K. Horiguchi; H. Bando; S. Saji; L.W.C. Chow Trastuzumab: Updates and future issues Trastuzumab: Updates and future issues Trastuzumab: Updates and future issues Cancer Chemotherapy and Pharmacology, 56, SUPPL. 7, s94-s99 Cancer Chemotherapy and Pharmacology, 56, SUPPL. 7, s94-s99 Cancer Chemotherapy and Pharmacology, 56, SUPPL. 7, s94-s99 2005 英語 公開
K.S. Albain; J. de la Garza Salazar; T. Pienkowski; M. Aapro; J. Bergh; M. Caleffi; R. Coleman; W. Eiermann; F. Içli; M. Pegram; M. Piccart; R. Snyder; M. Toi; G.N. Hortobagyi K.S. Albain; J. de la Garza Salazar; T. Pienkowski; M. Aapro; J. Bergh; M. Caleffi; R. Coleman; W. Eiermann; F. Içli; M. Pegram; M. Piccart; R. Snyder; M. Toi; G.N. Hortobagyi K.S. Albain; J. de la Garza Salazar; T. Pienkowski; M. Aapro; J. Bergh; M. Caleffi; R. Coleman; W. Eiermann; F. Içli; M. Pegram; M. Piccart; R. Snyder; M. Toi; G.N. Hortobagyi Reducing the global breast cancer burden: The importance of patterns of care research Reducing the global breast cancer burden: The importance of patterns of care research Reducing the global breast cancer burden: The importance of patterns of care research Clinical Breast Cancer, 6, 5, 412-420 Clinical Breast Cancer, 6, 5, 412-420 Clinical Breast Cancer, 6, 5, 412-420 2005 英語 公開
S. Ohno; M. Toi; K. Kuroi; S. Nakamura; H. Iwata; M. Kusama; N. Masuda; K. Yamazaki; K. Hisamatsu; Y. Sato; Y. Takatsuka; E. Shin; H. Kaise; M. Kurozumi; H. Tsuda; F. Akiyama S. Ohno; M. Toi; K. Kuroi; S. Nakamura; H. Iwata; M. Kusama; N. Masuda; K. Yamazaki; K. Hisamatsu; Y. Sato; Y. Takatsuka; E. Shin; H. Kaise; M. Kurozumi; H. Tsuda; F. Akiyama S. Ohno; M. Toi; K. Kuroi; S. Nakamura; H. Iwata; M. Kusama; N. Masuda; K. Yamazaki; K. Hisamatsu; Y. Sato; Y. Takatsuka; E. Shin; H. Kaise; M. Kurozumi; H. Tsuda; F. Akiyama Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S323-S324 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S323-S324 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S323-S324 2005 英語 公開
Md.Z. Dewan; H. Terunuma; S. Ahmed; K. Ohba; M. Takada; Y. Tanaka; M. Toi; N. Yamamoto Md.Z. Dewan; H. Terunuma; S. Ahmed; K. Ohba; M. Takada; Y. Tanaka; M. Toi; N. Yamamoto Md.Z. Dewan; H. Terunuma; S. Ahmed; K. Ohba; M. Takada; Y. Tanaka; M. Toi; N. Yamamoto Natural killer cells in breast cancer cell growth and metastasis in SCID mice Natural killer cells in breast cancer cell growth and metastasis in SCID mice Natural killer cells in breast cancer cell growth and metastasis in SCID mice Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S375-S379 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S375-S379 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S375-S379 2005 英語 公開
L.W.C. Chow; W.T.Y. Loo; C.C.Y. Wai; E.L.H. Lui; L. Zhu; M. Toi L.W.C. Chow; W.T.Y. Loo; C.C.Y. Wai; E.L.H. Lui; L. Zhu; M. Toi L.W.C. Chow; W.T.Y. Loo; C.C.Y. Wai; E.L.H. Lui; L. Zhu; M. Toi Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S298-S301 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S298-S301 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S298-S301 2005 英語 公開
T. Ueno; M. Toi; S. Linder T. Ueno; M. Toi; S. Linder T. Ueno; M. Toi; S. Linder Detection of epithelial cell death in the body by cytokeratin 18 measurement Detection of epithelial cell death in the body by cytokeratin 18 measurement Detection of epithelial cell death in the body by cytokeratin 18 measurement Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S359-S362 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S359-S362 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S359-S362 2005 英語 公開
L.W.C. Chow; C.W.L. Cheng; J.L.N. Wong; M. Toi L.W.C. Chow; C.W.L. Cheng; J.L.N. Wong; M. Toi L.W.C. Chow; C.W.L. Cheng; J.L.N. Wong; M. Toi Serum lipid profiles in patients receiving endocrine treatment for breast cancer - The results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial Serum lipid profiles in patients receiving endocrine treatment for breast cancer - The results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial Serum lipid profiles in patients receiving endocrine treatment for breast cancer - The results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S302-S305 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S302-S305 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S302-S305 2005 英語 公開
K. Kuroi; M. Toi; H. Tsuda; M. Kurosumi; F. Akiyama K. Kuroi; M. Toi; H. Tsuda; M. Kurosumi; F. Akiyama K. Kuroi; M. Toi; H. Tsuda; M. Kurosumi; F. Akiyama Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S387-S392 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S387-S392 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S387-S392 2005 英語 公開
L.W.C. Chow; M. Toi L.W.C. Chow; M. Toi L.W.C. Chow; M. Toi Translational research in oncology comes timely Translational research in oncology comes timely Translational research in oncology comes timely Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S263 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S263 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S263 2005 英語 公開
M. Toi; H. Bando; H.A. Weich M. Toi; H. Bando; H.A. Weich M. Toi; H. Bando; H.A. Weich Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: A hypothetical consideration Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: A hypothetical consideration Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: A hypothetical consideration Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S344-S347 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S344-S347 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S344-S347 2005 英語 公開
L.W.C. Chow; W.T.Y. Loo; M. Toi L.W.C. Chow; W.T.Y. Loo; M. Toi L.W.C. Chow; W.T.Y. Loo; M. Toi Current directions for COX-2 inhibition in breast cancer Current directions for COX-2 inhibition in breast cancer Current directions for COX-2 inhibition in breast cancer Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S281-S284 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S281-S284 Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S281-S284 2005 英語 公開
H.A. Weich; H. Bando; M. Brokelmann; P. Baumann; M. Toi; B. Barleon; K. Alitalo; B. Sipos; J. Sleeman H.A. Weich; H. Bando; M. Brokelmann; P. Baumann; M. Toi; B. Barleon; K. Alitalo; B. Sipos; J. Sleeman H.A. Weich; H. Bando; M. Brokelmann; P. Baumann; M. Toi; B. Barleon; K. Alitalo; B. Sipos; J. Sleeman Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA Journal of Immunological Methods, 285, 2, 145-155 Journal of Immunological Methods, 285, 2, 145-155 Journal of Immunological Methods, 285, 2, 145-155 2004 英語 公開
C. Nakanishi; T. Yamaguchi; T. Iijima; S. Saji; M. Toi; T. Mori; M. Miyaki C. Nakanishi; T. Yamaguchi; T. Iijima; S. Saji; M. Toi; T. Mori; M. Miyaki C. Nakanishi; T. Yamaguchi; T. Iijima; S. Saji; M. Toi; T. Mori; M. Miyaki Germline mutation of the LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome. Germline mutation of the LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome. Germline mutation of the LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome. Oncology, 67, 5-6, 476-479 Oncology, 67, 5-6, 476-479 Oncology, 67, 5-6, 476-479 2004 英語 公開
M. Toi; M. Takada; H. Bando; K. Toyama; H. Yamashiro; S. Horiguchi; S. Saji M. Toi; M. Takada; H. Bando; K. Toyama; H. Yamashiro; S. Horiguchi; S. Saji M. Toi; M. Takada; H. Bando; K. Toyama; H. Yamashiro; S. Horiguchi; S. Saji Current status of antibody therapy for breast cancer Current status of antibody therapy for breast cancer Current status of antibody therapy for breast cancer Breast Cancer, 11, 1, 10-14 Breast Cancer, 11, 1, 10-14 Breast Cancer, 11, 1, 10-14 2004 英語 公開
S. Saji; M. Hirose; M. Toi S. Saji; M. Hirose; M. Toi S. Saji; M. Hirose; M. Toi Novel sensitizing agents: Potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer Novel sensitizing agents: Potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer Novel sensitizing agents: Potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer Breast Cancer, 11, 2, 129-133 Breast Cancer, 11, 2, 129-133 Breast Cancer, 11, 2, 129-133 2004 英語 公開
S. Morita; M. Toi; T. Kobayashi; Y. Ito; Y. Hozumi; S. Ohno; H. Iwata; J. Sakamoto S. Morita; M. Toi; T. Kobayashi; Y. Ito; Y. Hozumi; S. Ohno; H. Iwata; J. Sakamoto S. Morita; M. Toi; T. Kobayashi; Y. Ito; Y. Hozumi; S. Ohno; H. Iwata; J. Sakamoto Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer Japanese Journal of Clinical Oncology, 34, 2, 104-106 Japanese Journal of Clinical Oncology, 34, 2, 104-106 Japanese Journal of Clinical Oncology, 34, 2, 104-106 2004 英語 公開
M. Toi; H. Bando; S. Horiguchi; M. Takada; A. Kataoka; T. Ueno; S. Saji; M. Muta; N. Funata; S. Ohno M. Toi; H. Bando; S. Horiguchi; M. Takada; A. Kataoka; T. Ueno; S. Saji; M. Muta; N. Funata; S. Ohno M. Toi; H. Bando; S. Horiguchi; M. Takada; A. Kataoka; T. Ueno; S. Saji; M. Muta; N. Funata; S. Ohno Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer British Journal of Cancer, 90, 12, 2338-2343 British Journal of Cancer, 90, 12, 2338-2343 British Journal of Cancer, 90, 12, 2338-2343 2004 英語 公開
H. Bando; M. Brokelmann; M. Toi; K. Alitalo; J.P. Sleeman; B. Sipos; H.-J. Gröne; H.A. Weich H. Bando; M. Brokelmann; M. Toi; K. Alitalo; J.P. Sleeman; B. Sipos; H.-J. Gröne; H.A. Weich H. Bando; M. Brokelmann; M. Toi; K. Alitalo; J.P. Sleeman; B. Sipos; H.-J. Gröne; H.A. Weich Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues International Journal of Cancer, 111, 2, 184-191 International Journal of Cancer, 111, 2, 184-191 International Journal of Cancer, 111, 2, 184-191 2004 英語 公開
Y. Asami; H. Kakeya; R. Onose; Y.-H. Chang; M. Toi; H. Osada Y. Asami; H. Kakeya; R. Onose; Y.-H. Chang; M. Toi; H. Osada Y. Asami; H. Kakeya; R. Onose; Y.-H. Chang; M. Toi; H. Osada RK-805, an endothelial-cell-growth inhibitor produced by Neosartorya sp., and a docking model with methionine aminopeptidase-2 RK-805, an endothelial-cell-growth inhibitor produced by Neosartorya sp., and a docking model with methionine aminopeptidase-2 RK-805, an endothelial-cell-growth inhibitor produced by Neosartorya sp., and a docking model with methionine aminopeptidase-2 Tetrahedron, 60, 33, 7085-7091 Tetrahedron, 60, 33, 7085-7091 Tetrahedron, 60, 33, 7085-7091 2004 英語 公開
L. Zhu; L.W.C. Chow; W.T.Y. Loo; X.-Y. Guan; M. Toi L. Zhu; L.W.C. Chow; W.T.Y. Loo; X.-Y. Guan; M. Toi L. Zhu; L.W.C. Chow; W.T.Y. Loo; X.-Y. Guan; M. Toi Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trial Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trial Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trial Clinical Cancer Research, 10, 14, 4639-4644 Clinical Cancer Research, 10, 14, 4639-4644 Clinical Cancer Research, 10, 14, 4639-4644 2004 英語 公開
M. Kawakami; S. Saji; M. Toi M. Kawakami; S. Saji; M. Toi M. Kawakami; S. Saji; M. Toi Controversies in endocrine therapy for breast cancer Controversies in endocrine therapy for breast cancer Controversies in endocrine therapy for breast cancer Gan to kagaku ryoho. Cancer & chemotherapy, 31, 2, 181-187 Gan to kagaku ryoho. Cancer & chemotherapy, 31, 2, 181-187 Gan to kagaku ryoho. Cancer & chemotherapy, 31, 2, 181-187 2004 英語 公開
G. Matsumoto; M.A. Rahman; M. Muta; T. Nakamura; H. Bando; S. Saji; K. Tsuruta; A. Okamoto; M. Toi G. Matsumoto; M.A. Rahman; M. Muta; T. Nakamura; H. Bando; S. Saji; K. Tsuruta; A. Okamoto; M. Toi G. Matsumoto; M.A. Rahman; M. Muta; T. Nakamura; H. Bando; S. Saji; K. Tsuruta; A. Okamoto; M. Toi DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice Oncology Reports, 12, 2, 281-285 Oncology Reports, 12, 2, 281-285 Oncology Reports, 12, 2, 281-285 2004 英語 公開
T. Tominaga; M. Kimura; T. Asaga; M. Yoshida; H. Awane; H. Koyama; Y. Takatsuka; S. Mitsuyama; T. Ikeda; M. Ogita; H. Aoyama; M. Sano; R. Abe; T. Nishi; T. Wada; M. Danno; M. Toi; S. Takashima T. Tominaga; M. Kimura; T. Asaga; M. Yoshida; H. Awane; H. Koyama; Y. Takatsuka; S. Mitsuyama; T. Ikeda; M. Ogita; H. Aoyama; M. Sano; R. Abe; T. Nishi; T. Wada; M. Danno; M. Toi; S. Takashima T. Tominaga; M. Kimura; T. Asaga; M. Yoshida; H. Awane; H. Koyama; Y. Takatsuka; S. Mitsuyama; T. Ikeda; M. Ogita; H. Aoyama; M. Sano; R. Abe; T. Nishi; T. Wada; M. Danno; M. Toi; S. Takashima 1-Hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: A randomized controlled trial 1-Hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: A randomized controlled trial 1-Hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: A randomized controlled trial Oncology Reports, 12, 4, 797-803 Oncology Reports, 12, 4, 797-803 Oncology Reports, 12, 4, 797-803 2004 英語 公開
M. Takada; A. Kataoka; M. Toi; H. Bando; K. Toyama; S. Horiguchi; T. Ueno; S. Linder; S. Saji; Y. Hayashi; N. Funata; J. Kinoshita; S. Murakami; S. Ohono M. Takada; A. Kataoka; M. Toi; H. Bando; K. Toyama; S. Horiguchi; T. Ueno; S. Linder; S. Saji; Y. Hayashi; N. Funata; J. Kinoshita; S. Murakami; S. Ohono M. Takada; A. Kataoka; M. Toi; H. Bando; K. Toyama; S. Horiguchi; T. Ueno; S. Linder; S. Saji; Y. Hayashi; N. Funata; J. Kinoshita; S. Murakami; S. Ohono A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. International journal of oncology, 25, 2, 397-405 International journal of oncology, 25, 2, 397-405 International journal of oncology, 25, 2, 397-405 2004 英語 公開
M. Kawakita; K. Hiramatsu; M. Sugimoto; K. Takahashi; M. Toi M. Kawakita; K. Hiramatsu; M. Sugimoto; K. Takahashi; M. Toi M. Kawakita; K. Hiramatsu; M. Sugimoto; K. Takahashi; M. Toi Clinical usefulness of urinary diacetylpolyamines as novel tumor markers Clinical usefulness of urinary diacetylpolyamines as novel tumor markers Clinical usefulness of urinary diacetylpolyamines as novel tumor markers Rinsho byori. The Japanese journal of clinical pathology, 52, 4, 321-327 Rinsho byori. The Japanese journal of clinical pathology, 52, 4, 321-327 Rinsho byori. The Japanese journal of clinical pathology, 52, 4, 321-327 2004 英語 公開
H. Yamashiro; K. Toyama; H. Bando; S. Saji; M. Toi H. Yamashiro; K. Toyama; H. Bando; S. Saji; M. Toi H. Yamashiro; K. Toyama; H. Bando; S. Saji; M. Toi Trastuzumab treatment for breast cancer Trastuzumab treatment for breast cancer Trastuzumab treatment for breast cancer Nippon rinsho. Japanese journal of clinical medicine, 62, 7, 1305-1311 Nippon rinsho. Japanese journal of clinical medicine, 62, 7, 1305-1311 Nippon rinsho. Japanese journal of clinical medicine, 62, 7, 1305-1311 2004 英語 公開
M. Kuwano; Y. Oda; H. Izumi; S.-J. Yang; T. Uchiumi; Y. Iwamoto; M. Toi; T. Fujii; H. Yamana; H. Kinoshita; T. Kamura; M. Tsuneyoshi; K. Yasumoto; K. Kohno M. Kuwano; Y. Oda; H. Izumi; S.-J. Yang; T. Uchiumi; Y. Iwamoto; M. Toi; T. Fujii; H. Yamana; H. Kinoshita; T. Kamura; M. Tsuneyoshi; K. Yasumoto; K. Kohno M. Kuwano; Y. Oda; H. Izumi; S.-J. Yang; T. Uchiumi; Y. Iwamoto; M. Toi; T. Fujii; H. Yamana; H. Kinoshita; T. Kamura; M. Tsuneyoshi; K. Yasumoto; K. Kohno The role of nuclear Y-box binding protein 1 as a global marker in drug resistance The role of nuclear Y-box binding protein 1 as a global marker in drug resistance The role of nuclear Y-box binding protein 1 as a global marker in drug resistance Molecular Cancer Therapeutics, 3, 11, 1485-1492 Molecular Cancer Therapeutics, 3, 11, 1485-1492 Molecular Cancer Therapeutics, 3, 11, 1485-1492 2004 英語 公開
T. Tominaga; I. Adachi; Y. Sasaki; T. Tabei; T. Ikeda; Y. Takatsuka; M. Toi; T. Suwa; Y. Ohashi T. Tominaga; I. Adachi; Y. Sasaki; T. Tabei; T. Ikeda; Y. Takatsuka; M. Toi; T. Suwa; Y. Ohashi T. Tominaga; I. Adachi; Y. Sasaki; T. Tabei; T. Ikeda; Y. Takatsuka; M. Toi; T. Suwa; Y. Ohashi Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer Annals of Oncology, 14, 1, 62-70 Annals of Oncology, 14, 1, 62-70 Annals of Oncology, 14, 1, 62-70 2003 英語 公開
O. Ogura; A. Kanzaki; H. Bando; T. Ogura; M. Toi; Y. Takebayashi O. Ogura; A. Kanzaki; H. Bando; T. Ogura; M. Toi; Y. Takebayashi O. Ogura; A. Kanzaki; H. Bando; T. Ogura; M. Toi; Y. Takebayashi Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: Implication for method to detect expression of these molecules in clinic Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: Implication for method to detect expression of these molecules in clinic Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: Implication for method to detect expression of these molecules in clinic Cancer Letters, 190, 1, 97-104 Cancer Letters, 190, 1, 97-104 Cancer Letters, 190, 1, 97-104 2003 英語 公開
T. Tominaga; H. Koyama; T. Toge; S. Miura; K. Sugimachi; S. Yamaguchi; K. Hirata; Y. Monden; Y. Nomura; M. Toi; I. Kimijima; S. Noguchi; H. Sonoo; K. Asaishi; T. Ikeda; T. Morimoto; J. Ota; Y. Ohashi; O. Abe T. Tominaga; H. Koyama; T. Toge; S. Miura; K. Sugimachi; S. Yamaguchi; K. Hirata; Y. Monden; Y. Nomura; M. Toi; I. Kimijima; S. Noguchi; H. Sonoo; K. Asaishi; T. Ikeda; T. Morimoto; J. Ota; Y. Ohashi; O. Abe T. Tominaga; H. Koyama; T. Toge; S. Miura; K. Sugimachi; S. Yamaguchi; K. Hirata; Y. Monden; Y. Nomura; M. Toi; I. Kimijima; S. Noguchi; H. Sonoo; K. Asaishi; T. Ikeda; T. Morimoto; J. Ota; Y. Ohashi; O. Abe Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery Journal of Clinical Oncology, 21, 6, 991-998 Journal of Clinical Oncology, 21, 6, 991-998 Journal of Clinical Oncology, 21, 6, 991-998 2003 英語 公開
H. Saji; M. Toi; S. Saji; M. Koike; K. Kohno; M. Kuwano H. Saji; M. Toi; S. Saji; M. Koike; K. Kohno; M. Kuwano H. Saji; M. Toi; S. Saji; M. Koike; K. Kohno; M. Kuwano Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma Cancer Letters, 190, 2, 191-197 Cancer Letters, 190, 2, 191-197 Cancer Letters, 190, 2, 191-197 2003 英語 公開
K. Kuroi; H. Bando; S. Saji; M. Toi K. Kuroi; H. Bando; S. Saji; M. Toi K. Kuroi; H. Bando; S. Saji; M. Toi Weekly schedule of docetaxel in breast cancer: Evaluation of response and toxicity Weekly schedule of docetaxel in breast cancer: Evaluation of response and toxicity Weekly schedule of docetaxel in breast cancer: Evaluation of response and toxicity Breast Cancer, 10, 1, 10-14 Breast Cancer, 10, 1, 10-14 Breast Cancer, 10, 1, 10-14 2003 英語 公開
H. Bando; M. Toi; K. Kitada; M. Koike H. Bando; M. Toi; K. Kitada; M. Koike H. Bando; M. Toi; K. Kitada; M. Koike Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231 Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231 Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231 Biomedicine and Pharmacotherapy, 57, 8, 333-340 Biomedicine and Pharmacotherapy, 57, 8, 333-340 Biomedicine and Pharmacotherapy, 57, 8, 333-340 2003 英語 公開
L.W.C. Chow; J.L.N. Wong; M. Toi L.W.C. Chow; J.L.N. Wong; M. Toi L.W.C. Chow; J.L.N. Wong; M. Toi Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: Preliminary report Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: Preliminary report Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: Preliminary report Journal of Steroid Biochemistry and Molecular Biology, 86, 3-5, 443-447 Journal of Steroid Biochemistry and Molecular Biology, 86, 3-5, 443-447 Journal of Steroid Biochemistry and Molecular Biology, 86, 3-5, 443-447 2003 英語 公開
M.A. Rahman; M. Toi M.A. Rahman; M. Toi M.A. Rahman; M. Toi Anti-angiogenic therapy in breast cancer Anti-angiogenic therapy in breast cancer Anti-angiogenic therapy in breast cancer Biomedicine and Pharmacotherapy, 57, 10, 463-470 Biomedicine and Pharmacotherapy, 57, 10, 463-470 Biomedicine and Pharmacotherapy, 57, 10, 463-470 2003 英語 公開
T. Ueno; M. Toi; K. Bivén; H. Bando; T. Ogawa; S. Linder T. Ueno; M. Toi; K. Bivén; H. Bando; T. Ogawa; S. Linder T. Ueno; M. Toi; K. Bivén; H. Bando; T. Ogawa; S. Linder Measurement of an apoptotic product in the sera of breast cancer patients Measurement of an apoptotic product in the sera of breast cancer patients Measurement of an apoptotic product in the sera of breast cancer patients European Journal of Cancer, 39, 6, 769-774 European Journal of Cancer, 39, 6, 769-774 European Journal of Cancer, 39, 6, 769-774 2003 英語 公開
M. Toi; H. Bando; C. Ramachandran; S.J. Melnick; A. Imai; R.S. Fife; R.E. Carr; T. Oikawa; E.P. Lansky M. Toi; H. Bando; C. Ramachandran; S.J. Melnick; A. Imai; R.S. Fife; R.E. Carr; T. Oikawa; E.P. Lansky M. Toi; H. Bando; C. Ramachandran; S.J. Melnick; A. Imai; R.S. Fife; R.E. Carr; T. Oikawa; E.P. Lansky Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo Angiogenesis, 6, 2, 121-128 Angiogenesis, 6, 2, 121-128 Angiogenesis, 6, 2, 121-128 2003 英語 公開
K. Bivén; H. Erdal; M. Hägg; T. Ueno; R. Zhou; M. Lynch; B. Rowley; J. Wood; C. Zhang; M. Toi; M.C. Shoshan; S. Linder K. Bivén; H. Erdal; M. Hägg; T. Ueno; R. Zhou; M. Lynch; B. Rowley; J. Wood; C. Zhang; M. Toi; M.C. Shoshan; S. Linder K. Bivén; H. Erdal; M. Hägg; T. Ueno; R. Zhou; M. Lynch; B. Rowley; J. Wood; C. Zhang; M. Toi; M.C. Shoshan; S. Linder A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera Apoptosis, 8, 3, 263-268 Apoptosis, 8, 3, 263-268 Apoptosis, 8, 3, 263-268 2003 英語 公開
M. Toi; H. Bando; S. Saji M. Toi; H. Bando; S. Saji M. Toi; H. Bando; S. Saji Decision tree and paradigms of primary breast cancer: Changes elicited by preoperative therapy Decision tree and paradigms of primary breast cancer: Changes elicited by preoperative therapy Decision tree and paradigms of primary breast cancer: Changes elicited by preoperative therapy Medical Science Monitor, 9, 5, RA90-RA95 Medical Science Monitor, 9, 5, RA90-RA95 Medical Science Monitor, 9, 5, RA90-RA95 2003 英語 公開
K. Kuroi; M. Toi K. Kuroi; M. Toi K. Kuroi; M. Toi Male breast cancer Male breast cancer Male breast cancer Gan to kagaku ryoho. Cancer & chemotherapy, 30, 5, 599-605 Gan to kagaku ryoho. Cancer & chemotherapy, 30, 5, 599-605 Gan to kagaku ryoho. Cancer & chemotherapy, 30, 5, 599-605 2003 英語 公開
Y. Yamamoto; J.-I. Yamashita; M. Toi; M. Muta; S. Nagai; N. Hanai; A. Furuya; Y. Osawa; S. Saji; M. Ogawa Y. Yamamoto; J.-I. Yamashita; M. Toi; M. Muta; S. Nagai; N. Hanai; A. Furuya; Y. Osawa; S. Saji; M. Ogawa Y. Yamamoto; J.-I. Yamashita; M. Toi; M. Muta; S. Nagai; N. Hanai; A. Furuya; Y. Osawa; S. Saji; M. Ogawa Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues Oncology Reports, 10, 4, 791-796 Oncology Reports, 10, 4, 791-796 Oncology Reports, 10, 4, 791-796 2003 英語 公開
M. Muta; G. Matsumoto; K. Hiruma; S. Saji; E. Nakashima; M. Toi M. Muta; G. Matsumoto; K. Hiruma; S. Saji; E. Nakashima; M. Toi M. Muta; G. Matsumoto; K. Hiruma; S. Saji; E. Nakashima; M. Toi Impact of vasculogenesis on solid tumor growth in a rat model Impact of vasculogenesis on solid tumor growth in a rat model Impact of vasculogenesis on solid tumor growth in a rat model Oncology Reports, 10, 5, 1213-1218 Oncology Reports, 10, 5, 1213-1218 Oncology Reports, 10, 5, 1213-1218 2003 英語 公開
G. Matsumoto; S. Nagai; M. Muta; K. Tsuruta; A. Okamoto; M. Toi G. Matsumoto; S. Nagai; M. Muta; K. Tsuruta; A. Okamoto; M. Toi G. Matsumoto; S. Nagai; M. Muta; K. Tsuruta; A. Okamoto; M. Toi Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer Oncology Reports, 10, 5, 1201-1206 Oncology Reports, 10, 5, 1201-1206 Oncology Reports, 10, 5, 1201-1206 2003 英語 公開
K. Kuroi; H. Bando; S. Saji; M. Toi K. Kuroi; H. Bando; S. Saji; M. Toi K. Kuroi; H. Bando; S. Saji; M. Toi Protracted administration of weekly docetaxel in metastatic breast cancer Protracted administration of weekly docetaxel in metastatic breast cancer Protracted administration of weekly docetaxel in metastatic breast cancer Oncology Reports, 10, 5, 1479-1484 Oncology Reports, 10, 5, 1479-1484 Oncology Reports, 10, 5, 1479-1484 2003 英語 公開
M. Muta; G. Matsumoto; K. Hiruma; E. Nakashima; M. Toi M. Muta; G. Matsumoto; K. Hiruma; E. Nakashima; M. Toi M. Muta; G. Matsumoto; K. Hiruma; E. Nakashima; M. Toi Study of cancer gene therapy using IL-12-secreting endothelial progenitor cells in a rat solid tumor model. Study of cancer gene therapy using IL-12-secreting endothelial progenitor cells in a rat solid tumor model. Study of cancer gene therapy using IL-12-secreting endothelial progenitor cells in a rat solid tumor model. Oncology reports, 10, 6, 1765-1769 Oncology reports, 10, 6, 1765-1769 Oncology reports, 10, 6, 1765-1769 2003 英語 公開
G. Asai; N. Yamamoto; M. Toi; E. Shin; K. Nishiyama; T. Sekine; Y. Nomura; S. Takashima; M. Kimura; T. Tominaga G. Asai; N. Yamamoto; M. Toi; E. Shin; K. Nishiyama; T. Sekine; Y. Nomura; S. Takashima; M. Kimura; T. Tominaga G. Asai; N. Yamamoto; M. Toi; E. Shin; K. Nishiyama; T. Sekine; Y. Nomura; S. Takashima; M. Kimura; T. Tominaga Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer Cancer Chemotherapy and Pharmacology, 49, 6, 468-472 Cancer Chemotherapy and Pharmacology, 49, 6, 468-472 Cancer Chemotherapy and Pharmacology, 49, 6, 468-472 2002 英語 公開
S. Saji; Y. Omoto; C. Shimizu; S.-I. Horiguchi; T. Watanabe; N. Funata; S.-I. Hayashi; J.-A. Gustafsson; M. Toi S. Saji; Y. Omoto; C. Shimizu; S.-I. Horiguchi; T. Watanabe; N. Funata; S.-I. Hayashi; J.-A. Gustafsson; M. Toi S. Saji; Y. Omoto; C. Shimizu; S.-I. Horiguchi; T. Watanabe; N. Funata; S.-I. Hayashi; J.-A. Gustafsson; M. Toi Clinical impact of assay of estrogen receptorβcx in breast cancer Clinical impact of assay of estrogen receptorβcx in breast cancer Clinical impact of assay of estrogen receptorβcx in breast cancer Breast Cancer, 9, 4, 303-307 Breast Cancer, 9, 4, 303-307 Breast Cancer, 9, 4, 303-307 2002 英語 公開
M. Toi; H. Bando; T. Ogawa; M. Muta; C. Hornig; H.A. Weich M. Toi; H. Bando; T. Ogawa; M. Muta; C. Hornig; H.A. Weich M. Toi; H. Bando; T. Ogawa; M. Muta; C. Hornig; H.A. Weich Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer International Journal of Cancer, 98, 1, 14-18 International Journal of Cancer, 98, 1, 14-18 International Journal of Cancer, 98, 1, 14-18 2002 英語 公開
Y. Kumagai; M. Toi; H. Inoue Y. Kumagai; M. Toi; H. Inoue Y. Kumagai; M. Toi; H. Inoue Dynamism of tumour vasculature in the early phase of cancer progression: Outcomes from oesophageal cancer research Dynamism of tumour vasculature in the early phase of cancer progression: Outcomes from oesophageal cancer research Dynamism of tumour vasculature in the early phase of cancer progression: Outcomes from oesophageal cancer research Lancet Oncology, 3, 10, 604-610 Lancet Oncology, 3, 10, 604-610 Lancet Oncology, 3, 10, 604-610 2002 英語 公開
S. Saji; M. Toi S. Saji; M. Toi S. Saji; M. Toi Aromatase inhibitors and other novel agents in breast cancer treatment Aromatase inhibitors and other novel agents in breast cancer treatment Aromatase inhibitors and other novel agents in breast cancer treatment Expert Opinion on Emerging Drugs, 7, 2, 303-319 Expert Opinion on Emerging Drugs, 7, 2, 303-319 Expert Opinion on Emerging Drugs, 7, 2, 303-319 2002 英語 公開
A. Kanzaki; Y. Takebayashi; H. Bando; J.F. Eliason; S.-I. Watanabe; H. Miyashita; M. Fukumoto; M. Toi; T. Uchida A. Kanzaki; Y. Takebayashi; H. Bando; J.F. Eliason; S.-I. Watanabe; H. Miyashita; M. Fukumoto; M. Toi; T. Uchida A. Kanzaki; Y. Takebayashi; H. Bando; J.F. Eliason; S.-I. Watanabe; H. Miyashita; M. Fukumoto; M. Toi; T. Uchida Expression of uridine and thymidine phosphorylase genes in human breast carcinoma Expression of uridine and thymidine phosphorylase genes in human breast carcinoma Expression of uridine and thymidine phosphorylase genes in human breast carcinoma International Journal of Cancer, 97, 5, 631-635 International Journal of Cancer, 97, 5, 631-635 International Journal of Cancer, 97, 5, 631-635 2002 英語 公開
A. Kanzaki; M. Toi; N. Neamati; H. Miyashita; M. Oubu; K. Nakayama; H. Bando; K. Ogawa; M. Mutoh; S. Mori; K. Terada; T. Sugiyama; M. Fukumoto; Y. Takebayashi A. Kanzaki; M. Toi; N. Neamati; H. Miyashita; M. Oubu; K. Nakayama; H. Bando; K. Ogawa; M. Mutoh; S. Mori; K. Terada; T. Sugiyama; M. Fukumoto; Y. Takebayashi A. Kanzaki; M. Toi; N. Neamati; H. Miyashita; M. Oubu; K. Nakayama; H. Bando; K. Ogawa; M. Mutoh; S. Mori; K. Terada; T. Sugiyama; M. Fukumoto; Y. Takebayashi Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma Japanese Journal of Cancer Research, 93, 1, 70-77 Japanese Journal of Cancer Research, 93, 1, 70-77 Japanese Journal of Cancer Research, 93, 1, 70-77 2002 英語 公開
H. Bando; G. Matsumoto; M. Bando; M. Muta; T. Ogawa; N. Funata; J. Nishihira; M. Koike; M. Toi H. Bando; G. Matsumoto; M. Bando; M. Muta; T. Ogawa; N. Funata; J. Nishihira; M. Koike; M. Toi H. Bando; G. Matsumoto; M. Bando; M. Muta; T. Ogawa; N. Funata; J. Nishihira; M. Koike; M. Toi Expression of macrophage migration inhibitory factor in human breast cancer: Association with nodal spread Expression of macrophage migration inhibitory factor in human breast cancer: Association with nodal spread Expression of macrophage migration inhibitory factor in human breast cancer: Association with nodal spread Japanese Journal of Cancer Research, 93, 4, 389-396 Japanese Journal of Cancer Research, 93, 4, 389-396 Japanese Journal of Cancer Research, 93, 4, 389-396 2002 英語 公開
M. Toi M. Toi M. Toi Proinflammation in human tumor microenvironment: Its status and implication [1] Proinflammation in human tumor microenvironment: Its status and implication [1] Proinflammation in human tumor microenvironment: Its status and implication [1] Medical Science Monitor, 8, 7, LE25-LE26 Medical Science Monitor, 8, 7, LE25-LE26 Medical Science Monitor, 8, 7, LE25-LE26 2002 英語 公開
T. Tominaga; M. Toi; Y. Ohashi T. Tominaga; M. Toi; Y. Ohashi T. Tominaga; M. Toi; Y. Ohashi Erratum: Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients (Clinical Breast Cancer (2002) vol. 3 (55-64)) Erratum: Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients (Clinical Breast Cancer (2002) vol. 3 (55-64)) Erratum: Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients (Clinical Breast Cancer (2002) vol. 3 (55-64)) Clinical Breast Cancer, 3, 2, 159- Clinical Breast Cancer, 3, 2, 159- Clinical Breast Cancer, 3, 2, 159- 2002 英語 公開
T. Tominaga; M. Toi; O. Abe; Y. Ohashi; J. Uchino; H. Hayasaka; R. Abe; M. Izuo; K. Enomoto; H. Watanabe; M. Yoshida; T. Taguchi; H. Koyama; T. Senoo; T. Toge; Y. Monden; T. Hattori; Y. Nomura; K. Sugimachi; K. Hirata; H. Nakazato; S. Miura; T. Morimoto; K. Asaishi; I. Kimijima; J. Ota; H. Sonoo; S. Yamaguchi T. Tominaga; M. Toi; O. Abe; Y. Ohashi; J. Uchino; H. Hayasaka; R. Abe; M. Izuo; K. Enomoto; H. Watanabe; M. Yoshida; T. Taguchi; H. Koyama; T. Senoo; T. Toge; Y. Monden; T. Hattori; Y. Nomura; K. Sugimachi; K. Hirata; H. Nakazato; S. Miura; T. Morimoto; K. Asaishi; I. Kimijima; J. Ota; H. Sonoo; S. Yamaguchi T. Tominaga; M. Toi; O. Abe; Y. Ohashi; J. Uchino; H. Hayasaka; R. Abe; M. Izuo; K. Enomoto; H. Watanabe; M. Yoshida; T. Taguchi; H. Koyama; T. Senoo; T. Toge; Y. Monden; T. Hattori; Y. Nomura; K. Sugimachi; K. Hirata; H. Nakazato; S. Miura; T. Morimoto; K. Asaishi; I. Kimijima; J. Ota; H. Sonoo; S. Yamaguchi The effect of adjuvant 5\\'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial. The effect of adjuvant 5\\'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial. The effect of adjuvant 5\\'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial. International journal of oncology, 20, 3, 517-525 International journal of oncology, 20, 3, 517-525 International journal of oncology, 20, 3, 517-525 2002 英語 公開
T. Watanabe; M. Sano; M. Toi; T. Saeki; K. Kanda; S. Miura; H. Inaji; H. Sono; H. Saeki; R. Nishimura; Y. Fujita T. Watanabe; M. Sano; M. Toi; T. Saeki; K. Kanda; S. Miura; H. Inaji; H. Sono; H. Saeki; R. Nishimura; Y. Fujita T. Watanabe; M. Sano; M. Toi; T. Saeki; K. Kanda; S. Miura; H. Inaji; H. Sono; H. Saeki; R. Nishimura; Y. Fujita Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents Japanese Journal of Cancer and Chemotherapy, 29, 7, 1211-1221 Japanese Journal of Cancer and Chemotherapy, 29, 7, 1211-1221 Japanese Journal of Cancer and Chemotherapy, 29, 7, 1211-1221 2002 英語 公開
S. Saji; Y. Omoto; C. Shimizu; M. Warner; Y. Hayashi; S.-I. Horiguchi; T. Watanabe; S.-I. Hayashi; J.-Å. Gustafsson; M. Toi S. Saji; Y. Omoto; C. Shimizu; M. Warner; Y. Hayashi; S.-I. Horiguchi; T. Watanabe; S.-I. Hayashi; J.-Å. Gustafsson; M. Toi S. Saji; Y. Omoto; C. Shimizu; M. Warner; Y. Hayashi; S.-I. Horiguchi; T. Watanabe; S.-I. Hayashi; J.-Å. Gustafsson; M. Toi Expression of estrogen receptor (ER) βcx protein in ERα-positive breast cancer: Specific correlation with progesterone receptor Expression of estrogen receptor (ER) βcx protein in ERα-positive breast cancer: Specific correlation with progesterone receptor Expression of estrogen receptor (ER) βcx protein in ERα-positive breast cancer: Specific correlation with progesterone receptor Cancer Research, 62, 17, 4849-4853 Cancer Research, 62, 17, 4849-4853 Cancer Research, 62, 17, 4849-4853 2002 英語 公開
C. Nakanishi; M. Toi; S. Saji; H. Bando C. Nakanishi; M. Toi; S. Saji; H. Bando C. Nakanishi; M. Toi; S. Saji; H. Bando Current indications for mastectomy in patients with breast cancer Current indications for mastectomy in patients with breast cancer Current indications for mastectomy in patients with breast cancer Nippon Geka Gakkai zasshi, 103, 11, 821-824 Nippon Geka Gakkai zasshi, 103, 11, 821-824 Nippon Geka Gakkai zasshi, 103, 11, 821-824 2002 英語 公開
K. Tsuruta; A. Okamoto; M. Toi; H. Saji; T. Takahashi K. Tsuruta; A. Okamoto; M. Toi; H. Saji; T. Takahashi K. Tsuruta; A. Okamoto; M. Toi; H. Saji; T. Takahashi Impact of selective glisson transection on survival of hepatocellular carcinoma Impact of selective glisson transection on survival of hepatocellular carcinoma Impact of selective glisson transection on survival of hepatocellular carcinoma Hepato-Gastroenterology, 49, 48, 1607-1610 Hepato-Gastroenterology, 49, 48, 1607-1610 Hepato-Gastroenterology, 49, 48, 1607-1610 2002 英語 公開
S. Saji; N. Okumura; H. Eguchi; S. Nakashima; A. Suzuki; M. Toi; Y. Nozawa; S. Saji; S.-I. Hayashi S. Saji; N. Okumura; H. Eguchi; S. Nakashima; A. Suzuki; M. Toi; Y. Nozawa; S. Saji; S.-I. Hayashi S. Saji; N. Okumura; H. Eguchi; S. Nakashima; A. Suzuki; M. Toi; Y. Nozawa; S. Saji; S.-I. Hayashi MDM2 enhances the function of estrogen receptor in human breast cancer cells MDM2 enhances the function of estrogen receptor in human breast cancer cells MDM2 enhances the function of estrogen receptor in human breast cancer cells Biochemical and Biophysical Research Communications, 281, 1, 259-265 Biochemical and Biophysical Research Communications, 281, 1, 259-265 Biochemical and Biophysical Research Communications, 281, 1, 259-265 2001 英語 公開
A. Mandic; K. Viktorsson; M. Molin; G. Akusjärvi; H. Eguchi; S.-I. Hayashi; M. Toi; J. Hansson; S. Linder; M.C. Shoshan A. Mandic; K. Viktorsson; M. Molin; G. Akusjärvi; H. Eguchi; S.-I. Hayashi; M. Toi; J. Hansson; S. Linder; M.C. Shoshan A. Mandic; K. Viktorsson; M. Molin; G. Akusjärvi; H. Eguchi; S.-I. Hayashi; M. Toi; J. Hansson; S. Linder; M.C. Shoshan Cisplatin induces the proapoptotic conformation of Bak in a ΔMEKK1-dependent manner Cisplatin induces the proapoptotic conformation of Bak in a ΔMEKK1-dependent manner Cisplatin induces the proapoptotic conformation of Bak in a ΔMEKK1-dependent manner Molecular and Cellular Biology, 21, 11, 3684-3691 Molecular and Cellular Biology, 21, 11, 3684-3691 Molecular and Cellular Biology, 21, 11, 3684-3691 2001 英語 公開
K. Hattori; M. Muta; M. Toi; H. Iizasa; M. Shinsei; T. Terasaki; M. Obinata; M. Ueda; E. Nakashima K. Hattori; M. Muta; M. Toi; H. Iizasa; M. Shinsei; T. Terasaki; M. Obinata; M. Ueda; E. Nakashima K. Hattori; M. Muta; M. Toi; H. Iizasa; M. Shinsei; T. Terasaki; M. Obinata; M. Ueda; E. Nakashima Establishment of bone marrow-derived endothelial cell lines from ts-SV40 T-antigen gene transgenic rats Establishment of bone marrow-derived endothelial cell lines from ts-SV40 T-antigen gene transgenic rats Establishment of bone marrow-derived endothelial cell lines from ts-SV40 T-antigen gene transgenic rats Pharmaceutical Research, 18, 1, 9-15 Pharmaceutical Research, 18, 1, 9-15 Pharmaceutical Research, 18, 1, 9-15 2001 英語 公開
G. Gasparini; M. Toi; E. Biganzoli; R. Dittadi; M. Fanelli; A. Morabito; P. Boracchi; M. Gion G. Gasparini; M. Toi; E. Biganzoli; R. Dittadi; M. Fanelli; A. Morabito; P. Boracchi; M. Gion G. Gasparini; M. Toi; E. Biganzoli; R. Dittadi; M. Fanelli; A. Morabito; P. Boracchi; M. Gion Thrombospondin-1 and -2 in node-negative breast cancer: Correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis Thrombospondin-1 and -2 in node-negative breast cancer: Correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis Thrombospondin-1 and -2 in node-negative breast cancer: Correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis Oncology, 60, 1, 72-80 Oncology, 60, 1, 72-80 Oncology, 60, 1, 72-80 2001 英語 公開
M. Toi; T. Matsumoto; H. Bando M. Toi; T. Matsumoto; H. Bando M. Toi; T. Matsumoto; H. Bando Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications Lancet Oncology, 2, 11, 667-673 Lancet Oncology, 2, 11, 667-673 Lancet Oncology, 2, 11, 667-673 2001 英語 公開
H. Saji; M. Koike; T. Yamori; S. Saji; M. Seiki; K. Matsushima; M. Toi H. Saji; M. Koike; T. Yamori; S. Saji; M. Seiki; K. Matsushima; M. Toi H. Saji; M. Koike; T. Yamori; S. Saji; M. Seiki; K. Matsushima; M. Toi Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma Cancer, 92, 5, 1085-1091 Cancer, 92, 5, 1085-1091 Cancer, 92, 5, 1085-1091 2001 英語 公開
M. Toi; H. Bando; S. Saji M. Toi; H. Bando; S. Saji M. Toi; H. Bando; S. Saji Aromatase and aromatase inhibitors Aromatase and aromatase inhibitors Aromatase and aromatase inhibitors Breast Cancer, 8, 4, 329-332 Breast Cancer, 8, 4, 329-332 Breast Cancer, 8, 4, 329-332 2001 英語 公開
S. Umemura; G. Sakamoto; H. Sasano; H. Tsuda; F. Akiyama; M. Kurosumi; Y. Tokuda; T. Watanabe; M. Toi; T. Hasegawa; R. Yoshiyuki Osamura S. Umemura; G. Sakamoto; H. Sasano; H. Tsuda; F. Akiyama; M. Kurosumi; Y. Tokuda; T. Watanabe; M. Toi; T. Hasegawa; R. Yoshiyuki Osamura S. Umemura; G. Sakamoto; H. Sasano; H. Tsuda; F. Akiyama; M. Kurosumi; Y. Tokuda; T. Watanabe; M. Toi; T. Hasegawa; R. Yoshiyuki Osamura Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab) Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab) Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab) Breast Cancer, 8, 4, 316-320 Breast Cancer, 8, 4, 316-320 Breast Cancer, 8, 4, 316-320 2001 英語 公開
K. Nakayama; A. Kanzaki; Y. Takebayashi; M. Toi; H. Bando; T. Nabei; K. Miyazaki; M. Fukumoto K. Nakayama; A. Kanzaki; Y. Takebayashi; M. Toi; H. Bando; T. Nabei; K. Miyazaki; M. Fukumoto K. Nakayama; A. Kanzaki; Y. Takebayashi; M. Toi; H. Bando; T. Nabei; K. Miyazaki; M. Fukumoto Different features of angiogenesis between ovarian and breast carcinoma Different features of angiogenesis between ovarian and breast carcinoma Different features of angiogenesis between ovarian and breast carcinoma Cancer Letters, 170, 2, 161-167 Cancer Letters, 170, 2, 161-167 Cancer Letters, 170, 2, 161-167 2001 英語 公開
A. Kanzaki; M. Toi; K. Nakayama; H. Bando; M. Mutoh; T. Uchida; M. Fukumoto; Y. Takebayashi A. Kanzaki; M. Toi; K. Nakayama; H. Bando; M. Mutoh; T. Uchida; M. Fukumoto; Y. Takebayashi A. Kanzaki; M. Toi; K. Nakayama; H. Bando; M. Mutoh; T. Uchida; M. Fukumoto; Y. Takebayashi Expression of multidrug resistance-related transporters in human breast carcinoma Expression of multidrug resistance-related transporters in human breast carcinoma Expression of multidrug resistance-related transporters in human breast carcinoma Japanese Journal of Cancer Research, 92, 4, 452-458 Japanese Journal of Cancer Research, 92, 4, 452-458 Japanese Journal of Cancer Research, 92, 4, 452-458 2001 英語 公開
K. Kuroi; M. Toi K. Kuroi; M. Toi K. Kuroi; M. Toi Circulating angiogenesis regulators in cancer patients Circulating angiogenesis regulators in cancer patients Circulating angiogenesis regulators in cancer patients International Journal of Biological Markers, 16, 1, 5-26 International Journal of Biological Markers, 16, 1, 5-26 International Journal of Biological Markers, 16, 1, 5-26 2001 英語 公開
N. Tsuneyoshi; K. Fukudome; S.-I. Horiguchi; X. Ye; M. Matsuzaki; M. Toi; K. Suzuki; M. Kimoto N. Tsuneyoshi; K. Fukudome; S.-I. Horiguchi; X. Ye; M. Matsuzaki; M. Toi; K. Suzuki; M. Kimoto N. Tsuneyoshi; K. Fukudome; S.-I. Horiguchi; X. Ye; M. Matsuzaki; M. Toi; K. Suzuki; M. Kimoto Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines Thrombosis and Haemostasis, 85, 2, 356-361 Thrombosis and Haemostasis, 85, 2, 356-361 Thrombosis and Haemostasis, 85, 2, 356-361 2001 英語 公開
O. Ohno; Y. Shima; Y. Ikeda; S.I. Kondo; K. Kato; M. Toi; K. Umezawa O. Ohno; Y. Shima; Y. Ikeda; S.I. Kondo; K. Kato; M. Toi; K. Umezawa O. Ohno; Y. Shima; Y. Ikeda; S.I. Kondo; K. Kato; M. Toi; K. Umezawa Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. International journal of oncology, 18, 5, 1009-1015 International journal of oncology, 18, 5, 1009-1015 International journal of oncology, 18, 5, 1009-1015 2001 英語 公開
G. Matsumoto; S. Nagai; M. Toi; S. Ishiyama; K. Kuroi; K. Turuta; A. Okamoto; T. Takahashi G. Matsumoto; S. Nagai; M. Toi; S. Ishiyama; K. Kuroi; K. Turuta; A. Okamoto; T. Takahashi G. Matsumoto; S. Nagai; M. Toi; S. Ishiyama; K. Kuroi; K. Turuta; A. Okamoto; T. Takahashi KRN7000 inhibit hepatic metastasis of pancreatic cancer KRN7000 inhibit hepatic metastasis of pancreatic cancer KRN7000 inhibit hepatic metastasis of pancreatic cancer Nippon Geka Gakkai zasshi, 102, 5, 421- Nippon Geka Gakkai zasshi, 102, 5, 421- Nippon Geka Gakkai zasshi, 102, 5, 421- 2001 英語 公開
K. Kuroi; H. Bando; S. Nagai; C. Tanaka; K. Hayashi; M. Toi K. Kuroi; H. Bando; S. Nagai; C. Tanaka; K. Hayashi; M. Toi K. Kuroi; H. Bando; S. Nagai; C. Tanaka; K. Hayashi; M. Toi Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer Japanese Journal of Cancer and Chemotherapy, 28, 6, 797-802 Japanese Journal of Cancer and Chemotherapy, 28, 6, 797-802 Japanese Journal of Cancer and Chemotherapy, 28, 6, 797-802 2001 英語 公開
K. Kuroi; C. Tanaka; M. Toi K. Kuroi; C. Tanaka; M. Toi K. Kuroi; C. Tanaka; M. Toi Clinical significance of plasma nucleosome levels in cancer patients. Clinical significance of plasma nucleosome levels in cancer patients. Clinical significance of plasma nucleosome levels in cancer patients. International journal of oncology, 19, 1, 143-148 International journal of oncology, 19, 1, 143-148 International journal of oncology, 19, 1, 143-148 2001 英語 公開
M. Shitashige; M. Toi; T. Yano; M. Shibata; Y. Matsuo; F. Shibasaki M. Shitashige; M. Toi; T. Yano; M. Shibata; Y. Matsuo; F. Shibasaki M. Shitashige; M. Toi; T. Yano; M. Shibata; Y. Matsuo; F. Shibasaki Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2<sup>1</sup> Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2<sup>1</sup> Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2<sup>1</sup> Journal of Biochemistry, 130, 6, 741-748 Journal of Biochemistry, 130, 6, 741-748 Journal of Biochemistry, 130, 6, 741-748 2001 英語 公開
M. Toi; Y. Bando; S. Saji; T. Matsumoto M. Toi; Y. Bando; S. Saji; T. Matsumoto M. Toi; Y. Bando; S. Saji; T. Matsumoto Tumor angiogenesis and hypoxia Tumor angiogenesis and hypoxia Tumor angiogenesis and hypoxia Biotherapy, 15, 6, 663-668 Biotherapy, 15, 6, 663-668 Biotherapy, 15, 6, 663-668 2001 英語 公開
H. Kodama; I. To; J. Ishiwata; Y. Shinohara; N. Katayanagi; K. Kubota; T. Murakami; K. Kuroi; K. Hayashi; M. Toi H. Kodama; I. To; J. Ishiwata; Y. Shinohara; N. Katayanagi; K. Kubota; T. Murakami; K. Kuroi; K. Hayashi; M. Toi H. Kodama; I. To; J. Ishiwata; Y. Shinohara; N. Katayanagi; K. Kubota; T. Murakami; K. Kuroi; K. Hayashi; M. Toi MEN2A incidentally detected by high level of CEA and family history MEN2A incidentally detected by high level of CEA and family history MEN2A incidentally detected by high level of CEA and family history [Zasshi] Journal. Nihon Naika Gakkai, 90, 4, 683-686 [Zasshi] Journal. Nihon Naika Gakkai, 90, 4, 683-686 [Zasshi] Journal. Nihon Naika Gakkai, 90, 4, 683-686 2001 英語 公開
J. Kurebayashi; H. Sonoo; H. Inaji; R. Nishimura; Y. Iino; M. Toi; S. Kobayashi; T. Saeki J. Kurebayashi; H. Sonoo; H. Inaji; R. Nishimura; Y. Iino; M. Toi; S. Kobayashi; T. Saeki J. Kurebayashi; H. Sonoo; H. Inaji; R. Nishimura; Y. Iino; M. Toi; S. Kobayashi; T. Saeki Endocrine therapies for patients with recurrent breast cancer: Predictive factors for responses to first- and second-line endocrine therapies Endocrine therapies for patients with recurrent breast cancer: Predictive factors for responses to first- and second-line endocrine therapies Endocrine therapies for patients with recurrent breast cancer: Predictive factors for responses to first- and second-line endocrine therapies Oncology, 59, SUPPL. 1, 31-37 Oncology, 59, SUPPL. 1, 31-37 Oncology, 59, SUPPL. 1, 31-37 2000 英語 公開
H. Eguchi; K. Suga; H. Saji; M. Toi; K. Nakachi; S.-I. Hayashi H. Eguchi; K. Suga; H. Saji; M. Toi; K. Nakachi; S.-I. Hayashi H. Eguchi; K. Suga; H. Saji; M. Toi; K. Nakachi; S.-I. Hayashi Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene Cell Death and Differentiation, 7, 5, 439-446 Cell Death and Differentiation, 7, 5, 439-446 Cell Death and Differentiation, 7, 5, 439-446 2000 英語 公開
T. Ueno; M. Toi; M. Koike; S. Nakamura; T. Tominaga T. Ueno; M. Toi; M. Koike; S. Nakamura; T. Tominaga T. Ueno; M. Toi; M. Koike; S. Nakamura; T. Tominaga Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration British Journal of Cancer, 83, 2, 164-170 British Journal of Cancer, 83, 2, 164-170 British Journal of Cancer, 83, 2, 164-170 2000 英語 公開
S. Nagai; M. Toi S. Nagai; M. Toi S. Nagai; M. Toi Interleukin-4 and breast cancer Interleukin-4 and breast cancer Interleukin-4 and breast cancer Breast Cancer, 7, 3, 181-186 Breast Cancer, 7, 3, 181-186 Breast Cancer, 7, 3, 181-186 2000 英語 公開
M. Toi; H. Bando; K. Kuroi M. Toi; H. Bando; K. Kuroi M. Toi; H. Bando; K. Kuroi The predictive value of angiogenesis for adjuvant therapy in breast cancer The predictive value of angiogenesis for adjuvant therapy in breast cancer The predictive value of angiogenesis for adjuvant therapy in breast cancer Breast Cancer, 7, 4, 311-314 Breast Cancer, 7, 4, 311-314 Breast Cancer, 7, 4, 311-314 2000 英語 公開
K. Mori; M. Hasegawa; M. Nishida; H. Toma; M. Fukuda; T. Kubota; N. Nagasue; H. Yamana; K. Hirakawa-YS Chung; T. Ikeda; K. Takasaki; M. Oka; M. Kameyama; M. Toi; H. Fujii; M. Kitamura; M. Murai; H. Sasaki; S. Ozono; H. Makuuchi; Y. Shimada; Y. Onishi; S. Aoyagi; K. Mizutani; M. Ogawa; A. Nakao; H. Kinoshita; T. Tono; H. Imamoto; Y. Nakashima; T. Manabe K. Mori; M. Hasegawa; M. Nishida; H. Toma; M. Fukuda; T. Kubota; N. Nagasue; H. Yamana; K. Hirakawa-YS Chung; T. Ikeda; K. Takasaki; M. Oka; M. Kameyama; M. Toi; H. Fujii; M. Kitamura; M. Murai; H. Sasaki; S. Ozono; H. Makuuchi; Y. Shimada; Y. Onishi; S. Aoyagi; K. Mizutani; M. Ogawa; A. Nakao; H. Kinoshita; T. Tono; H. Imamoto; Y. Nakashima; T. Manabe K. Mori; M. Hasegawa; M. Nishida; H. Toma; M. Fukuda; T. Kubota; N. Nagasue; H. Yamana; K. Hirakawa-YS Chung; T. Ikeda; K. Takasaki; M. Oka; M. Kameyama; M. Toi; H. Fujii; M. Kitamura; M. Murai; H. Sasaki; S. Ozono; H. Makuuchi; Y. Shimada; Y. Onishi; S. Aoyagi; K. Mizutani; M. Ogawa; A. Nakao; H. Kinoshita; T. Tono; H. Imamoto; Y. Nakashima; T. Manabe Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. International journal of oncology, 17, 1, 33-38 International journal of oncology, 17, 1, 33-38 International journal of oncology, 17, 1, 33-38 2000 英語 公開
M. Miyaki; T. Iijima; K. Hosono; R. Ishii; M. Yasuno; T. Mori; M. Toi; T. Hishima; N. Shitara; K. Tamura; J. Utsunomiya; N. Kobayashi; T. Kuroki; T. Iwama M. Miyaki; T. Iijima; K. Hosono; R. Ishii; M. Yasuno; T. Mori; M. Toi; T. Hishima; N. Shitara; K. Tamura; J. Utsunomiya; N. Kobayashi; T. Kuroki; T. Iwama M. Miyaki; T. Iijima; K. Hosono; R. Ishii; M. Yasuno; T. Mori; M. Toi; T. Hishima; N. Shitara; K. Tamura; J. Utsunomiya; N. Kobayashi; T. Kuroki; T. Iwama Somatic mutations of LKB1 and β-catenin genes in gastrointestinal polyps from patients with Peutz-Jeghers syndrome Somatic mutations of LKB1 and β-catenin genes in gastrointestinal polyps from patients with Peutz-Jeghers syndrome Somatic mutations of LKB1 and β-catenin genes in gastrointestinal polyps from patients with Peutz-Jeghers syndrome Cancer Research, 60, 22, 6311-6313 Cancer Research, 60, 22, 6311-6313 Cancer Research, 60, 22, 6311-6313 2000 英語 公開
M. Tozaki; M. Toi; Y. Miyamoto; K. Fukuda M. Tozaki; M. Toi; Y. Miyamoto; K. Fukuda M. Tozaki; M. Toi; Y. Miyamoto; K. Fukuda Power Doppler sonography of breast masses: Correlation of Doppler spectral parameters with tumor angiogenesis and histologic growth pattern Power Doppler sonography of breast masses: Correlation of Doppler spectral parameters with tumor angiogenesis and histologic growth pattern Power Doppler sonography of breast masses: Correlation of Doppler spectral parameters with tumor angiogenesis and histologic growth pattern Journal of Ultrasound in Medicine, 19, 9, 593-600 Journal of Ultrasound in Medicine, 19, 9, 593-600 Journal of Ultrasound in Medicine, 19, 9, 593-600 2000 英語 公開
T. Ueno; M. Toi; H. Saji; M. Muta; H. Bando; K. Kuroi; M. Koike; H. Inadera; K. Matsushima T. Ueno; M. Toi; H. Saji; M. Muta; H. Bando; K. Kuroi; M. Koike; H. Inadera; K. Matsushima T. Ueno; M. Toi; H. Saji; M. Muta; H. Bando; K. Kuroi; M. Koike; H. Inadera; K. Matsushima Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer Clinical Cancer Research, 6, 8, 3282-3289 Clinical Cancer Research, 6, 8, 3282-3289 Clinical Cancer Research, 6, 8, 3282-3289 2000 英語 公開
C. Tanaka; M. Toi C. Tanaka; M. Toi C. Tanaka; M. Toi Capecitabine for treatment of advanced breast cancers Capecitabine for treatment of advanced breast cancers Capecitabine for treatment of advanced breast cancers Nippon rinsho. Japanese journal of clinical medicine, 58 Suppl, 279-283 Nippon rinsho. Japanese journal of clinical medicine, 58 Suppl, 279-283 Nippon rinsho. Japanese journal of clinical medicine, 58 Suppl, 279-283 2000 英語 公開
K. Kuroi; M. Toi K. Kuroi; M. Toi K. Kuroi; M. Toi Angiogenesis as a prognostic factor of breast cancers Angiogenesis as a prognostic factor of breast cancers Angiogenesis as a prognostic factor of breast cancers Nippon rinsho. Japanese journal of clinical medicine, 58 Suppl, 435-441 Nippon rinsho. Japanese journal of clinical medicine, 58 Suppl, 435-441 Nippon rinsho. Japanese journal of clinical medicine, 58 Suppl, 435-441 2000 英語 公開
M. Toi; G. Matsumoto; H. Bando; K. Kuroi M. Toi; G. Matsumoto; H. Bando; K. Kuroi M. Toi; G. Matsumoto; H. Bando; K. Kuroi Antiangiogenesis therapy and hormone therapy--their resemblance and applications of prognostic and predictive factors Antiangiogenesis therapy and hormone therapy--their resemblance and applications of prognostic and predictive factors Antiangiogenesis therapy and hormone therapy--their resemblance and applications of prognostic and predictive factors Japanese Journal of Cancer and Chemotherapy, 27, 8, 1212-1216 Japanese Journal of Cancer and Chemotherapy, 27, 8, 1212-1216 Japanese Journal of Cancer and Chemotherapy, 27, 8, 1212-1216 2000 英語 公開
M. Toi; G. Matsumoto M. Toi; G. Matsumoto M. Toi; G. Matsumoto Isolated tumor cells and micrometastasis--clinical behavior and therapeutic implications Isolated tumor cells and micrometastasis--clinical behavior and therapeutic implications Isolated tumor cells and micrometastasis--clinical behavior and therapeutic implications Japanese Journal of Cancer and Chemotherapy, 27, 9, 1315-1336 Japanese Journal of Cancer and Chemotherapy, 27, 9, 1315-1336 Japanese Journal of Cancer and Chemotherapy, 27, 9, 1315-1336 2000 英語 公開
M. Seki; M. Toi; K. Kobayashi; K. Shitara; K. Umezawa; B.K. Seon; M. Kan; J.S. Rhim M. Seki; M. Toi; K. Kobayashi; K. Shitara; K. Umezawa; B.K. Seon; M. Kan; J.S. Rhim M. Seki; M. Toi; K. Kobayashi; K. Shitara; K. Umezawa; B.K. Seon; M. Kan; J.S. Rhim Differential behavior of VEGF receptor expression and response to TNP-470 in two immortalized human endothelial cell lines. Differential behavior of VEGF receptor expression and response to TNP-470 in two immortalized human endothelial cell lines. Differential behavior of VEGF receptor expression and response to TNP-470 in two immortalized human endothelial cell lines. International journal of oncology, 17, 3, 525-533 International journal of oncology, 17, 3, 525-533 International journal of oncology, 17, 3, 525-533 2000 英語 公開
H. Bando; M. Toi H. Bando; M. Toi H. Bando; M. Toi Tumor angiogenesis, macrophages, and cytokines Tumor angiogenesis, macrophages, and cytokines Tumor angiogenesis, macrophages, and cytokines Advances in Experimental Medicine and Biology, 476, 267-284 Advances in Experimental Medicine and Biology, 476, 267-284 Advances in Experimental Medicine and Biology, 476, 267-284 2000 英語 公開
K. Kuroi; C. Tanaka; M. Toi K. Kuroi; C. Tanaka; M. Toi K. Kuroi; C. Tanaka; M. Toi Plasma nucleosome levels in node-negative breast cancer patients Plasma nucleosome levels in node-negative breast cancer patients Plasma nucleosome levels in node-negative breast cancer patients Breast Cancer, 6, 4, 361-364 Breast Cancer, 6, 4, 361-364 Breast Cancer, 6, 4, 361-364 1999 英語 公開
H. Sonoo; J. Kurebayashi; Y. Lino; H. Inaji; T. Watanabe; M. Toi; S. Kobayashi; B. Sato; M. Yoshimoto H. Sonoo; J. Kurebayashi; Y. Lino; H. Inaji; T. Watanabe; M. Toi; S. Kobayashi; B. Sato; M. Yoshimoto H. Sonoo; J. Kurebayashi; Y. Lino; H. Inaji; T. Watanabe; M. Toi; S. Kobayashi; B. Sato; M. Yoshimoto Current status and controversial issues concerning endocrine therapy for patients with recurrent breast cancer in Japan Current status and controversial issues concerning endocrine therapy for patients with recurrent breast cancer in Japan Current status and controversial issues concerning endocrine therapy for patients with recurrent breast cancer in Japan Breast Cancer, 6, 4, 344-350 Breast Cancer, 6, 4, 344-350 Breast Cancer, 6, 4, 344-350 1999 英語 公開
T. Ueno; M. Toi; T. Tominaga T. Ueno; M. Toi; T. Tominaga T. Ueno; M. Toi; T. Tominaga Circulating soluble Fas concentration in breast cancer patients Circulating soluble Fas concentration in breast cancer patients Circulating soluble Fas concentration in breast cancer patients Clinical Cancer Research, 5, 11, 3529-3533 Clinical Cancer Research, 5, 11, 3529-3533 Clinical Cancer Research, 5, 11, 3529-3533 1999 英語 公開
S.-I. Kumeda; A. Deguchi; M. Toi; S. Omura; K. Umezawa S.-I. Kumeda; A. Deguchi; M. Toi; S. Omura; K. Umezawa S.-I. Kumeda; A. Deguchi; M. Toi; S. Omura; K. Umezawa Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells Anticancer Research, 19, 5 B, 3961-3968 Anticancer Research, 19, 5 B, 3961-3968 Anticancer Research, 19, 5 B, 3961-3968 1999 英語 公開
M. Toi; M. Seki M. Toi; M. Seki M. Toi; M. Seki Assessment of angiogenesis inhibitors using cultured endothelial cells Assessment of angiogenesis inhibitors using cultured endothelial cells Assessment of angiogenesis inhibitors using cultured endothelial cells Biotherapy, 13, 6, 675-678 Biotherapy, 13, 6, 675-678 Biotherapy, 13, 6, 675-678 1999 英語 公開
M. Toi; T. Ueno; H. Matsumoto; H. Saji; N. Funata; M. Koike; T. Tominaga M. Toi; T. Ueno; H. Matsumoto; H. Saji; N. Funata; M. Koike; T. Tominaga M. Toi; T. Ueno; H. Matsumoto; H. Saji; N. Funata; M. Koike; T. Tominaga Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer Clinical Cancer Research, 5, 5, 1131-1137 Clinical Cancer Research, 5, 5, 1131-1137 Clinical Cancer Research, 5, 5, 1131-1137 1999 英語 公開
G. Gasparini; M. Toi; R. Miceli; P.B. Vermeulen; R. Dittadi; E. Biganzoli; A. Morabito; M. Fanelli; C. Gatti; H. Suzuki; T. Tominaga; L.Y. Dirix; M. Gion G. Gasparini; M. Toi; R. Miceli; P.B. Vermeulen; R. Dittadi; E. Biganzoli; A. Morabito; M. Fanelli; C. Gatti; H. Suzuki; T. Tominaga; L.Y. Dirix; M. Gion G. Gasparini; M. Toi; R. Miceli; P.B. Vermeulen; R. Dittadi; E. Biganzoli; A. Morabito; M. Fanelli; C. Gatti; H. Suzuki; T. Tominaga; L.Y. Dirix; M. Gion Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy Cancer Journal from Scientific American, 5, 2, 101-111 Cancer Journal from Scientific American, 5, 2, 101-111 Cancer Journal from Scientific American, 5, 2, 101-111 1999 英語 公開
M. Toi; H. Saji M. Toi; H. Saji M. Toi; H. Saji Thymidine phosphorylase targeting treatment Thymidine phosphorylase targeting treatment Thymidine phosphorylase targeting treatment Biotherapy, 13, 2, 166-172 Biotherapy, 13, 2, 166-172 Biotherapy, 13, 2, 166-172 1999 英語 公開
S. Saji; S. Nakashima; S.-I. Hayashi; M. Toi; S. Saji; Y. Nozawa S. Saji; S. Nakashima; S.-I. Hayashi; M. Toi; S. Saji; Y. Nozawa S. Saji; S. Nakashima; S.-I. Hayashi; M. Toi; S. Saji; Y. Nozawa Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol Japanese Journal of Cancer Research, 90, 2, 210-218 Japanese Journal of Cancer Research, 90, 2, 210-218 Japanese Journal of Cancer Research, 90, 2, 210-218 1999 英語 公開
S. Ishigaki; M. Toi; T. Ueno; H. Matsumoto; M. Muta; M. Koike; M. Seiki S. Ishigaki; M. Toi; T. Ueno; H. Matsumoto; M. Muta; M. Koike; M. Seiki S. Ishigaki; M. Toi; T. Ueno; H. Matsumoto; M. Muta; M. Koike; M. Seiki Significance of membrane type 1 matrix metalloproteinase expression in breast cancer Significance of membrane type 1 matrix metalloproteinase expression in breast cancer Significance of membrane type 1 matrix metalloproteinase expression in breast cancer Japanese Journal of Cancer Research, 90, 5, 516-522 Japanese Journal of Cancer Research, 90, 5, 516-522 Japanese Journal of Cancer Research, 90, 5, 516-522 1999 英語 公開
S. Nagai; M. Toi; K. Kuroi; K. Hayashi; T. Tominaga S. Nagai; M. Toi; K. Kuroi; K. Hayashi; T. Tominaga S. Nagai; M. Toi; K. Kuroi; K. Hayashi; T. Tominaga Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline Gan to kagaku ryoho. Cancer & chemotherapy, 26, 13, 2037-2042 Gan to kagaku ryoho. Cancer & chemotherapy, 26, 13, 2037-2042 Gan to kagaku ryoho. Cancer & chemotherapy, 26, 13, 2037-2042 1999 英語 公開
M. Toi; M. Gion; H. Saji; M. Asano; R. Dittadi; S. Gilberti; N. Locopo; G. Gasparini M. Toi; M. Gion; H. Saji; M. Asano; R. Dittadi; S. Gilberti; N. Locopo; G. Gasparini M. Toi; M. Gion; H. Saji; M. Asano; R. Dittadi; S. Gilberti; N. Locopo; G. Gasparini Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma. Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma. Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma. International journal of oncology, 15, 6, 1169-1175 International journal of oncology, 15, 6, 1169-1175 International journal of oncology, 15, 6, 1169-1175 1999 英語 公開
M. Toi; S. Ishigaki; T. Tominaga M. Toi; S. Ishigaki; T. Tominaga M. Toi; S. Ishigaki; T. Tominaga Metalloproteinases and tissue inhibitors of metalloproteinases Metalloproteinases and tissue inhibitors of metalloproteinases Metalloproteinases and tissue inhibitors of metalloproteinases Breast Cancer Research and Treatment, 52, 1-3, 113-124 Breast Cancer Research and Treatment, 52, 1-3, 113-124 Breast Cancer Research and Treatment, 52, 1-3, 113-124 1998 英語 公開
S. Umemura; K. Komaki; S. Noguchi; E. Shiba; M. Toi; I. Kimijima; H. Itoh; Y.R. Osamura S. Umemura; K. Komaki; S. Noguchi; E. Shiba; M. Toi; I. Kimijima; H. Itoh; Y.R. Osamura S. Umemura; K. Komaki; S. Noguchi; E. Shiba; M. Toi; I. Kimijima; H. Itoh; Y.R. Osamura Prognostic factors for node-negative breast cancers: Results of a study program by the Japanese breast cancer society Prognostic factors for node-negative breast cancers: Results of a study program by the Japanese breast cancer society Prognostic factors for node-negative breast cancers: Results of a study program by the Japanese breast cancer society Breast Cancer, 5, 3, 243-249 Breast Cancer, 5, 3, 243-249 Breast Cancer, 5, 3, 243-249 1998 英語 公開
Y. Lino; M. Toi Y. Lino; M. Toi Y. Lino; M. Toi Chemoendocrine therapy: Basic science and clinical aspects Chemoendocrine therapy: Basic science and clinical aspects Chemoendocrine therapy: Basic science and clinical aspects Breast Cancer, 5, 4, 344-346 Breast Cancer, 5, 4, 344-346 Breast Cancer, 5, 4, 344-346 1998 英語 公開
M. Kitamura; M. Toi; K. Arai; Y. Iwasaki; H. Suzuki; K. Matsuo M. Kitamura; M. Toi; K. Arai; Y. Iwasaki; H. Suzuki; K. Matsuo M. Kitamura; M. Toi; K. Arai; Y. Iwasaki; H. Suzuki; K. Matsuo Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients Oncology Reports, 5, 6, 1419-1424 Oncology Reports, 5, 6, 1419-1424 Oncology Reports, 5, 6, 1419-1424 1998 英語 公開
A. Suzuki; M. Toi; Y. Yamamoto; S. Saji; M. Muta; T. Tominaga A. Suzuki; M. Toi; Y. Yamamoto; S. Saji; M. Muta; T. Tominaga A. Suzuki; M. Toi; Y. Yamamoto; S. Saji; M. Muta; T. Tominaga Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma Japanese Journal of Cancer Research, 89, 2, 221-227 Japanese Journal of Cancer Research, 89, 2, 221-227 Japanese Journal of Cancer Research, 89, 2, 221-227 1998 英語 公開
M. Toi; T. Taniguchi; T. Ueno; M. Asano; N. Funata; K. Sekiguchi; H. Iwanari; T. Tominaga M. Toi; T. Taniguchi; T. Ueno; M. Asano; N. Funata; K. Sekiguchi; H. Iwanari; T. Tominaga M. Toi; T. Taniguchi; T. Ueno; M. Asano; N. Funata; K. Sekiguchi; H. Iwanari; T. Tominaga Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer Clinical Cancer Research, 4, 3, 659-664 Clinical Cancer Research, 4, 3, 659-664 Clinical Cancer Research, 4, 3, 659-664 1998 英語 公開
G. Gasparini; M. Toi; P. Verderio; G. Ranieri; S. Dante; E. Bonoldi; P. Boracchi; M. Fanelli; T. Tominaga G. Gasparini; M. Toi; P. Verderio; G. Ranieri; S. Dante; E. Bonoldi; P. Boracchi; M. Fanelli; T. Tominaga G. Gasparini; M. Toi; P. Verderio; G. Ranieri; S. Dante; E. Bonoldi; P. Boracchi; M. Fanelli; T. Tominaga Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: Subanalysis in node-positive and node- negative patients Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: Subanalysis in node-positive and node- negative patients Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: Subanalysis in node-positive and node- negative patients International Journal of Oncology, 12, 5, 1117-1125 International Journal of Oncology, 12, 5, 1117-1125 International Journal of Oncology, 12, 5, 1117-1125 1998 英語 公開
T. Kurizaki; M. Toi; T. Tominaga T. Kurizaki; M. Toi; T. Tominaga T. Kurizaki; M. Toi; T. Tominaga Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma Oncology Reports, 5, 3, 673-677 Oncology Reports, 5, 3, 673-677 Oncology Reports, 5, 3, 673-677 1998 英語 公開
M. Toi M. Toi M. Toi Antiangiogenic therapy Antiangiogenic therapy Antiangiogenic therapy Gan to kagaku ryoho. Cancer & chemotherapy, 25, 13, 2003-2009 Gan to kagaku ryoho. Cancer & chemotherapy, 25, 13, 2003-2009 Gan to kagaku ryoho. Cancer & chemotherapy, 25, 13, 2003-2009 1998 英語 公開
K. Tsuruta; M. Toi; M. Kondo; A. Okamoto K. Tsuruta; M. Toi; M. Kondo; A. Okamoto K. Tsuruta; M. Toi; M. Kondo; A. Okamoto Removal of primary tumor might alter the growth rate of metastatic tumor in hepatocellular carcinoma Removal of primary tumor might alter the growth rate of metastatic tumor in hepatocellular carcinoma Removal of primary tumor might alter the growth rate of metastatic tumor in hepatocellular carcinoma Cancer Journal, 10, 1, 53-55 Cancer Journal, 10, 1, 53-55 Cancer Journal, 10, 1, 53-55 1997 英語 公開
M. Toi M. Toi M. Toi The increase of apoptosis and the decrease of proliferation by angiogenesis inhibitor in rat mammary tumors The increase of apoptosis and the decrease of proliferation by angiogenesis inhibitor in rat mammary tumors The increase of apoptosis and the decrease of proliferation by angiogenesis inhibitor in rat mammary tumors Oncology Reports, 4, 1, 111-114 Oncology Reports, 4, 1, 111-114 Oncology Reports, 4, 1, 111-114 1997 英語 公開
M. Toi; S. Saji; A. Suzuki; Y. Yamamoto; T. Tominaga M. Toi; S. Saji; A. Suzuki; Y. Yamamoto; T. Tominaga M. Toi; S. Saji; A. Suzuki; Y. Yamamoto; T. Tominaga MDM2 in breast cancer MDM2 in breast cancer MDM2 in breast cancer Breast Cancer, 4, 4, 264-268 Breast Cancer, 4, 4, 264-268 Breast Cancer, 4, 4, 264-268 1997 英語 公開
G. Gasparini; M. Toi; M. Gion; P. Verderio; R. Dittadi; M. Hanatani; I. Matsubara; O. Vinante; E. Bonoldi; P. Boracchi; C. Gatti; H. Suzuki; T. Tominaga G. Gasparini; M. Toi; M. Gion; P. Verderio; R. Dittadi; M. Hanatani; I. Matsubara; O. Vinante; E. Bonoldi; P. Boracchi; C. Gatti; H. Suzuki; T. Tominaga G. Gasparini; M. Toi; M. Gion; P. Verderio; R. Dittadi; M. Hanatani; I. Matsubara; O. Vinante; E. Bonoldi; P. Boracchi; C. Gatti; H. Suzuki; T. Tominaga Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma Journal of the National Cancer Institute, 89, 2, 139-147 Journal of the National Cancer Institute, 89, 2, 139-147 Journal of the National Cancer Institute, 89, 2, 139-147 1997 英語 公開
T. Taniguchi; M. Kitamura; K. Arai; Y. Iwasaki; Y. Yamamoto; A. Igari; M. Toi T. Taniguchi; M. Kitamura; K. Arai; Y. Iwasaki; Y. Yamamoto; A. Igari; M. Toi T. Taniguchi; M. Kitamura; K. Arai; Y. Iwasaki; Y. Yamamoto; A. Igari; M. Toi Increase in the circulating level of hepatocyte growth factor in gastric cancer patients Increase in the circulating level of hepatocyte growth factor in gastric cancer patients Increase in the circulating level of hepatocyte growth factor in gastric cancer patients British Journal of Cancer, 75, 5, 673-677 British Journal of Cancer, 75, 5, 673-677 British Journal of Cancer, 75, 5, 673-677 1997 英語 公開
M. Toi; S. Tanaka; M. Bando; K. Hayashi; T. Tominaga M. Toi; S. Tanaka; M. Bando; K. Hayashi; T. Tominaga M. Toi; S. Tanaka; M. Bando; K. Hayashi; T. Tominaga Outcome of surgical resection for chest wall recurrence in breast cancer patients Outcome of surgical resection for chest wall recurrence in breast cancer patients Outcome of surgical resection for chest wall recurrence in breast cancer patients Journal of Surgical Oncology, 64, 1, 23-26 Journal of Surgical Oncology, 64, 1, 23-26 Journal of Surgical Oncology, 64, 1, 23-26 1997 英語 公開
M. Toi; M. Gion; E. Biganzoli; R. Dittadi; P. Boracchi; R. Miceli; S. Meli; K. Mori; T. Tominaga; G. Gasparini M. Toi; M. Gion; E. Biganzoli; R. Dittadi; P. Boracchi; R. Miceli; S. Meli; K. Mori; T. Tominaga; G. Gasparini M. Toi; M. Gion; E. Biganzoli; R. Dittadi; P. Boracchi; R. Miceli; S. Meli; K. Mori; T. Tominaga; G. Gasparini Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: Prognostic implications Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: Prognostic implications Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: Prognostic implications Angiogenesis, 1, 1, 71-83 Angiogenesis, 1, 1, 71-83 Angiogenesis, 1, 1, 71-83 1997 英語 公開
M. Toi; S. Saji; T. Tominaga M. Toi; S. Saji; T. Tominaga M. Toi; S. Saji; T. Tominaga Novel target of biotherapy: Angiogenesis Novel target of biotherapy: Angiogenesis Novel target of biotherapy: Angiogenesis Biotherapy, 11, 6, 738-742 Biotherapy, 11, 6, 738-742 Biotherapy, 11, 6, 738-742 1997 英語 公開
K. Abe; K. Suzuki; N. Kamata; Y. Yokoyama; T. Ushimi; T. Masumoto; M. Koike; M. Toi K. Abe; K. Suzuki; N. Kamata; Y. Yokoyama; T. Ushimi; T. Masumoto; M. Koike; M. Toi K. Abe; K. Suzuki; N. Kamata; Y. Yokoyama; T. Ushimi; T. Masumoto; M. Koike; M. Toi Case report ; pulmonary thromboembolism due to medroxyprogesterone acetate Case report ; pulmonary thromboembolism due to medroxyprogesterone acetate Case report ; pulmonary thromboembolism due to medroxyprogesterone acetate Japanese Journal of Clinical Radiology, 42, 6, 719-722 Japanese Journal of Clinical Radiology, 42, 6, 719-722 Japanese Journal of Clinical Radiology, 42, 6, 719-722 1997 英語 公開
T. Narita; N. Kimura; C. Mitsuoka; M. Toi; M. Sato; N. Matsuura; K. Matsumoto; T. Nakamura; R. Kannagi T. Narita; N. Kimura; C. Mitsuoka; M. Toi; M. Sato; N. Matsuura; K. Matsumoto; T. Nakamura; R. Kannagi T. Narita; N. Kimura; C. Mitsuoka; M. Toi; M. Sato; N. Matsuura; K. Matsumoto; T. Nakamura; R. Kannagi Biological and clinical significance of hepatocyte growth factor in breast cancer Biological and clinical significance of hepatocyte growth factor in breast cancer Biological and clinical significance of hepatocyte growth factor in breast cancer International Journal of Oncology, 11, 6, 1305-1310 International Journal of Oncology, 11, 6, 1305-1310 International Journal of Oncology, 11, 6, 1305-1310 1997 英語 公開
T. Narita; C. Mitsuoka; N. Kimura; M. Toi; T. Nakashio; K. Sekiguchi; H. Iwanari; R. Kannagi T. Narita; C. Mitsuoka; N. Kimura; M. Toi; T. Nakashio; K. Sekiguchi; H. Iwanari; R. Kannagi T. Narita; C. Mitsuoka; N. Kimura; M. Toi; T. Nakashio; K. Sekiguchi; H. Iwanari; R. Kannagi Increased concentration of hepatocyte growth factor in the sera of patients with gastrointestinal cancer Increased concentration of hepatocyte growth factor in the sera of patients with gastrointestinal cancer Increased concentration of hepatocyte growth factor in the sera of patients with gastrointestinal cancer Oncology Reports, 4, 6, 1239-1241 Oncology Reports, 4, 6, 1239-1241 Oncology Reports, 4, 6, 1239-1241 1997 英語 公開
N. Nagaya; M. Toi; S. Sunahara; F. Kurimoto; T. Tominaga N. Nagaya; M. Toi; S. Sunahara; F. Kurimoto; T. Tominaga N. Nagaya; M. Toi; S. Sunahara; F. Kurimoto; T. Tominaga Determination of intratumoral estrone (E<sub>1</sub>) and estradiol (E<sub>2</sub>) in primary breast cancer tissues by sensitive HPLC-RIA Determination of intratumoral estrone (E<sub>1</sub>) and estradiol (E<sub>2</sub>) in primary breast cancer tissues by sensitive HPLC-RIA Determination of intratumoral estrone (E<sub>1</sub>) and estradiol (E<sub>2</sub>) in primary breast cancer tissues by sensitive HPLC-RIA Japanese Journal of Cancer and Chemotherapy, 24, 3, 329-336 Japanese Journal of Cancer and Chemotherapy, 24, 3, 329-336 Japanese Journal of Cancer and Chemotherapy, 24, 3, 329-336 1997 英語 公開
M. Toi; S. Kondo; H. Suzuki; Y. Yamamoto; K. Inada; T. Imazawa; T. Taniguchi; T. Tominaga M. Toi; S. Kondo; H. Suzuki; Y. Yamamoto; K. Inada; T. Imazawa; T. Taniguchi; T. Tominaga M. Toi; S. Kondo; H. Suzuki; Y. Yamamoto; K. Inada; T. Imazawa; T. Taniguchi; T. Tominaga Quantitative analysis of vascular endothelial growth factor in primary breast cancer Quantitative analysis of vascular endothelial growth factor in primary breast cancer Quantitative analysis of vascular endothelial growth factor in primary breast cancer Cancer, 77, 6, 1101-1106 Cancer, 77, 6, 1101-1106 Cancer, 77, 6, 1101-1106 1996 英語 公開
K. Inada; T. Tominaga; M. Toi; Y. Yamamoto; M. Abe; J.-I. Yamashita; M. Ogawa K. Inada; T. Tominaga; M. Toi; Y. Yamamoto; M. Abe; J.-I. Yamashita; M. Ogawa K. Inada; T. Tominaga; M. Toi; Y. Yamamoto; M. Abe; J.-I. Yamashita; M. Ogawa Protective effect of leuprolide acetate on 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinogenesis in rats Protective effect of leuprolide acetate on 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinogenesis in rats Protective effect of leuprolide acetate on 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinogenesis in rats European Journal of Surgical Oncology, 22, 6, 583-587 European Journal of Surgical Oncology, 22, 6, 583-587 European Journal of Surgical Oncology, 22, 6, 583-587 1996 英語 公開
M. Toi; T. Taniguchi; Y. Yamamoto; T. Kurisaki; H. Suzuki; T. Tominaga M. Toi; T. Taniguchi; Y. Yamamoto; T. Kurisaki; H. Suzuki; T. Tominaga M. Toi; T. Taniguchi; Y. Yamamoto; T. Kurisaki; H. Suzuki; T. Tominaga Clinical significance of the determination of angiogenic factors Clinical significance of the determination of angiogenic factors Clinical significance of the determination of angiogenic factors European Journal of Cancer Part A, 32, 14, 2513-2519 European Journal of Cancer Part A, 32, 14, 2513-2519 European Journal of Cancer Part A, 32, 14, 2513-2519 1996 英語 公開
P.E. Vermeulen; G. Gasparini; S.B. Fox; M. Toi; L. Martin; P. McCulloch; F. Pezzella; G. Viale; N. Weidner; A.L. Harris; L.Y. Dirix P.E. Vermeulen; G. Gasparini; S.B. Fox; M. Toi; L. Martin; P. McCulloch; F. Pezzella; G. Viale; N. Weidner; A.L. Harris; L.Y. Dirix P.E. Vermeulen; G. Gasparini; S.B. Fox; M. Toi; L. Martin; P. McCulloch; F. Pezzella; G. Viale; N. Weidner; A.L. Harris; L.Y. Dirix Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation European Journal of Cancer Part A, 32, 14, 2474-2484 European Journal of Cancer Part A, 32, 14, 2474-2484 European Journal of Cancer Part A, 32, 14, 2474-2484 1996 英語 公開
K. Umezawa; T. Taniguchi; M. Toi; T. Ohse; N. Tsutsumi; T. Yamamoto; T. Koyano; M. Ishizuka K. Umezawa; T. Taniguchi; M. Toi; T. Ohse; N. Tsutsumi; T. Yamamoto; T. Koyano; M. Ishizuka K. Umezawa; T. Taniguchi; M. Toi; T. Ohse; N. Tsutsumi; T. Yamamoto; T. Koyano; M. Ishizuka Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice Drugs under Experimental and Clinical Research, 22, 2, 35-40 Drugs under Experimental and Clinical Research, 22, 2, 35-40 Drugs under Experimental and Clinical Research, 22, 2, 35-40 1996 英語 公開
Y. Yamamoto; M. Toi; T. Tominaga Y. Yamamoto; M. Toi; T. Tominaga Y. Yamamoto; M. Toi; T. Tominaga Prediction of the effect of 5\\'-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients Prediction of the effect of 5\\'-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients Prediction of the effect of 5\\'-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients Oncology Reports, 3, 5, 863-865 Oncology Reports, 3, 5, 863-865 Oncology Reports, 3, 5, 863-865 1996 英語 公開
T. Tominaga; M. Toi; Y. Yamamoto T. Tominaga; M. Toi; Y. Yamamoto T. Tominaga; M. Toi; Y. Yamamoto Tumor angiogenesis as a key prognostic factor in breast cancer Tumor angiogenesis as a key prognostic factor in breast cancer Tumor angiogenesis as a key prognostic factor in breast cancer Biotherapy, 10, 7, 958-962 Biotherapy, 10, 7, 958-962 Biotherapy, 10, 7, 958-962 1996 英語 公開
M. Toi; T. Tominaga M. Toi; T. Tominaga M. Toi; T. Tominaga Breast cancer angiogenesis Breast cancer angiogenesis Breast cancer angiogenesis Japanese Journal of Cancer and Chemotherapy, 23, 6, 659-666 Japanese Journal of Cancer and Chemotherapy, 23, 6, 659-666 Japanese Journal of Cancer and Chemotherapy, 23, 6, 659-666 1996 英語 公開
S. Saji; M. Toi; T. Tominaga S. Saji; M. Toi; T. Tominaga S. Saji; M. Toi; T. Tominaga The importance of tumor angiogenesis as a prognostic indicator in primary breast cancer The importance of tumor angiogenesis as a prognostic indicator in primary breast cancer The importance of tumor angiogenesis as a prognostic indicator in primary breast cancer Nippon Geka Gakkai zasshi, 97, 5, 368-374 Nippon Geka Gakkai zasshi, 97, 5, 368-374 Nippon Geka Gakkai zasshi, 97, 5, 368-374 1996 英語 公開
M. Toi; Y. Yamamoto; T. Taniguchi; S. Saji; K. Hayashi; T. Tominaga M. Toi; Y. Yamamoto; T. Taniguchi; S. Saji; K. Hayashi; T. Tominaga M. Toi; Y. Yamamoto; T. Taniguchi; S. Saji; K. Hayashi; T. Tominaga Regulation of endothelial growth factor expressions in breast cancer. Regulation of endothelial growth factor expressions in breast cancer. Regulation of endothelial growth factor expressions in breast cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 23 Suppl 1, 75-79 Gan to kagaku ryoho. Cancer & chemotherapy, 23 Suppl 1, 75-79 Gan to kagaku ryoho. Cancer & chemotherapy, 23 Suppl 1, 75-79 1996 英語 公開
Y. Yamamoto; M. Toi; S. Kondo; T. Matsumoto; H. Suzuki; M. Kitamura; K. Tsuruta; T. Taniguchi; A. Okamoto; T. Mori; M. Yoshida; T. Ikeda; T. Tominaga Y. Yamamoto; M. Toi; S. Kondo; T. Matsumoto; H. Suzuki; M. Kitamura; K. Tsuruta; T. Taniguchi; A. Okamoto; T. Mori; M. Yoshida; T. Ikeda; T. Tominaga Y. Yamamoto; M. Toi; S. Kondo; T. Matsumoto; H. Suzuki; M. Kitamura; K. Tsuruta; T. Taniguchi; A. Okamoto; T. Mori; M. Yoshida; T. Ikeda; T. Tominaga Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients Clinical Cancer Research, 2, 5, 821-826 Clinical Cancer Research, 2, 5, 821-826 Clinical Cancer Research, 2, 5, 821-826 1996 英語 公開
M. Toi; S. Hoshina; T. Taniguchi; Y. Yamamoto; H. ishitsuka; T. Tominaga M. Toi; S. Hoshina; T. Taniguchi; Y. Yamamoto; H. ishitsuka; T. Tominaga M. Toi; S. Hoshina; T. Taniguchi; Y. Yamamoto; H. ishitsuka; T. Tominaga Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer International Journal of Cancer, 64, 2, 79-82 International Journal of Cancer, 64, 2, 79-82 International Journal of Cancer, 64, 2, 79-82 1995 英語 公開
M. Toi; K. Inada; H. Suzuki; T. Tominaga M. Toi; K. Inada; H. Suzuki; T. Tominaga M. Toi; K. Inada; H. Suzuki; T. Tominaga Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression Breast Cancer Research and Treatment, 36, 2, 193-204 Breast Cancer Research and Treatment, 36, 2, 193-204 Breast Cancer Research and Treatment, 36, 2, 193-204 1995 英語 公開
M. Toi; T. Taniguchi; K. Hayashi; T. Tominaga M. Toi; T. Taniguchi; K. Hayashi; T. Tominaga M. Toi; T. Taniguchi; K. Hayashi; T. Tominaga The effect of combination treatment consisted of 5\\'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patients The effect of combination treatment consisted of 5\\'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patients The effect of combination treatment consisted of 5\\'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patients Japanese Journal of Cancer and Chemotherapy, 22, 6, 799-804 Japanese Journal of Cancer and Chemotherapy, 22, 6, 799-804 Japanese Journal of Cancer and Chemotherapy, 22, 6, 799-804 1995 英語 公開
Y. Yamamoto; M. Toi; R. Yamada; T. Tominaga Y. Yamamoto; M. Toi; R. Yamada; T. Tominaga Y. Yamamoto; M. Toi; R. Yamada; T. Tominaga Combination effect of an angiogenesis inhibitor AGM-1470 with 5\\'-deoxy-5-fluorouridine, and with hormonal drugs in DMBA-induced rat mammary tumors Combination effect of an angiogenesis inhibitor AGM-1470 with 5\\'-deoxy-5-fluorouridine, and with hormonal drugs in DMBA-induced rat mammary tumors Combination effect of an angiogenesis inhibitor AGM-1470 with 5\\'-deoxy-5-fluorouridine, and with hormonal drugs in DMBA-induced rat mammary tumors Oncology Reports, 2, 5, 793-796 Oncology Reports, 2, 5, 793-796 Oncology Reports, 2, 5, 793-796 1995 英語 公開
M. Toi; K. Inada; S. Hoshina; H. Suzuki; S. Kondo; T. Tominaga M. Toi; K. Inada; S. Hoshina; H. Suzuki; S. Kondo; T. Tominaga M. Toi; K. Inada; S. Hoshina; H. Suzuki; S. Kondo; T. Tominaga Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer Clinical Cancer Research, 1, 9, 961-964 Clinical Cancer Research, 1, 9, 961-964 Clinical Cancer Research, 1, 9, 961-964 1995 英語 公開
T. Taniguchi; M. Toi; K. Inada; T. Imazawa; Y. Yamamoto; T. Tominaga T. Taniguchi; M. Toi; K. Inada; T. Imazawa; Y. Yamamoto; T. Tominaga T. Taniguchi; M. Toi; K. Inada; T. Imazawa; Y. Yamamoto; T. Tominaga Serum concentrations of hepatocyte growth factor in breast cancer patients Serum concentrations of hepatocyte growth factor in breast cancer patients Serum concentrations of hepatocyte growth factor in breast cancer patients Clinical Cancer Research, 1, 9, 1031-1034 Clinical Cancer Research, 1, 9, 1031-1034 Clinical Cancer Research, 1, 9, 1031-1034 1995 英語 公開
M. Toi M. Toi M. Toi Endothelial growth factors: A target for antiangiogenesis Endothelial growth factors: A target for antiangiogenesis Endothelial growth factors: A target for antiangiogenesis Cancer Journal, 8, 6, 315-319 Cancer Journal, 8, 6, 315-319 Cancer Journal, 8, 6, 315-319 1995 英語 公開
M. Toi; T. Tominaga; A. Osaki; T. Toge M. Toi; T. Tominaga; A. Osaki; T. Toge M. Toi; T. Tominaga; A. Osaki; T. Toge Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study Breast Cancer Research and Treatment, 29, 1, 51-58 Breast Cancer Research and Treatment, 29, 1, 51-58 Breast Cancer Research and Treatment, 29, 1, 51-58 1994 英語 公開
T. Taniguchi; M. Toi; T. Tominaga T. Taniguchi; M. Toi; T. Tominaga T. Taniguchi; M. Toi; T. Tominaga Increase in the circulating level of hepatocyte growth factor in breast cancer patients with distant metastases Increase in the circulating level of hepatocyte growth factor in breast cancer patients with distant metastases Increase in the circulating level of hepatocyte growth factor in breast cancer patients with distant metastases Oncology Reports, 1, 6, 1199-1201 Oncology Reports, 1, 6, 1199-1201 Oncology Reports, 1, 6, 1199-1201 1994 英語 公開
M. Kitamura; K. Takahashi; T. Tominaga; M. Toi M. Kitamura; K. Takahashi; T. Tominaga; M. Toi M. Kitamura; K. Takahashi; T. Tominaga; M. Toi Preventive effect of whole peptidoglycan (WPG) on the occurrence of rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene (DMBA) Preventive effect of whole peptidoglycan (WPG) on the occurrence of rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene (DMBA) Preventive effect of whole peptidoglycan (WPG) on the occurrence of rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene (DMBA) Oncology Reports, 1, 2, 309-312 Oncology Reports, 1, 2, 309-312 Oncology Reports, 1, 2, 309-312 1994 英語 公開
M. Toi; T. Takayanagi; R. Souma; T. Tominaga M. Toi; T. Takayanagi; R. Souma; T. Tominaga M. Toi; T. Takayanagi; R. Souma; T. Tominaga Inhibition of vascular endothelial growth factor induced cell growth by an angiogenesis inhibitor AGM-1470 in capillary endothelial cells Inhibition of vascular endothelial growth factor induced cell growth by an angiogenesis inhibitor AGM-1470 in capillary endothelial cells Inhibition of vascular endothelial growth factor induced cell growth by an angiogenesis inhibitor AGM-1470 in capillary endothelial cells Oncology Reports, 1, 2, 423-426 Oncology Reports, 1, 2, 423-426 Oncology Reports, 1, 2, 423-426 1994 英語 公開
M. Toi; K. Hayashi; T. Tominaga M. Toi; K. Hayashi; T. Tominaga M. Toi; K. Hayashi; T. Tominaga Feasibility of adjuvant high-dose CAF (cyclophosphamide, adriamycin, 5-FU) therapy for primary breast cancer patients Feasibility of adjuvant high-dose CAF (cyclophosphamide, adriamycin, 5-FU) therapy for primary breast cancer patients Feasibility of adjuvant high-dose CAF (cyclophosphamide, adriamycin, 5-FU) therapy for primary breast cancer patients Japanese Journal of Cancer and Chemotherapy, 21, 12, 2057-2060 Japanese Journal of Cancer and Chemotherapy, 21, 12, 2057-2060 Japanese Journal of Cancer and Chemotherapy, 21, 12, 2057-2060 1994 英語 公開
T. Taniguchi; M. Toi; T. Tominaga T. Taniguchi; M. Toi; T. Tominaga T. Taniguchi; M. Toi; T. Tominaga Rapid induction of hepatocyte growth factor by heparin [3] Rapid induction of hepatocyte growth factor by heparin [3] Rapid induction of hepatocyte growth factor by heparin [3] Lancet, 344, 8920, 470- Lancet, 344, 8920, 470- Lancet, 344, 8920, 470- 1994 英語 公開
M. Toi; S. Hoshima; T. Takayanagi; T. Tominaga M. Toi; S. Hoshima; T. Takayanagi; T. Tominaga M. Toi; S. Hoshima; T. Takayanagi; T. Tominaga Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer Japanese Journal of Cancer Research, 85, 10, 1045-1049 Japanese Journal of Cancer Research, 85, 10, 1045-1049 Japanese Journal of Cancer Research, 85, 10, 1045-1049 1994 英語 公開
K. Inada; M. Toi; T. Imazawa; S. Hoshina; K. Hayashi; T. Tominaga K. Inada; M. Toi; T. Imazawa; S. Hoshina; K. Hayashi; T. Tominaga K. Inada; M. Toi; T. Imazawa; S. Hoshina; K. Hayashi; T. Tominaga Significance of overexpression of p53 protein in human breast cancer Significance of overexpression of p53 protein in human breast cancer Significance of overexpression of p53 protein in human breast cancer Japanese Journal of Cancer and Chemotherapy, 21, 6, 817-821 Japanese Journal of Cancer and Chemotherapy, 21, 6, 817-821 Japanese Journal of Cancer and Chemotherapy, 21, 6, 817-821 1994 英語 公開
M. Toi; S. Hoshina; Y. Yamamoto; T. Ishii; K. Hayashi; T. Tominaga M. Toi; S. Hoshina; Y. Yamamoto; T. Ishii; K. Hayashi; T. Tominaga M. Toi; S. Hoshina; Y. Yamamoto; T. Ishii; K. Hayashi; T. Tominaga Tumor angiogenesis in breast cancer: significance of vessel density as a prognostic indicator Tumor angiogenesis in breast cancer: significance of vessel density as a prognostic indicator Tumor angiogenesis in breast cancer: significance of vessel density as a prognostic indicator Japanese Journal of Cancer and Chemotherapy, 21 Suppl 2, 178-182 Japanese Journal of Cancer and Chemotherapy, 21 Suppl 2, 178-182 Japanese Journal of Cancer and Chemotherapy, 21 Suppl 2, 178-182 1994 英語 公開
T. Oikawa; H. Ito; H. Ashino; M. Toi; T. Tominaga; I. Morita; S.-i. Murota T. Oikawa; H. Ito; H. Ashino; M. Toi; T. Tominaga; I. Morita; S.-i. Murota T. Oikawa; H. Ito; H. Ashino; M. Toi; T. Tominaga; I. Morita; S.-i. Murota Radicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis Radicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis Radicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis European Journal of Pharmacology, 241, 2-3, 221-227 European Journal of Pharmacology, 241, 2-3, 221-227 European Journal of Pharmacology, 241, 2-3, 221-227 1993 英語 公開
M. Toi; J. Kashitani; T. Tominaga M. Toi; J. Kashitani; T. Tominaga M. Toi; J. Kashitani; T. Tominaga Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma International Journal of Cancer, 55, 3, 371-374 International Journal of Cancer, 55, 3, 371-374 International Journal of Cancer, 55, 3, 371-374 1993 英語 公開
M. Toi; A.L. Harris; R. Bicknell M. Toi; A.L. Harris; R. Bicknell M. Toi; A.L. Harris; R. Bicknell cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo British Journal of Cancer, 68, 6, 1088-1096 British Journal of Cancer, 68, 6, 1088-1096 British Journal of Cancer, 68, 6, 1088-1096 1993 英語 公開
K. Kuroi; A. Osaki; H. Yamada; M. Toi; T. Toge; Y. Takimoto; A. Kuramoto; K. Arihiro; K. Inai K. Kuroi; A. Osaki; H. Yamada; M. Toi; T. Toge; Y. Takimoto; A. Kuramoto; K. Arihiro; K. Inai K. Kuroi; A. Osaki; H. Yamada; M. Toi; T. Toge; Y. Takimoto; A. Kuramoto; K. Arihiro; K. Inai Primary squamous cell carcinoma of the breast after cured Hodgkin\\'s disease Primary squamous cell carcinoma of the breast after cured Hodgkin\\'s disease Primary squamous cell carcinoma of the breast after cured Hodgkin\\'s disease Surgery Today, 23, 1, 81-84 Surgery Today, 23, 1, 81-84 Surgery Today, 23, 1, 81-84 1993 英語 公開
M. Toi; Y. Yamamoto; T. Imazawa; T. Takayanagi; K. Akutsu; T. Tominaga M. Toi; Y. Yamamoto; T. Imazawa; T. Takayanagi; K. Akutsu; T. Tominaga M. Toi; Y. Yamamoto; T. Imazawa; T. Takayanagi; K. Akutsu; T. Tominaga Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats International Journal of Oncology, 3, 3, 525-528 International Journal of Oncology, 3, 3, 525-528 International Journal of Oncology, 3, 3, 525-528 1993 英語 公開
T. Tominaga; M. Toi; T. Shirasaka T. Tominaga; M. Toi; T. Shirasaka T. Tominaga; M. Toi; T. Shirasaka Enhanced inhibition of thymidylate synthase by 5-fluorouracil and [6S] leucovorin combination therapy for breast cancer Enhanced inhibition of thymidylate synthase by 5-fluorouracil and [6S] leucovorin combination therapy for breast cancer Enhanced inhibition of thymidylate synthase by 5-fluorouracil and [6S] leucovorin combination therapy for breast cancer Anticancer Research, 13, 6 B, 2425-2427 Anticancer Research, 13, 6 B, 2425-2427 Anticancer Research, 13, 6 B, 2425-2427 1993 英語 公開
M. Toi; T. Hattori; M. Akagi; K. Inokuchi; K. Orita; K. Sugimachi; K. Dohi; Y. Nomura; Y. Monden; Y. Hamada; T. Morimoto; N. Ogawa M. Toi; T. Hattori; M. Akagi; K. Inokuchi; K. Orita; K. Sugimachi; K. Dohi; Y. Nomura; Y. Monden; Y. Hamada; T. Morimoto; N. Ogawa M. Toi; T. Hattori; M. Akagi; K. Inokuchi; K. Orita; K. Sugimachi; K. Dohi; Y. Nomura; Y. Monden; Y. Hamada; T. Morimoto; N. Ogawa Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the Nishi-Nippon group of the adjuvant chemoendocrine therapy for breast cancer organization Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the Nishi-Nippon group of the adjuvant chemoendocrine therapy for breast cancer organization Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the Nishi-Nippon group of the adjuvant chemoendocrine therapy for breast cancer organization Cancer, 70, 10, 2475-2483 Cancer, 70, 10, 2475-2483 Cancer, 70, 10, 2475-2483 1992 英語 公開
A. Osaki; M. Toi; H. Yamada; H. Kawami; K. Kuroi; T. Toge A. Osaki; M. Toi; H. Yamada; H. Kawami; K. Kuroi; T. Toge A. Osaki; M. Toi; H. Yamada; H. Kawami; K. Kuroi; T. Toge Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients The American Journal of Surgery, 164, 4, 323-326 The American Journal of Surgery, 164, 4, 323-326 The American Journal of Surgery, 164, 4, 323-326 1992 英語 公開
M. Toi; R. Bicknell; A.L. Harris M. Toi; R. Bicknell; A.L. Harris M. Toi; R. Bicknell; A.L. Harris Inhibition of colon and breast carcinoma cell growth by interleukin-4 Inhibition of colon and breast carcinoma cell growth by interleukin-4 Inhibition of colon and breast carcinoma cell growth by interleukin-4 Cancer Research, 52, 2, 275-279 Cancer Research, 52, 2, 275-279 Cancer Research, 52, 2, 275-279 1992 英語 公開
M. Toi; A. Osaki; H. Yamada; T. Toge M. Toi; A. Osaki; H. Yamada; T. Toge M. Toi; A. Osaki; H. Yamada; T. Toge Epidermal growth factor receptor expression as a prognostic indicator in breast cancer Epidermal growth factor receptor expression as a prognostic indicator in breast cancer Epidermal growth factor receptor expression as a prognostic indicator in breast cancer European Journal of Cancer and Clinical Oncology, 27, 8, 977-980 European Journal of Cancer and Clinical Oncology, 27, 8, 977-980 European Journal of Cancer and Clinical Oncology, 27, 8, 977-980 1991 英語 公開
M. Toi; A.L. Harris; R. Bicknell M. Toi; A.L. Harris; R. Bicknell M. Toi; A.L. Harris; R. Bicknell Interleukin-4 is a potent mitogen for capillary endothelium Interleukin-4 is a potent mitogen for capillary endothelium Interleukin-4 is a potent mitogen for capillary endothelium Biochemical and Biophysical Research Communications, 174, 3, 1287-1293 Biochemical and Biophysical Research Communications, 174, 3, 1287-1293 Biochemical and Biophysical Research Communications, 174, 3, 1287-1293 1991 英語 公開
H. Mukaida; M. Toi; T. Hirai; Y. Yamashita; T. Toge H. Mukaida; M. Toi; T. Hirai; Y. Yamashita; T. Toge H. Mukaida; M. Toi; T. Hirai; Y. Yamashita; T. Toge Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer Cancer, 68, 1, 142-148 Cancer, 68, 1, 142-148 Cancer, 68, 1, 142-148 1991 英語 公開
K. Yoshinaka; M. Yagi; S. Ohtagaki; M. Toi; T. Toge K. Yoshinaka; M. Yagi; S. Ohtagaki; M. Toi; T. Toge K. Yoshinaka; M. Yagi; S. Ohtagaki; M. Toi; T. Toge 5\\'-deoxy-5-fluorouridine (5\\'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer 5\\'-deoxy-5-fluorouridine (5\\'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer 5\\'-deoxy-5-fluorouridine (5\\'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer Japanese Journal of Cancer and Chemotherapy, 18, 1, 115-118 Japanese Journal of Cancer and Chemotherapy, 18, 1, 115-118 Japanese Journal of Cancer and Chemotherapy, 18, 1, 115-118 1991 英語 公開
K. Umezaza; M. Toi K. Umezaza; M. Toi K. Umezaza; M. Toi Inhibitors of growth factor functions, possible antineoplastic agents Inhibitors of growth factor functions, possible antineoplastic agents Inhibitors of growth factor functions, possible antineoplastic agents Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 36, 7, 1429-1435 Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 36, 7, 1429-1435 Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 36, 7, 1429-1435 1991 英語 公開
H. Mukaida; T. Yamamoto; T. Hirai; M. Toi; T. Nakamura; T. Wada; Y. Yamashita; K. Kawano; M. Niimoto H. Mukaida; T. Yamamoto; T. Hirai; M. Toi; T. Nakamura; T. Wada; Y. Yamashita; K. Kawano; M. Niimoto H. Mukaida; T. Yamamoto; T. Hirai; M. Toi; T. Nakamura; T. Wada; Y. Yamashita; K. Kawano; M. Niimoto Expression of human epidermal growth factor and its receptor in esophageal cancer Expression of human epidermal growth factor and its receptor in esophageal cancer Expression of human epidermal growth factor and its receptor in esophageal cancer The Japanese Journal of Surgery, 20, 3, 275-282 The Japanese Journal of Surgery, 20, 3, 275-282 The Japanese Journal of Surgery, 20, 3, 275-282 1990 英語 公開
M. Toi; T. Wada; H. Yamada; A. Ohsaki; A. Yamamoto; T. Nakamura; M. Nimoto; T. Hattori M. Toi; T. Wada; H. Yamada; A. Ohsaki; A. Yamamoto; T. Nakamura; M. Nimoto; T. Hattori M. Toi; T. Wada; H. Yamada; A. Ohsaki; A. Yamamoto; T. Nakamura; M. Nimoto; T. Hattori Growth fractions of breast cancer in relation to epidermal growth factor receptor and estrogen receptor Growth fractions of breast cancer in relation to epidermal growth factor receptor and estrogen receptor Growth fractions of breast cancer in relation to epidermal growth factor receptor and estrogen receptor The Japanese Journal of Surgery, 20, 3, 327-330 The Japanese Journal of Surgery, 20, 3, 327-330 The Japanese Journal of Surgery, 20, 3, 327-330 1990 英語 公開
M. Niimoto; T. Saeki; M. Toi; M. Nishiyama; T. Hirai; E. Yanagawa; T. Hattori M. Niimoto; T. Saeki; M. Toi; M. Nishiyama; T. Hirai; E. Yanagawa; T. Hattori M. Niimoto; T. Saeki; M. Toi; M. Nishiyama; T. Hirai; E. Yanagawa; T. Hattori Prospective randomized controlled study on bestatin in resectable gastric cancer -Third report- Prospective randomized controlled study on bestatin in resectable gastric cancer -Third report- Prospective randomized controlled study on bestatin in resectable gastric cancer -Third report- The Japanese Journal of Surgery, 20, 2, 186-191 The Japanese Journal of Surgery, 20, 2, 186-191 The Japanese Journal of Surgery, 20, 2, 186-191 1990 英語 公開
M. Toi; H. Mukaida; T. Wada; N. Hirabayashi; T. Toge; T. Hori; K. Umezawa M. Toi; H. Mukaida; T. Wada; N. Hirabayashi; T. Toge; T. Hori; K. Umezawa M. Toi; H. Mukaida; T. Wada; N. Hirabayashi; T. Toge; T. Hori; K. Umezawa Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice European Journal of Cancer and Clinical Oncology, 26, 6, 722-724 European Journal of Cancer and Clinical Oncology, 26, 6, 722-724 European Journal of Cancer and Clinical Oncology, 26, 6, 722-724 1990 英語 公開
M. Toi; T. Nakamura; H. Mukaida; T. Wada; A. Osaki; H. Yamada; T. Toge; M. Niimoto; T. Hattori M. Toi; T. Nakamura; H. Mukaida; T. Wada; A. Osaki; H. Yamada; T. Toge; M. Niimoto; T. Hattori M. Toi; T. Nakamura; H. Mukaida; T. Wada; A. Osaki; H. Yamada; T. Toge; M. Niimoto; T. Hattori Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer Cancer, 65, 9, 1980-1984 Cancer, 65, 9, 1980-1984 Cancer, 65, 9, 1980-1984 1990 英語 公開
S.-i. Suehiro; Y. Hamada; M. Toi; T. Nakamura; M. Niimoto; T. Hattori S.-i. Suehiro; Y. Hamada; M. Toi; T. Nakamura; M. Niimoto; T. Hattori S.-i. Suehiro; Y. Hamada; M. Toi; T. Nakamura; M. Niimoto; T. Hattori Nuclear DNA content in breast carcinoma with special reference to the parameters of malignant potentiality Nuclear DNA content in breast carcinoma with special reference to the parameters of malignant potentiality Nuclear DNA content in breast carcinoma with special reference to the parameters of malignant potentiality The Japanese Journal of Surgery, 20, 1, 115-118 The Japanese Journal of Surgery, 20, 1, 115-118 The Japanese Journal of Surgery, 20, 1, 115-118 1990 英語 公開
E. Miyahara; M. Toi; T. Wada; H. Yamada; A. Osaki; E. Yanagawa; T. Toge E. Miyahara; M. Toi; T. Wada; H. Yamada; A. Osaki; E. Yanagawa; T. Toge E. Miyahara; M. Toi; T. Wada; H. Yamada; A. Osaki; E. Yanagawa; T. Toge The expression of NCC-ST-439, a tumor marker, in human breast cancer patients The expression of NCC-ST-439, a tumor marker, in human breast cancer patients The expression of NCC-ST-439, a tumor marker, in human breast cancer patients Gan no rinsho. Japan journal of cancer clinics, 36, 11, 2023-2026 Gan no rinsho. Japan journal of cancer clinics, 36, 11, 2023-2026 Gan no rinsho. Japan journal of cancer clinics, 36, 11, 2023-2026 1990 英語 公開
M. Toi; Y. Hamada; T. Nakamura; H. Mukaida; S. Suehiro; T. Wada; T. Toge; M. Niimoto; T. Hattori M. Toi; Y. Hamada; T. Nakamura; H. Mukaida; S. Suehiro; T. Wada; T. Toge; M. Niimoto; T. Hattori M. Toi; Y. Hamada; T. Nakamura; H. Mukaida; S. Suehiro; T. Wada; T. Toge; M. Niimoto; T. Hattori Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: Relationship to estrogen receptor and lymphatic invasion Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: Relationship to estrogen receptor and lymphatic invasion Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: Relationship to estrogen receptor and lymphatic invasion International Journal of Cancer, 43, 2, 220-225 International Journal of Cancer, 43, 2, 220-225 International Journal of Cancer, 43, 2, 220-225 1989 英語 公開
M. Toi; T. Nakamura; T. Wada; A. Yamamoto; T. Toge; M. Niimoto; T. Hattori M. Toi; T. Nakamura; T. Wada; A. Yamamoto; T. Toge; M. Niimoto; T. Hattori M. Toi; T. Nakamura; T. Wada; A. Yamamoto; T. Toge; M. Niimoto; T. Hattori The acceptable delay between biopsy and radical mastectomy in breast cancer patients The acceptable delay between biopsy and radical mastectomy in breast cancer patients The acceptable delay between biopsy and radical mastectomy in breast cancer patients The Japanese Journal of Surgery, 19, 6, 679-683 The Japanese Journal of Surgery, 19, 6, 679-683 The Japanese Journal of Surgery, 19, 6, 679-683 1989 英語 公開
M. Toi; T. Nakamura; T. Wada; A. Yamamoto; T. Toge; M. Niimoto; T. Hattori M. Toi; T. Nakamura; T. Wada; A. Yamamoto; T. Toge; M. Niimoto; T. Hattori M. Toi; T. Nakamura; T. Wada; A. Yamamoto; T. Toge; M. Niimoto; T. Hattori The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy The Japanese Journal of Surgery, 19, 6, 768-772 The Japanese Journal of Surgery, 19, 6, 768-772 The Japanese Journal of Surgery, 19, 6, 768-772 1989 英語 公開
T. Saeki; K. Jinushi; R. Kim; M. Toi; K. Saeki; K. Yoshinaka; E. Yanagawa; M. Niimoto; T. Hattori T. Saeki; K. Jinushi; R. Kim; M. Toi; K. Saeki; K. Yoshinaka; E. Yanagawa; M. Niimoto; T. Hattori T. Saeki; K. Jinushi; R. Kim; M. Toi; K. Saeki; K. Yoshinaka; E. Yanagawa; M. Niimoto; T. Hattori Combination chemotherapy of CPM-MTX-5-FU for non-resectable and recurrent cancer patients Combination chemotherapy of CPM-MTX-5-FU for non-resectable and recurrent cancer patients Combination chemotherapy of CPM-MTX-5-FU for non-resectable and recurrent cancer patients Japanese Journal of Cancer and Chemotherapy, 16, 4 I, 827-831 Japanese Journal of Cancer and Chemotherapy, 16, 4 I, 827-831 Japanese Journal of Cancer and Chemotherapy, 16, 4 I, 827-831 1989 英語 公開
S. Suehiro; K. Inai; S. Tokuoka; Y. Hamada; M. Toi; M. Niimoto; T. Hattori S. Suehiro; K. Inai; S. Tokuoka; Y. Hamada; M. Toi; M. Niimoto; T. Hattori S. Suehiro; K. Inai; S. Tokuoka; Y. Hamada; M. Toi; M. Niimoto; T. Hattori Involvement of the nipple in early carcinoma of the breast Involvement of the nipple in early carcinoma of the breast Involvement of the nipple in early carcinoma of the breast Surgery Gynecology and Obstetrics, 168, 3, 244-248 Surgery Gynecology and Obstetrics, 168, 3, 244-248 Surgery Gynecology and Obstetrics, 168, 3, 244-248 1989 英語 公開
M. Toi; Y. Hamada; Y. Seto; M. Tanimoto; T. Nakamura; T. Toge; M. Niimoto; T. Hattori M. Toi; Y. Hamada; Y. Seto; M. Tanimoto; T. Nakamura; T. Toge; M. Niimoto; T. Hattori M. Toi; Y. Hamada; Y. Seto; M. Tanimoto; T. Nakamura; T. Toge; M. Niimoto; T. Hattori Immunocytochemical study on the variation in estrogen receptors of primary and nodal metastases of breast cancer Immunocytochemical study on the variation in estrogen receptors of primary and nodal metastases of breast cancer Immunocytochemical study on the variation in estrogen receptors of primary and nodal metastases of breast cancer The Japanese Journal of Surgery, 18, 2, 228-231 The Japanese Journal of Surgery, 18, 2, 228-231 The Japanese Journal of Surgery, 18, 2, 228-231 1988 英語 公開
Y. Nomura; H. Tashiro; K. Hisamatsu; M. Toi Y. Nomura; H. Tashiro; K. Hisamatsu; M. Toi Y. Nomura; H. Tashiro; K. Hisamatsu; M. Toi Effects of high-dose medroxyprogesterone acetate for advanced breast cancer with special reference to prior endocrine therapy and hormone receptors Effects of high-dose medroxyprogesterone acetate for advanced breast cancer with special reference to prior endocrine therapy and hormone receptors Effects of high-dose medroxyprogesterone acetate for advanced breast cancer with special reference to prior endocrine therapy and hormone receptors Japanese Journal of Cancer and Chemotherapy, 15, 3, 513-518 Japanese Journal of Cancer and Chemotherapy, 15, 3, 513-518 Japanese Journal of Cancer and Chemotherapy, 15, 3, 513-518 1988 英語 公開
M. Toi M. Toi M. Toi Comparative study on estrogen receptor, epidermal growth factor and epidermal growth factor receptor using immunocytochemical and biochemical assays in breast cancer Comparative study on estrogen receptor, epidermal growth factor and epidermal growth factor receptor using immunocytochemical and biochemical assays in breast cancer Comparative study on estrogen receptor, epidermal growth factor and epidermal growth factor receptor using immunocytochemical and biochemical assays in breast cancer Nippon Geka Gakkai zasshi, 89, 5, 725-736 Nippon Geka Gakkai zasshi, 89, 5, 725-736 Nippon Geka Gakkai zasshi, 89, 5, 725-736 1988 英語 公開
M. Toi; Y. Hamada; Y. Seto; K. Hisamatsu; S. Suehiro; T. Toge; M. Niimoto; T. Hattori M. Toi; Y. Hamada; Y. Seto; K. Hisamatsu; S. Suehiro; T. Toge; M. Niimoto; T. Hattori M. Toi; Y. Hamada; Y. Seto; K. Hisamatsu; S. Suehiro; T. Toge; M. Niimoto; T. Hattori Comparative study of estrogen receptor assays between immunocytochemical assay using monoclonal antibody and the dextran- coated charcoal method Comparative study of estrogen receptor assays between immunocytochemical assay using monoclonal antibody and the dextran- coated charcoal method Comparative study of estrogen receptor assays between immunocytochemical assay using monoclonal antibody and the dextran- coated charcoal method Gan to kagaku ryoho. Cancer & chemotherapy, 13, 10, 3056-3062 Gan to kagaku ryoho. Cancer & chemotherapy, 13, 10, 3056-3062 Gan to kagaku ryoho. Cancer & chemotherapy, 13, 10, 3056-3062 1986 英語 公開
K. Hisamatsu; T. Toge; E. Yanagawa; Y. Hamada; Y. Seto; H. Yamada; M. Toi; T. Hattori K. Hisamatsu; T. Toge; E. Yanagawa; Y. Hamada; Y. Seto; H. Yamada; M. Toi; T. Hattori K. Hisamatsu; T. Toge; E. Yanagawa; Y. Hamada; Y. Seto; H. Yamada; M. Toi; T. Hattori Immune reactivities of lymphocytes from peripheral blood, regional lymph nodes and tumor-infiltrating lymphocytes in breast cancer patients Immune reactivities of lymphocytes from peripheral blood, regional lymph nodes and tumor-infiltrating lymphocytes in breast cancer patients Immune reactivities of lymphocytes from peripheral blood, regional lymph nodes and tumor-infiltrating lymphocytes in breast cancer patients Japanese Journal of Cancer and Chemotherapy, 13, 8, 2555-2561 Japanese Journal of Cancer and Chemotherapy, 13, 8, 2555-2561 Japanese Journal of Cancer and Chemotherapy, 13, 8, 2555-2561 1986 英語 公開
M. Toi; T. Shiramizu; T. Yonemura; T. Ezaki; N. Oka; T. Yoshida; H. Tsurumaru M. Toi; T. Shiramizu; T. Yonemura; T. Ezaki; N. Oka; T. Yoshida; H. Tsurumaru M. Toi; T. Shiramizu; T. Yonemura; T. Ezaki; N. Oka; T. Yoshida; H. Tsurumaru Intraperitoneal cisplatin in peritoneal carcinomatosis patients Intraperitoneal cisplatin in peritoneal carcinomatosis patients Intraperitoneal cisplatin in peritoneal carcinomatosis patients Gan no rinsho. Japan journal of cancer clinics, 31, 5, 522-526 Gan no rinsho. Japan journal of cancer clinics, 31, 5, 522-526 Gan no rinsho. Japan journal of cancer clinics, 31, 5, 522-526 1985 英語 公開
M. Toi; K. Matsuki; K. Nakagami; M. Hirono; M. Niimoto; T. Hattori M. Toi; K. Matsuki; K. Nakagami; M. Hirono; M. Niimoto; T. Hattori M. Toi; K. Matsuki; K. Nakagami; M. Hirono; M. Niimoto; T. Hattori A case of minute carcinoma associated with an atypical epithelial lesion of the stomach and histopathological analysis A case of minute carcinoma associated with an atypical epithelial lesion of the stomach and histopathological analysis A case of minute carcinoma associated with an atypical epithelial lesion of the stomach and histopathological analysis Gan no rinsho. Japan journal of cancer clinics, 30, 5, 519-523 Gan no rinsho. Japan journal of cancer clinics, 30, 5, 519-523 Gan no rinsho. Japan journal of cancer clinics, 30, 5, 519-523 1984 英語 公開
戸井 雅和 戸井 雅和 TOI Masakazu 5-Chloro-2,4-dihydroxypyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. 5-Chloro-2,4-dihydroxypyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. 5-Chloro-2,4-dihydroxypyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. Cancer Med, 7(2), 463-470 Cancer Med, 7(2), 463-470 Cancer Med, 7(2), 463-470 公開
Tsuda M, Ishiguro H, Yano I, Toi M Tsuda M, Ishiguro H, Yano I, Toi M Tsuda M, Ishiguro H, Yano I, Toi M Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment J Natl Cancer Inst, 106, 7 J Natl Cancer Inst, 106, 7 J Natl Cancer Inst, 106, 7 公開
戸井 雅和 戸井 雅和 TOI Masakazu SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer. SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer. SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer. Cancer Med, Feb;7(2), 454-462 Cancer Med, Feb;7(2), 454-462 Cancer Med, Feb;7(2), 454-462 公開
戸井 雅和 戸井 雅和 Matsumoto Y, Asao Y, Yoshikawa A, Sekiguchi H, Takada M, Furu M, Saito S, Kataoka M, Abe H, Yagi T, Togashi K, Toi M. Label-free photoacoustic imaging of human palmar vessels: a structural morphological analysis. Label-free photoacoustic imaging of human palmar vessels: a structural morphological analysis. Label-free photoacoustic imaging of human palmar vessels: a structural morphological analysis. Sci Rep, 15;8(1), 786 Sci Rep, 15;8(1), 786 Sci Rep, 15;8(1), 786 公開
戸井 雅和 戸井 雅和 Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M. Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. BMC Cancer, 16;16, 230-doi: 10 BMC Cancer, 16;16, 230-doi: 10 BMC Cancer, 16;16, 230-doi: 10 公開
Ishiguro H, Takashima S, Yoshimura K, Yano I, Yamamoto T, Niimi M, Yamashiro H, Ueno T, Takeuchi M, Sugie T, Yanagihara K, Toi M, Fukushima M. Degree Ishiguro H, Takashima S, Yoshimura K, Yano I, Yamamoto T, Niimi M, Yamashiro H, Ueno T, Takeuchi M, Sugie T, Yanagihara K, Toi M, Fukushima M. Degree Ishiguro H, Takashima S, Yoshimura K, Yano I, Yamamoto T, Niimi M, Yamashiro H, Ueno T, Takeuchi M, Sugie T, Yanagihara K, Toi M, Fukushima M. Degree Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients Support Care Cancer. 2011 Nov 1 Support Care Cancer. 2011 Nov 1 Support Care Cancer. 2011 Nov 1 英語 公開
Eswaran J, Gupta S, Dutt A, Toi M, Pillai MR, Costa L, Knapp S, Badwe RA, Kumar R Eswaran J, Gupta S, Dutt A, Toi M, Pillai MR, Costa L, Knapp S, Badwe RA, Kumar R Eswaran J, Gupta S, Dutt A, Toi M, Pillai MR, Costa L, Knapp S, Badwe RA, Kumar R The Global Cancer Genomics Consortium: Interfacing Genomics and Cancer Medicine The Global Cancer Genomics Consortium: Interfacing Genomics and Cancer Medicine The Global Cancer Genomics Consortium: Interfacing Genomics and Cancer Medicine Cancer Res. 2012 May 24. [Epub ahead of print] Cancer Res. 2012 May 24. [Epub ahead of print] Cancer Res. 2012 May 24. [Epub ahead of print] 英語 公開
Takeuchi M, Sugie T, Abdelazeem K, Kato H, Shinkura N, Takada M, Yamashiro H, Ueno T, Toi M. Takeuchi M, Sugie T, Abdelazeem K, Kato H, Shinkura N, Takada M, Yamashiro H, Ueno T, Toi M. Takeuchi M, Sugie T, Abdelazeem K, Kato H, Shinkura N, Takada M, Yamashiro H, Ueno T, Toi M. Lymphatic Mapping With Fluorescence Navigation Using Indocyanine Green and Axillary Surgery in Patients With Primary Breast Cancer Lymphatic Mapping With Fluorescence Navigation Using Indocyanine Green and Axillary Surgery in Patients With Primary Breast Cancer Lymphatic Mapping With Fluorescence Navigation Using Indocyanine Green and Axillary Surgery in Patients With Primary Breast Cancer Breast J. 2012 Sep 26. Breast J. 2012 Sep 26. Breast J. 2012 Sep 26. 英語 公開
Imami K, Sugiyama N, Imamura H, Wakabayashi M, Tomita M, Taniguchi M, Ueno T, Toi M, Ishihama Y. Imami K, Sugiyama N, Imamura H, Wakabayashi M, Tomita M, Taniguchi M, Ueno T, Toi M, Ishihama Y. Imami K, Sugiyama N, Imamura H, Wakabayashi M, Tomita M, Taniguchi M, Ueno T, Toi M, Ishihama Y. Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics. 2012 Sep 10. Mol Cell Proteomics. 2012 Sep 10. Mol Cell Proteomics. 2012 Sep 10. 英語 公開
Sugimoto M, Takada M, Toi M. Sugimoto M, Takada M, Toi M. Sugimoto M, Takada M, Toi M. Comparison of robustness against missing values of alternative decision tree and multiple logistic regression for predicting clinical data in primary breast cancer. Comparison of robustness against missing values of alternative decision tree and multiple logistic regression for predicting clinical data in primary breast cancer. Comparison of robustness against missing values of alternative decision tree and multiple logistic regression for predicting clinical data in primary breast cancer. Conf Proc IEEE Eng Med Biol Soc. 2013 Conf Proc IEEE Eng Med Biol Soc. 2013 Conf Proc IEEE Eng Med Biol Soc. 2013 英語 公開
Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuva Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuva Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuva Breast Cancer Res Treat. 2013 Oct 12 Breast Cancer Res Treat. 2013 Oct 12 Breast Cancer Res Treat. 2013 Oct 12 英語 公開
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. Adjuvant bevacizumab- containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial Adjuvant bevacizumab- containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial Adjuvant bevacizumab- containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial Lancet Oncol. 2013 Lancet Oncol. 2013 Lancet Oncol. 2013 英語 公開
戸井 雅和 戸井 雅和 TOI Masakazu Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. Toi M, Shao Z, Hurvitz S, Tseng LM, Zhang Q, Shen K, Liu D, Feng J, Xu B, Wang X, Lee KS, Ng TY, Ridolfi A, Noel-Baron F, Ringeisen F, Jiang Z. Breast Cancer Res, 19(1), 2017 Apr 11;19(1):47. doi: 10. Breast Cancer Res, 19(1), 2017 Apr 11;19(1):47. doi: 10. Breast Cancer Res, 19(1), 2017 Apr 11;19(1):47. doi: 10. 公開
Suzuki R, Saji S, Toi M Suzuki R, Saji S, Toi M Suzuki R, Saji S, Toi M Impact of body mass index on breast cancer in accordance with the life-stage of women. Impact of body mass index on breast cancer in accordance with the life-stage of women. Impact of body mass index on breast cancer in accordance with the life-stage of women. Front Oncol. 2012;2:123 Front Oncol. 2012;2:123 Front Oncol. 2012;2:123 英語 公開
Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, Pires R, Fuqua SA, Toi M, Costa L, Nair SS, Sukumar S, Kumar R Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, Pires R, Fuqua SA, Toi M, Costa L, Nair SS, Sukumar S, Kumar R Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, Pires R, Fuqua SA, Toi M, Costa L, Nair SS, Sukumar S, Kumar R Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing Sci Rep. 2013 Jul 25;3:2256. doi: 10.1038/srep02256. Sci Rep. 2013 Jul 25;3:2256. doi: 10.1038/srep02256. Sci Rep. 2013 Jul 25;3:2256. doi: 10.1038/srep02256. 英語 公開
戸井 雅和 戸井 雅和 Miyake KK, Nakamoto Y, Saji S, Sugie T, Kurihara K, Kanao S, Ikeda DM, Toi M, Togashi K Impact of physiological hormonal fluctuations on 18F-fluorodeoxyglucose uptake in breast cancer. Impact of physiological hormonal fluctuations on 18F-fluorodeoxyglucose uptake in breast cancer. Impact of physiological hormonal fluctuations on 18F-fluorodeoxyglucose uptake in breast cancer. Breast Cancer Res Treat, 169(3), 437-446 Breast Cancer Res Treat, 169(3), 437-446 , 169(3), 437-446 公開
戸井 雅和 戸井 雅和 Asao Y, Hashizume Y, Suita T, Nagae KI, Fukutani K, Sudo Y, Matsushita T, Kobayashi S, Tokiwa M, Yamaga I, Fakhrejahani E, Torii M, Kawashima M, Takada M, Kanao S, Kataoka M, Shiina T, Toi M. Photoacoustic mammography capable of simultaneously acquiring photoacoustic and ultrasound images. Photoacoustic mammography capable of simultaneously acquiring photoacoustic and ultrasound images. Photoacoustic mammography capable of simultaneously acquiring photoacoustic and ultrasound images. J Biomed Opt, 1;21, 11, :116009. J Biomed Opt, 1;21, 11, :116009. J Biomed Opt, 1;21, 11, :116009. 公開
戸井 雅和 戸井 雅和 André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. J Clin Oncol, 20;34, 18, 2115-2124 J Clin Oncol, 20;34, 18, 2115-2124 J Clin Oncol, 20;34, 18, 2115-2124 公開

  • <<
  • >>
  • 表示
タイトル言語:
外部資金:競争的資金・科学研究費補助金
種別 代表/分担 テーマ(日本語) テーマ(英語) 期間
平成21年‐23年度厚生労働科学研究費 代表 「光超音波マンモグラフィにおける乳がんの診断基準の整備と高機能化のための広帯域PATプローブの開発」
厚生労働科学研究費平成22年‐24年度 代表 「抗がん剤効果予測による乳がん患者の再発リスク抑制と毒性軽減および医療経済低減に関する検証的研究」
科学研究費基盤研究B 平成21‐23年度 代表 「癌患者における血中循環癌細胞の特性解析と癌転移動態の分析に関する研究 」
科学研究費基盤研究費A平成22-24年度 分担 「時空間変調に基づく光超音波融合高機能生体イメージング法の開発」
科学研究費挑戦的萌芽平成21年‐23年度 分担 「乳がん診断・治療におけるマイクロRNA発現プロファイルの応用」
基盤研究(B) 癌患者における血中循環癌細胞の特性解析と癌転移動態の分析に関する研究 2009〜2011
次世代がん 分担 血中循環乳がん細胞に対するエピジェネティクスマルチマーカーの実用化開発 2012/02/20〜
科研費 分担 血清を用いた新たな乳がん検出法の開発 2014/04/01〜2015/03/31
科研費 分担 ベイズ流アプローチによる探索的がん臨床試験デザインの開発 2012/07/03〜2015/03/31
厚生労働科研費 分担 統合リピドミクス・ゲノミクスを用いたホルモン感受性癌における革新的先制医療シーズの探索 2014/05/01〜2015/03/31
受託研究 代表 革新的研究開発推進プログラム(ImPACT)「イノベーティブな可視化技術による新成長産業の創出」(価値実証:医療と美容健康) 2014/10/02〜2018/03/31
基盤研究(B) 代表 新規概念によるNMR測定を用いた乳がん血清診断法の開発 (平成30年度分) 2018/04/01〜2019/03/31

  • <<
  • >>
  • 表示
担当科目
講義名(日本語) 講義名(英語) 開講期 学部/研究科 年度
S20a 臨床腫瘍学 Clinical Oncology 後期前半 医学部 2013/04〜2014/03
臨床腫瘍学(がんプロ) 通年不定 医学研究科 2013/04〜2014/03
緩和医療学(がんプロ) 通年不定 医学研究科 2013/04〜2014/03
S20a 臨床腫瘍学 Clinical Oncology 後期前半 医学部 2014/04〜2015/03
臨床腫瘍学(がんプロ) Clinical Oncology 通年不定 医学研究科 2014/04〜2015/03
緩和医療学(がんプロ) Palliative Medicine 通年不定 医学研究科 2014/04〜2015/03
S20a 臨床腫瘍学 Clinical Oncology 後期前半 医学部 2015/04〜2016/03
緩和医療学(がんプロ) Palliative Medicine 通年不定 医学研究科 2015/04〜2016/03
臨床腫瘍学(がんプロ) Clinical Oncology 通年不定 医学研究科 2015/04〜2016/03
S20a 臨床腫瘍学 Clinical Oncology 後期前半 医学部 2016/04〜2017/03
緩和医療学(がんプロ) Palliative Medicine 通年不定 医学研究科 2016/04〜2017/03
臨床腫瘍学(がんプロ) Clinical Oncology 通年不定 医学研究科 2016/04〜2017/03
S20a 臨床腫瘍学 Clinical Oncology 後期前半 医学部 2017/04〜2018/03
緩和医療学(がんプロ) Palliative Medicine 通年不定 医学研究科 2017/04〜2018/03
臨床腫瘍学(がんプロ) Clinical Oncology 通年不定 医学研究科 2017/04〜2018/03
C10 産科学・婦人科学・女性腫瘍学 Gynecology and Obstetrics/Women Oncology 後期後半 医学部 2018/04〜2019/03
S20a 臨床腫瘍学 Clinical Oncology 後期前半 医学部 2018/04〜2019/03
C10 産科学・婦人科学・女性腫瘍学 Gynecology and Obstetrics/Women Oncology 後期後半 医学部 2019/04〜2020/03
S20a 臨床腫瘍学 Clinical Oncology 後期前半 医学部 2019/04〜2020/03

  • <<
  • >>
  • 表示
全学運営(役職等)
役職名 期間
A群部会委員
環境保全委員、
医学部附属病院 病歴委員, レジメン委員会委員長
産官学連携本部運営協議会 3号委員 2016/04/01〜2016/09/30
京都大学産学共同実用化促進事業実施委員会 4号委員 2016/04/01〜2017/09/09
産官学連携本部運営協議会 委員 2016/10/01〜2018/09/30
文部科学省「次代を担うがん研究者・医療人養成プラン」がんプロフェッショナル養成基盤推進プラン大学担当コーディネーター 2012/04/01〜2015/03/31
文部科学省「次代を担うがん研究者・医療人養成プラン」がんプロフェッショナル養成基盤推進プラン事業推進責任者 2015/04/01〜2017/03/31
文部科学省「次代を担うがん研究者・医療人養成プラン」がんプロフェッショナル養成基盤推進プラン事業推進責任者 2017/04/01〜
京都大学産学共同実用化促進事業実施委員会 委員 2016/04/01〜2019/09/09
部局運営(役職等)
役職名 期間
共用試験委員会(委員長)
がん専門職教育管理委員会(委員)
EBMセンター運営委員会(委員)
がん専門職教育管理委員会(委員長)
医学部附属病院外科長 2008/04/01〜2009/03/31
寄附講座運営委員会(標的治療腫瘍学) 2011/07/01〜2017/06/30
寄附講座運営委員会(臨床システム腫瘍学) 2014/04/01〜2020/03/31
寄附講座運営委員会(臨床腫瘍薬理学・緩和医療学) 2011/04/01〜2020/03/31
寄附講座運営委員会(集学的がん診療学) 2012/04/01〜2015/03/31
動物実験施設管理委員会 2015/04/01〜2017/03/31
医学図書館運営委員会 2017/04/01〜2021/03/31
期限付特定教員採用審査委員会 2016/11/01〜2020/10/31

  • <<
  • >>
  • 表示
その他活動:国・地方公共団体での活動
委員会名(日本語) 委員会名(英語) 役職名 公共団体の名称 期間
厚生労働科学研究費補助金(第3次がん総合戦略研究事業)がん対策のための戦略研究 研究評価委員会(委員)、
医師国家試験委員
京都発革新的医療技術研究開発助成事業 委員 京都市産業観光局新産業振興室 〜2018/03/31